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Modulation of Cannabinoid Receptor Activity by Allosteric Modulators, 
Inverse Agonists and Receptor Binding Partners 
Mariam Mohamed Mahmoud, PhD 
University of Connecticut, 2015 
 
The regulation of G protein coupled receptors (GPCRs) plays a fundamental role in physiologic 
homeostasis. There are two cannabinoid receptors: CB1, found on neurons of the central and 
peripheral nervous system and regulate neuromodulatory processes and CB2, found in peripheral 
tissues, particularly in immune tissues. In this research, three different modulation mechanisms 
of the cannabinoid receptors are studied. Chapter 2 focuses on the structure-activity relationships 
of novel allosteric modulators from the indole-2-carboxamide class of compounds. These novel 
allosteric modulators were optimized for their KB (binding affinity to the allosteric site) and their 
cooperativity factor α (magnitude by which affinity of orthosteric ligand is changed). Although 
these positive allosteric modulators enhanced orthosteric CP55, 950 agonist affinity and 
decreased SR141716A inverse agonist affinity to CB1 consistent with an active receptor 
conformation, they antagonized basal and agonist-induced G protein coupling. Chapter 3 focuses 
on the characterization of a group of new inverse agonists from the class of benzhydryl 
piperazine analogs. These compounds exhibit high nanomolar binding affinities to CB1, 
antagonize basal as well as agonist-induced G protein coupling and increase receptor cell surface 
localization, consistent with inverse agonist behavior. Docking and mutational analyses revealed 
SR141716A-like interactions in the CB1 binding pocket. However, this benzhydryl piperazine  
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scaffold is structurally distinct from first generation CB1 inverse agonists and holds promise for 
developing peripherally active CB1 inverse agonists with fewer psychiatric side effects. Chapter 
4 focuses on the development and optimization of a novel technique using the photo-cross-
linking unnatural amino acid p-benzoyl-L-phenylalanine (pBpa) in live cells. This will elucidate 
the binding partners of the CB2 receptor at defined locations and time points in real-time using 
mass spectrometry. To this end, I determined the best detergent to solubilize CB2, the ratios of 
DNA to tRNA and pBpa-synthetase needed, the optimal concentration of pBpa in the media and 
the ideal UV exposure times needed for the efficient incorporation of pBpa into the full-length 
CB2 receptor. Additionally, pilot experiments using different CB2 ligands and varying treatment 
times were performed and possible CB2-binding partner complexes were observed. These results 
will aid in the discovery of more effective and selective GPCR ligands.  
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CHAPTER 1 
INTRODUCTION 
1.1 The G protein-coupled receptor (GPCR) superfamily 
G protein-coupled receptors (GPCRs) constitute the largest family of cell surface receptors 
(about 900 members) (Jalink and Moolenaar, 2010). Among 35,000 human genes in the human 
genome, approximately 750 genes encode for GPCRs (Foord et al., 2005; Kroeze et al., 2003; 
Vassilatis et al., 2003; Wise et al., 2004). GPCRs facilitate a host of cellular responses and 
transduce signals across the biological membrane to mediate the senses of smell, sight and taste 
(Davies et al., 2007; Gether, 2000). They are involved in many diseases and are currently the 
target of about 40% of therapeutic drugs (Overington et al., 2006).  
1.1.1 GPCR classification system 
GPCRs are divided into 6 classes (A-F) based mainly on sequence homology and functional 
similarity (Figure 1.1). The largest and most studied subfamily is the rhodopsin-like class A 
superfamily. This subclass, which includes rhodopsins, adrenergic receptors, and cannabinoid 
receptors, shares highly conserved regions such as an Glu/Asp-Arg-Tyr (E/DRY) motif on the 
intracellular side of TM3, and an Asn-Pro-X-X-Tyr (NPXXY) motif on the intracellular side of 
TM7. Often within this family a cysteine residue in the carboxyl terminus is palmitoylated 
resulting in membrane association and causing the membrane proximal region of the carboxyl 
terminus to form a fourth cytoplasmic loop. It is also common for an α-helix, typically referred 
to as helix 8 (H8), to form at the start of the carboxyl terminus. The class B superfamily is 
composed of members such as the secretin receptor, calcitonin receptor, parathyroid receptor, 
and the glucagon receptor. This class is characterized by ligands that are mostly peptide 
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hormones. These receptors have large extracellular loops and a high degree of diversification in 
the relatively long amino terminus that often contains many well-characterized protein domains 
such as EGF domains (McKnight and Gordon, 1996; Otaki and Firestein, 2001; Segre and 
Goldring, 1993; Zendman et al., 1999). The amino terminus is also thought to directly modulate 
ligand binding as well as interact with chaperones and or accessory proteins such as receptor 
activity modifying proteins (RAMPs) (Bomberger et al., 2005). Another major GPCR family is 
class C represented by eight metabotropic glutamate receptors (GRM), two aminobutyric acid 
(GABA) receptors, and a calcium sensing receptor (CASR). This GPCR family is characterized 
by long amino termini that can be as long as 600 amino acids (Bockaert, 2012) which play a 
primary role in ligand recognition. The remaining three GPCR families are relatively minor and 
include the class D fungal mating pheromone receptor, the class E cyclic AMP receptors, and the 
class F frizzled/smoothened-related receptors.  
 
Figure 1.1 Classification of major GPCR families. The superfamily of G-protein-coupled 
receptors (GPCRs) is the largest single class of receptors. Despite extremely diverse roles in the 
 3 
 
cell, all GPCRs share the structural hallmark of seven helical transmembrane domains. (modified 
from jenabioscience.com) 
 
The most recent and commonly used system is the GRAFS classification system (Schioth and 
Fredriksson, 2005) which has been developed using phylogenetic analyses. Within this system, 
the GPCR superfamily is subdivided into five main families based on several common structural 
features indicating that the human GPCRs in the GRAFS families share a common ancestor. The 
GPCR subfamilies are as follows: rhodopsin (former class A), glutamate (former class C), 
adhesion (part of former class B), frizzled/taste2 (former class F), and secretin (part of former 
class B). Other former classes, D (fungal mating pheromone receptors) and E (cyclic AMP 
receptors), do not contain human receptors and are therefore not included in the GRAFS 
classification.  
The older A–F class system is designed to cover all GPCRs, in both vertebrates and 
invertebrates. Some families in the A–F system do not exist in humans. Examples of this are 
classes D and E, which represent fungal pheromone receptors and cAMP receptors, family IV in 
class A, which is composed of invertebrate opsin receptors, and class F, which contains 
archaebacterial opsins. The overall classification of the GPCRs has been hampered by the large 
sequence differences between mammalian and invertebrate GPCRs. The GRAFS system 
classifies GPCRs based on chromosomal localization and positioning in paralogous groups of the 
genes and this gave insight into the mechanism involved in creating the receptor genes. The 
different families were also analyzed for common sequence motifs and showed common descent 
between GPCRs of the same family (Fredriksson et al., 2003). 
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1.1.2 General structural features of GPCRs 
Generally, GPCRs comprise seven membrane spanning α-helices (7TM) composed of 
predominantly hydrophobic amino acids that are connected by three extracellular loops (EC1-
EC3) and three intracellular loops (IC1-IC3). The extracellular region (EC), which may be 
involved in ligand binding, also includes the amino terminus that can range from relatively short 
sequences in rhodopsin-like receptors to large extracellular domains in other classes of GPCRs, 
such as the hormone-binding domain in adhesion receptors (Katritch et al., 2012). The 
intracellular (IC) region interacts with G proteins, arrestins and other downstream effectors. It 
includes cytoplasmic H8 and a carboxyl terminus that may provide sites for palmitoylation 
(Figure 1.2a). Within the membrane bilayer, the 7 TM GPCR is arranged as a helical bundle and 
is stabilized by non-covalent interactions (reviewed in (Rosenbaum et al., 2009); Figure 1.2b). 
The bundle also contains a number of kinks, mostly induced by Pro residues. In general, 
sequence diversity among GPCRs is highest within the EC region which can be involved in 
ligand binding and undergoes small movements during activation. In contrast, the IC region, 
which is usually involved in binding downstream proteins including G proteins and arrestins, is 
more conserved within each GPCR family but is subjected to much larger conformational 
changes upon receptor activation than the EC regions ((Katritch et al., 2012); Figure 1.3).  
The 7TM core also contains well conserved motifs that are characteristic of GPCRs. These 
include the E/DRY motif in TM3, the CWXP in TM6 and the NPXXY motif in TM7 
(Mirzadegan et al., 2003) (Figure 1.2). Even for members of the same subfamily, such as 
rhodopsin and the β2-adrenergic receptor (β2AR) (Figure 1.3), their structural diversity still 
makes homology modeling challenging. 
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(a) 
(b) 
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Figure 1.2 Conserved residues and functional microdomains in GPCRs. (a) Schematic 2-D 
diagram of the human CB1 receptor showing its amino terminus with a Y to mark glycosylated 
residues, extracellular (EC) loops with a disulfide bond between 2 Cys residues, heptahelical 
transmembrane (TM) domains, intracellular (IC) loops, helix H8 and the carboxyl terminus with 
a membrane palmitoylation anchor on a Cys residue. (b) Rhodopsin (PDB accession 1GZM) 
with bound inverse agonist 11-cis-retinal is shown as a representative GPCR. TM domains are 
helical in structure and exist in a bundle stabilized by various inter- and intra-molecular 
interactions. The cytoplasmic helix H8 follows directly after TM7 and is frequently terminated 
by one or two palmitoylated Cys residues (Cys 322 and Cys 323 in rhodopsin). Oligosaccharide 
chains are bonded to residues at the amino terminus (Asn2 and Asn15 in rhodopsin). A 
conserved disulfide bridge constrains the EC end of TM3 and the middle of loop EC2 (Cys110 
and Cys187 in rhodopsin) is shown. The most conserved residue in each TM helix is shown in 
blue. According to Ballesteros-Weinstein numbering, these residues are designated x.50, where x 
is the TM helix number, and other residues are designated relative to the reference residue on 
each helix (Ballesteros and Weinstein, 1992). (Figure 1.2b and conserved motifs are modified 
from (Hofmann et al., 2009)).  
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Figure 1.3 Crystal structures of (a) rhodopsin (PDB id:1F88) and (b) β2-adrenergic 
receptor (PDB id: 2RH1). Top, view along the membrane plane; bottom, from the extracellular 
side. (modified from (Latek et al., 2012)). 
 
1.1.3 GPCR ligands and receptor states  
The molecules which bind to and regulate GPCR activation are called ligands. These ligands 
bind the receptor at an orthosteric site typically within the transmembrane (TM) domain. There 
are more than 250 ―known‖ GPCRs for which the endogenous ligand has been identified, while 
receptors for which the endogenous ligand has not been identified are referred to as "orphan" 
receptors. The ligands that bind and activate these receptors include light-sensitive compounds, 
odors, pheromones, hormones, and neurotransmitters, and vary in size from small molecules to 
peptides to large proteins. There are different binding domains, depending upon each receptor 
and its ligands, that are located in the amino terminal end or within the TM domain.  
(a) (b) 
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Some GPCRs are also known to have constitutive activity, i.e. activity in the absence of 
endogenous ligand or agonist. This observation of ligand-independent constitutive activity (R') 
led to the classical two-state model for receptor-G protein activation (Leff, 1995). Constitutive 
activity may be considered to be an equilibrium of a GPCR population including receptors in the 
ground state with no activity (R) and receptors in their fully activated state (R*). Agonists can 
still bind to constitutively active GPCRs to produce further activity. Moreover, some compounds 
can bind to constitutively active receptors and produce opposite responses to agonists. For 
example, if an agonist of a particular GPCR stimulates an increase in Ca
++
 mobilization and the 
constitutively active receptor has high basal Ca
++
 mobilization, some ligands are able to bind to 
this receptor to reduce basal Ca
++
 mobilization towards the ground state. These ligands are 
referred to as ‗inverse agonists‘. In many cases, these ligands were originally characterized as 
antagonists on non-constitutively active GPCRs and their inverse agonism is primarily observed 
when they interact with constitutively active GPCRs. The existence of constitutive activity has 
required a reconsideration of how we think about GPCR antagonists. Antagonists are classically 
considered compounds that bind to GPCRs to block binding and activation by agonists, but do 
not change the distribution of receptor in the active and inactive states. In fact, compounds that 
block both agonist and inverse agonist binding but produce no response by GPCRs are now 
referred to as ‗neutral antagonists‘. The model of GPCR activation has therefore been adapted to 
account for multiple activation states (De Lean et al., 1980) with distinguishing biochemical 
characteristics, including extent and selectivity of promiscuous G protein coupling and arrestins 
for signaling (Figure 1.4). 
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R* 
R′ 
R 
 
 
  
 
 
 
Figure 1.4 GPCR activation states. Agonists promote the active R* state of the receptor and 
enhance the biological activity and signal transduction of the receptor while inverse agonists 
promote the inactive R form of the receptor reducing basal R' levels of signal transduction. 
Antagonists bind the orthosteric site competitively but do not alter the equilibrium of R and R* 
and do not directly modulate signal transduction levels. 
 
1.1.4 GPCR crystal structures: inactive and active receptor forms 
The structural determination of GPCRs has been remarkably accelerated in recent years due to 
innovative protein engineering such as fusion proteins and chimeric proteins (Chun et al., 2012; 
Kobilka and Schertler, 2008; Tate, 2012), novel crystallization techniques (Caffrey et al., 2012), 
and crystallography methods (Moukhametzianov et al., 2008; Riekel et al., 2005). Despite these 
advances, only a few GPCRs are crystallized in the active conformation (Choe et al., 2011; 
Deupi et al., 2012; Singhal et al., 2013; Standfuss et al., 2011; White et al., 2012) and only one 
structure of an active GPCR in complex with a G protein exists (Rasmussen et al., 2011).  
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The structures of the different GPCRs crystallized to date exhibit limited differences even though 
they were crystallized differently, i.e. in different crystal packing orientations, with different 
antagonists and inverse agonists bound and also in two different activation states, either activated 
(agonist bound) or inactivated (antagonist or inverse-agonist bound) (Rasmussen et al., 2011). 
The first X-ray crystal structure of any GPCR was that of ground-state rhodopsin (Palczewski et 
al., 2000). Refinement of crystallization conditions yielded higher resolution data, extending the 
rhodopsin model to 2.2 Å, the highest resolution of all rhodopsin structures determined to date 
(Okada et al., 2004). The first structure of a diffusible ligand-responsive GPCR resulted from the 
work of Kobilka and Stevens, who reported the crystal structure of a human β2AR-T4 lysozyme 
fusion protein bound to its partial inverse agonist carazolol at 2.4 Å resolution (Cherezov et al., 
2007; Rosenbaum et al., 2007). The highest resolution structure of any GPCR with well-defined 
Na
+
 ions and water molecules is the 1.8 Å resolution structure of the engineered human A2A 
adenosine receptor with its third intracellular loop replaced with apocytochrome b(562)RIL (Liu 
et al., 2012). Water molecules play critical roles in the GPCR activation process by stabilizing 
intramolecular interactions (Garczarek and Gerwert, 2006; Osyczka et al., 2005; Wikstrom et al., 
2003). Along with amino acid side chains, water molecules have been observed to form a signal 
transmission network extending from the ligand binding site to the cytoplasmic surface (Angel et 
al., 2009; Orban et al., 2010). 
Subsequent improvements in resolution of the initial rhodopsin and β2AR structures have 
provided templates for the creation of homology models (Filipek et al., 2003; Zhang et al., 2006). 
To date, there are 15 unique GPCR structures deposited in the Protein Data Bank (PDB) 
involving a variety of ligands, activation states and point mutations. These structures all belong 
to the rhodopsin-like family of GPCRs and include the amine receptors (histamine H1R, 
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dopamine D3R, muscarinic M2R and M3R, β1- and β2-adrenergic receptors), opsins 
(rhodopsin), adenosine A2AR and lipid S1P1R receptors. In addition, the neurotensin receptor 
has also been crystallized.  
Rhodopsin is one of the most extensively studied members of the GPCR family. It works as a 
photoreceptor pigment protein in retinal rod cells where it senses light via covalently bound 11-
cis-retinal that in the dark acts as a potent inverse agonist and suppresses the activity of the 
receptor (Li et al., 2004; Okada et al., 2004; Palczewski et al., 2000) (Figure 1.2b). Upon the 
absorption of light, the inverse agonist 11-cis-retinal isomerizes to the full agonist all-trans-
retinal which in turn activates the receptor.  The two highly conserved E/DRY and NPXXY 
motifs (Mirzadegan et al., 2003) are part of functional microdomains that constrain the 7TM 
helix bundle in this compact inactive conformation. In rhodopsin, Arg135 of the E/DRY motif on 
TM3 plays a key role in tethering TM3 to TM6. It forms a hydrogen bonding network with 
Glu134 on TM3 and Glu247 on TM6; in rhodopsin the network also includes Thr251 (Figure 
1.2b). This TM3-TM6 ionic lock revolving around Arg135 is also proposed for other class A 
GPCRs (Ballesteros et al., 2001; Dror et al., 2009). The NPXXY motif on TM7-H8 constrains 
both TM7 with TM1 and TM2 and also TM7 with H8. The latter is enabled by an electrostatic 
interaction between the aromatic side chains of Tyr306 on TM7 and Phe313 on H8. Asn302 at 
the N-terminal part of the NPXXY motif and the two residues Ala299 and Ser298 in the 
preceding helix turn are involved in a hydrogen bonding network with Asn55 on TM1 and 
Asp83 on TM2 and form the TM1-TM2-TM7 network (Figure 1.2b). TM6 is interrupted due to a 
proline kink induced by Pro267, which is part of the conserved CWXXP motif, which is the 
basis of the rotamer toggle switch hypothesis (Shi et al., 2002). In GPCR activation, the rotamer 
states of Trp265 and Phe269 are predicted to change at the same time during receptor activation, 
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thus providing a link between the CWXXP motif and motion of the cytoplasmic part of TM6 
(Shi et al., 2002). In the case of rhodopsin, the phenyl side chain of Phe269 is missing, but the β-
ionone ring of the inverse agonist 11-cis-retinal is in direct contact with Trp265. It is assumed 
that this β-ionone ring of retinal, together with Ala269, plays the role of the missing Phe269 
(Crocker et al., 2006).  
Upon the absorption of light, the inverse agonist 11-cis-retinal isomerizes to the full agonist, all-
trans-retinal, which in turn activates the receptor. The crystal structure of the active ligand-free 
opsin (Park et al., 2008) alone and in complex with a short G protein peptide fragment (Scheerer 
et al., 2008b), were solved at 2.9 Å and 3.2 Å, respectively, in 2008. In Figure 1.5 (Hofmann et 
al., 2009), the structures of rhodopsin, opsin and opsin in complex with a Gα-derived carboxyl-
terminal peptide directly show that inactive and active GPCR conformations differ at their 
cytoplasmic side (Park et al., 2008; Scheerer et al., 2008b). The cytoplasmic part of TM6 is tilted 
outwards from the helix bundle by 6-7 Å. TM5 is extended by 1.5-2.5 helix turns and moves 2-3 
Å towards TM6. This helix rearrangement results in the formation of an opening/deep crevice at 
the cytoplasmic side of the receptor, which contains the conserved Arg135 of the E/DRY motif 
that is involved in the TM3-TM6 ionic lock (Park et al., 2008; Scheerer et al., 2008b). In the 
active opsin conformation (Figure 1.5b), Tyr223 forms a hydrogen bond to Arg135 and replaces 
Glu134, thereby stabilizing the cytoplasmic TM3-TM5 interface. Glu247, which loses its contact 
with Arg135, now forms a salt bridge with Lys231. These changes in the TM3-TM6 ionic lock 
happen in parallel with changes in the TM7-H8 constraint of the NPXXY motif. Tyr306 is 
released from Phe313 and rotated into the helix bundle shown below Arg135 to keep TM6 in the 
outward position. The crevice that is formed in the opsin receptor allows the binding of the Gα 
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carboxyl terminus (Figure 1.5c). Two backbone carbonyl oxygens of the Gα-derived peptide 
form a hydrogen bonding network to Arg135 and Gln312, respectively (Figure 1.5c). 
 
Figure 1.5 Crystal structures of inactive rhodopsin and active opsin conformations. 
Cytoplasmic (top row) and lateral (bottom row) views of (a) inactive rhodopsin ground state 
(shown in green, PDB accession 1U19) and (b) ligand-free opsin (shown in orange, PDB 
accession 3CAP). Resides of the TM3-TM6 ionic lock (Glu134, Arg135, Glu247) and the TM7-
H8 microdomain (Tyr306, Phe313) are shown as stick models. Side chain movements upon 
receptor activation are indicated by black arrows, whereas helix movement is indicated by a 
yellow arrow. (c) Lateral view and close-up of the cytoplasmic domain of opsin in complex with 
a C-terminal peptide derive from the transducsin Gα-subunit. The peptide binds into the 
cytoplasmic crevice of opsin opened by movement of TM5 and TM6. (modified from (Hofmann 
et al., 2009)). 
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The only crystal structure of an active GPCR/G-protein complex is that of the agonist-occupied 
monomeric β2AR with a nucleotide-free Gs heterotrimer (Figure 1.6) (Rasmussen et al., 2011). 
The β2AR has long been a model system for GPCR signaling and the cooperative interactions 
between the receptor and Gs observed in ligand binding assays were the basis and foundation of 
the receptor ternary complex model of GPCR activation (De Lean et al., 1980; Ross et al., 1977). 
Figure 1.6 compares the structures of the agonist-bound receptor in the β2AR-Gs complex 
(Rasmussen et al., 2011) and the inactive carazolol-bound β2AR (Rosenbaum et al., 2007). The 
largest difference between the inactive and active structures is a 14 Å outward movement of 
TM6 when measured at the Cα carbon of Glu268. There is also a smaller outward movement and 
extension of the cytoplasmic end of the TM5 helix by 7 residues. Another notable difference is 
the second IC loop, which forms an extended loop in the inactive β2AR structure and an α-helix 
in the β2AR-Gs complex.  
 
Figure 1.6 Comparison of active and inactive β2-adrenergic receptor structures. Side and 
cytoplasmic views of the β2-adrenergic-Gs structure (green) compared to the inactive carazolol-
bound β2-adrenergic receptor structure (blue). Significant structural changes are seen for the 
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intracellular domains of TM5 and TM6. TM5 is extended by two helical turns whereas TM6 is 
moved outward by 14 Å as measured at the a-carbons of Glu268 (yellow arrow) in the two 
structures. (modified from (Rasmussen et al., 2011)). 
 
The principal interactions between the β2AR and Gs involve the amino- and carboxyl-terminal 
α-helices of the Gs. The β2AR is stabilized by extensive interactions with GαsRas. The α5-helix 
of Gαs docks into a cavity formed on the intracellular side of the receptor by the opening of TM 
helices 5 and 6. Within the TM core, the interactions are primarily non-polar. An exception 
involves packing of Tyr391 of the α5-helix against Arg131 of the conserved E/DRY sequence in 
TM3. Arg131 also packs against Tyr326 of the conserved NPXXY sequence in TM7. As α5-
helix exits the receptor it forms a network of polar interactions with TM5 and TM3. Receptor 
residues Thr68 and Asp130 interact with IC2 of the β2AR via Tyr141, positioning the helix so 
that Phe139 of the receptor docks into a hydrophobic pocket on the G protein surface, thereby 
structurally linking receptor-G protein interactions with the highly conserved E/DRY motif of 
the β2AR (Rasmussen et al., 2011). 
The structural characterization of GPCRs has been an ongoing challenge because of their highly 
hydrophobic transmembrane domains, their large highly flexible IC and EC domains (including 
the amino and carboxyl termini), their low natural abundance, and their poor structural stability 
in native tissues. Apart from rhodopsin, structures of active GPCRs are obtained from heavily 
modified proteins with truncated termini and loops, fusion domains and co-crystallized 
antibodies (Maeda et al., 2014). Further structures from additional receptors with minimal 
modifications and in complex with other types of G proteins, kinases, and arrestins are therefore 
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needed for a more comprehensive understanding of the molecular mechanisms of GPCR 
signaling. 
1.1.5 GPCRs in drug discovery  
The medicinal importance of GPCRs can be partially appreciated by considering their location 
and function within the cell. The physical location of GPCRs spanning the cell's plasma 
membrane connecting extra- and intracellular environments, provides a direct mechanism for the 
transduction of extracellular messages into intracellular responses. Emerging knowledge of 
GPCR structural data has provided critical information on the molecular nature of drug 
interaction with GPCRs, and also provides approaches that allow for crystallization of other 
GPCRs, revealing a more rational method for drug development. This structural picture provides 
information on the physical properties of the ligand binding site(s) and helps to design 
pharmacophore models of the ligand when docked. This lays the foundation for screening 
structural families of molecules with predictable chemical characteristics as well as optimal 
functional properties to modulate the molecular target (reviewed in (Eglen and Reisine, 2011)). 
Common biological actions attributed to GPCRs include the following: modulation of neuronal 
firing, regulation of ion transport across the plasma membrane and within intracellular 
organelles, modulation of homeostasis, control of cell division/proliferation, and modification of 
cell morphology. When any of these fundamental processes go awry, the results can lead to acute 
or chronic human disease, a partial listing of which includes cardiovascular disease (β1-
adrenergic receptor) (Drake et al., 2006), asthma (β2-adrenergic receptor) (Kawakami et al., 
2004), and strokes and cerebral hypoperfusion (A2a-adenosine receptor) (Chen et al., 2007; 
Duan et al., 2009). Other disease states directly linked to mutations in GPCRs include retinitis 
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pigmentosa (rhodopsin), female infertility (follicle-stimulating hormone receptor), nephrogenic 
diabetes insipidus (vasopressin receptor), familial exudative vitreoretinopathy (frizzled 
receptors), and dominant and recessive obesity (melanocortin receptors) (reviewed in (Insel et 
al., 2007)).  
Due to this critical role that GPCRs play in cell-cell communication and as causal agents in 
disease, they are a major target for the development of numerous drugs with an estimated 30 to 
50% of marketed drugs acting directly on GPCRs or through GPCR-associated mechanisms 
(Flower, 1999; Robas et al., 2003). As of 2008, 5 of the top 15 generic drugs and 7 (Milligan, 
2009) of the top 15 prescription drugs targeted GPCRs (McGrath et al., 2010). Many of the top 
brand name prescription drugs that target GPCRs include Claritin® (allergies), Prozac®  
(depression), Vasotec® (hypertension), and Ventolin® (bronchospasm). 
1.1.6 Allosteric modulators of GPCRs 
Allosteric modulators are compounds that bind to an allosteric site that is topographically distinct 
from the orthosteric site. There are three types of allosteric modulators (Figure 1.7). Positive 
allosteric modulators (PAMs) are allosteric ligands that bind to a site topographically distinct 
from the orthosteric site and enhance the affinity (cooperativity factor-α) and/or efficacy 
(modulation factor-β) of the orthosteric agonist. Negative allosteric modulators (NAMs) are 
allosteric ligands that decrease the affinity (cooperativity factor-α) and/or efficacy (modulation 
factor-β) of an orthosteric compound. Allosteric ligands that have no effect on the affinity and/or 
efficacy mediated by the orthosteric compounds are termed neutral or silent allosteric modulators 
(SAMs). The cooperativity factor-α is a value that quantifies the magnitude by which the affinity 
of one ligand is changed by the other ligand when both are bound to the receptor simultaneously 
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to form a ternary complex. If α is greater than 1.0, the modulator increases orthosteric ligand 
binding (PAM). If α is less than 1.0, the modulator reduces orthosteric ligand binding affinity 
(NAM). When α is 1.0, the modulator does not affect the binding of the orthosteric ligand (SAM) 
(reviewed in (Christopoulos and Kenakin, 2002)). 
 Allosteric modulators have several advantages over traditional orthosteric ligands. For example, 
they can inhibit or potentiate orthosteric ligand binding affinity and/or modulate their signaling 
efficacy, whereas the orthosteric ligands only bind and act competitively. In addition, allosteric 
modulators can be designed to achieve high selectivity and pharmacokinetic properties (Conn et 
al., 2009a; Gao and Jacobson, 2006; Kenakin and Miller, 2010). Because the orthosteric binding 
site is conserved across most subtypes of a given GPCR family, selectivity using orthosteric 
ligands for a particular receptor subtype within one family is hard to achieve. On the other hand, 
selective allosteric modulators can be developed successfully by targeting the less conserved 
allosteric sites. For example, several novel selective allosteric potentiators for specific 
muscarinic acetylcholine receptor (mAChR) subtypes have been identified. For instance, TBPB 
and 77-LH-28-1 have been reported as highly selective agonists of M1 relative to other mAChR 
subtypes. Both of these compounds are systemically active and are proving to be useful for in 
vivo studies of M1 activation. TBPB selectively activates M1 in cell lines and has no agonist 
activity at any other mAChR subtypes, while 77-LH-28-1 is also highly selective for M1 relative 
to other mAChR subtypes but does have weak agonist activity at M3 (reviewed in (Conn et al., 
2009b)).  
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Figure 1.7 Effect of allosteric modulators on orthosteric ligands. Orthosteric agonists bind to 
the GPCR, which induces a conformational change that results in the activation of downstream 
signaling. Positive allosteric modulators (PAMs) are allosteric ligands that bind to a 
topographically distinct site to the orthosteric agonist and enhance the affinity (cooperativity 
factor-α) and/or efficacy (modulation factor-β) of the orthosteric agonist. Negative allosteric 
modulators (NAMs) are allosteric ligands that decrease the affinity (cooperativity factor-α) 
and/or efficacy (modulation factor-β) of the orthosteric agonist. Allosteric ligands that have no 
effect on the affinity and/or efficacy mediated by the orthosteric agonist are termed neutral 
allosteric ligands. The red arrows denote the allosteric interaction of the modulator with the 
orthosteric ligand, and the black arrows denote the allosteric interaction between the ligand 
binding sites and the effector binding site within the GPCR, resulting in downstream activation 
of signaling pathways (this is known as orthosteric agonism). (modified from (Wootten et al., 
2013)). 
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Another advantage is that allosteric modulators with limited positive or negative cooperativity 
would impose a ‗ceiling‘ on the magnitude of their allosteric effect. This property allows for a 
high degree of titratability of the pharmacological effect, which means that large doses of 
allosteric modulators can be administered with a lower propensity towards target-based toxicity 
than orthosteric agonists or antagonists. Moreover, limited cooperativity modulators introduce a 
new level of pharmacological responsiveness, whereby they can allow for a subtle re-setting of 
endogenous ligand activity. 
Furthermore, there is growing evidence showing that some allosteric modulators mediate 
receptor activation in their own right in addition to  modulating orthosteric ligand pharmacology 
(Knudsen et al., 2007; Zhang et al., 2005). This is known as allosteric agonism. For instance, 
McN-A-343 and AC-42 inhibited the binding of N-methylscopolamine to rat M2 and human M1 
mAChRs and played a partial agonist role for the receptors in the absence of orthosteric ligand 
(Langmead et al., 2006; Valant et al., 2008).  
Cinacalcet (Sensipar™) was the first allosteric GPCR modulator to gain FDA marketing 
approval (Jensen and Brauner-Osborne, 2007). Cinacalcet is a PAM of the Ca
++
 sensing receptor 
(CaR), a member of the type C family of GPCRs. Ca
++
 binds to the amino-terminus of CaR and a 
critical role of this receptor is to regulate circulating Ca
++
 levels to maintain control of 
parathyroid hormone (PTH) release and levels. Cinacalcet is a small molecule that binds to the 
transmembrane region of the receptor to alter conformation to enhance affinity for Ca
++
. The 
compound is therapeutically useful because in kidney disease, hypocalcinemia results in 
excessive PTH which causes bone fractures, pain and cardiovascular disorders. Cinacalcet 
increases sensitivity of CaR to Ca
++
 to suppress excess PTH release despite hypocalcaemia. 
Thus, Cinacalcet is an allosteric modulator that binds to the transmembrane regions and the 
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hydrophobic pocket of the CaR distal to the orthosteric binding domains in the N-terminus 
(Jensen and Brauner-Osborne, 2007).  
The approval of Cinacalcet was followed by marketing approval from the FDA for Maraviroc 
(Celzentry™) for treating HIV disease (reviewed in (Wood and Armour, 2005)). Maraviroc is an 
allosteric inhibitor or NAM of the CCR5 receptor. Maraviroc was shown to be an allosteric 
inhibitor by its ability to differentially affect the binding of different chemokines to the receptors. 
Its therapeutic mechanism of action is believed to involve preventing HIV entry into immune 
cells via the CCR5 receptor.  
1.1.7 Functional selectivity of GPCRs 
Recent pharmacological studies have shown that GPCRs adopt multiple conformations that can 
lead to different downstream signaling events. These different conformations are dependent on 
the type of ligand bound, causing ligand-biased signal transduction (Kenakin, 2007) and 
functional selectivity (Kenakin and Miller, 2010). This concept is based on the idea that GPCRs 
can couple to different G proteins, activate selective pathways (either G protein or β-arrestin) and 
ultimately activate multiple downstream signaling pathways (Figure 1.8), and selectively engage 
different kinases that can direct phosphorylation at different sites. Evidence has emerged that in 
addition to β-arrestin‘s role in cellular internalization, it can also act as a signaling protein, 
recruiting its own subset of signaling molecules (Violin and Lefkowitz, 2007). Thus GPCR 
function can be mediated via G protein-dependent mechanisms or through G protein-independent 
mechanisms such as those involving β-arrestin (Violin and Lefkowitz, 2007). Biased agonism 
thus provides pathway-selective drugs that can have the potential to separate therapeutic drug 
effects from their unwanted negative side effects. 
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One of the early examples of biased agonism was that of serotonin type 2A and 2C receptors (5-
HT2A/2C) (Berg and Clarke, 2009; Berg et al., 1998). They observed that different agonists could 
preferentially activate either phospholipase C-mediated inositol phosphate (IP) accumulation or 
phospholipase A2-mediated arachidonic acid (AA) release. This was determined by measuring 
the maximal response (Emax) of each agonist and was found to be different for the two pathways 
measured, whereas the relative potency remained unchanged. Consequently, they found that the 
agonists lysergic acid diethylamide (LSD) and bufotenin favored AA release while 3-
trifluoromethlyphenylpiperazine (TFMPP) and quipazine preferentially activated the IP pathway 
(Berg and Clarke, 2009; Berg et al., 1998).  
An increasing number of studies have also  identified ―β-arrestin-biased‖ synthetic ligands for 
the Angiotensin 1A receptor (Wei et al., 2003) and the β2AR (Drake et al., 2008; Wisler et al., 
2007), and the parathyroid hormone (PTH) receptor (Gesty-Palmer et al., 2006). As an example, 
the PTH receptor plays an important role in regulating the continuous process of bone formation 
and resorption, with recombinant human PTH 1-34 (Forteo®) currently approved for the 
treatment of osteoporosis. Previous studies have shown that β-arrestin 2 plays a role in regulating 
PTH-receptor-mediated signaling (Castro et al., 2002; Ferrari et al., 1999; Ferrari and Bisello, 
2001; Sneddon and Friedman, 2007; Vilardaga et al., 2001; Vilardaga et al., 2002), with effects 
on bone formation and resorption (Bouxsein et al., 2005; Ferrari et al., 2005), as well as related 
gene expression (Bianchi and Ferrari, 2009; Pierroz et al., 2009). Furthermore, studies have 
shown that the PTH receptor can stimulate both G protein- and β-arrestin-mediated signals, and 
that these signals can be selectively engaged by both G protein- and β-arrestin-biased ligands 
(Bisello et al., 2002; Gesty-Palmer et al., 2006). Most recently, it has been shown that the β-
arrestin-biased ligand (D-Trp12,Tyr34)-PTH(7–34), which simultaneously stimulates receptor-
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mediated β-arrestin signaling and blocks G protein signaling, promotes anabolic bone formation 
in the absence of bone resorption, and that this activity is abolished in β-arrestin 2 knockout mice 
(Gesty-Palmer et al., 2009). These studies have thus identified a novel β-arrestin-mediated 
pathway and a unique β-arrestin-biased ligand that positively affects anabolic bone formation. 
Targeting of this newly identified mechanism of action could represent a novel therapeutic 
strategy for the treatment of osteoporosis. Such potential has also been highlighted for other 
GPCRs, notably β2AR for the treatment of heart failure (Galandrin and Bouvier, 2006; Wisler et 
al., 2007) and for GPR109A (the target for niacin) for the treatment of dyslipidemia (Richman et 
al., 2007; Walters et al., 2009). Even more recently, evidence has emerged for the functional 
selectivity of certain allosteric modulators. For example, 1-(4-ethoxyphenyl)-5-methoxy-2-
methylindole-3-carboxylic acid, an allosteric modulator of the chemoattractant receptor-
homologous molecule on T helper 2 cells (CRTH2), is inactive against prostaglandin D2-induced 
G-protein-linked pathways but is a potent antagonist of G-protein-independent, β-arrestin 
coupling to the same receptor (Mathiesen et al., 2005). In another recent study, performed on 
native metabotropic glutamate receptor 5 (mGluR5) expressed in cultured rat cortical astrocytes, 
the allosteric modulator, CPPHA, had different effects on calcium mobilization and ERK1/2 
phosphorylation, even though both pathways were linked to the endogenous mGluR5 receptor 
(Zhang et al., 2005). The ability to modulate selected signaling pathways that are associated with 
a given GPCR introduces an additional opportunity for fine-tuning intracellular signaling with 
allosteric modulators. Many more examples of β-arrestin biased ligands that possess therapeutic 
potential at GPCRs have been described and reviewed (Whalen et al., 2011).  
The idea that different kinases can be selectively engaged to direct phosphorylation at different 
sites based on the ligand bound or selectively activate certain signaling pathways is an avenue of 
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receptor regulation about which little is known. This notion has been supported by recent studies 
on the β2AR and CXC4R receptor where receptor phosphorylation by different members of the 
GRK family can mediate different signaling outcomes (Busillo et al., 2010; Violin et al., 2006). 
Furthermore, studies on the M3-muscarinic receptor have demonstrated that phosphorylation of 
this receptor subtype by protein kinase CK1α regulates receptor signaling to the phospholipase C 
and ERK pathways (Budd et al., 2001; Luo et al., 2008), whereas phosphorylation mediated by 
protein kinase CK2 has no impact on ERK/phospholipase C but rather regulates the coupling of 
the receptor to the JNK pathway (Torrecilla et al., 2007). These studies suggest that one 
mechanism by which receptors might direct signaling to one pathway (i.e. JNK) in preference to 
another (i.e. ERK) might be via specific phosphorylation profiles of the receptor. By adopting a 
specific ―phosphorylation signature,‖ a receptor could favor coupling to a particular pathway. In 
this way, the phosphorylation profile of a receptor could act as a ―bar code‖ that encodes a 
particular signaling outcome (Kim et al., 2005; Ren et al., 2005; Tobin et al., 2008; Zidar et al., 
2009). This suggests that one mechanism underlying functional selectivity may be centered on 
the capacity of ligands to promote receptor phosphorylation at specific sites (Butcher et al., 
2011) and consequently recruit either G proteins or arrestin to mediate their signaling.      
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Figure 1.8 A generalized model of the signaling of a GPCR. GPCRs can activate different G 
protein families (i.e. Gi/o, Gs, and Gq). Activated G proteins result in the inhibition or activation 
of an array of effector pathways including adenylyl cyclase (AC), mitogen-activated protein 
kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) pathways. Subsequent activation of 
the MAPK and PI3K pathways results in the phosphorylation of extracellular signal-regulated 
kinases (ERKs) and protein kinase B (PKB, also known as Akt), respectively. G protein 
independent signaling by arrestins is also possible. (modified from (Gao and Jacobson, 2013)). 
 
1.1.8 GPCR biosynthesis and cell surface trafficking 
The biosynthesis of GPCRs begins at the endoplasmic reticulum (ER), where they are 
synthesized, folded and assembled. Properly folded receptors are transported from the ER 
through the Golgi complex to the plasma membrane by passing a quality control process and 
undergoing post-translational modifications (e.g. glycosylation, methylation, and 
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palmitoylation). The first step in ER assembly is ER-membrane insertion. Some GPCRs possess 
cleavable signal peptides in their amino termini and these sequences help target the receptors for 
insertion into the ER membrane. However, the majority (about 90%) of GPCRs, especially those 
of the rhodopsin-like family of receptors, do not contain a signal peptide (Andersson et al., 2003; 
Wallin and von Heijne, 1995). For such receptors, the TM domains are believed to function as a 
reverse signal anchor sequence to initiate the protein‘s assembly process in the ER membrane 
(Friedlander and Blobel, 1985). Signal sequences have been found present in GPCR subfamilies 
that have large amino-termini, i.e.  receptors with signal peptide sequences likely have an amino 
terminus that contributes to ligand binding, and which therefore, comprises a stable fold that 
would otherwise be an impediment to the translocation of the receptor (Schulein et al., 2012). 
Membrane translocation of the extracellular amino terminus across the ER membrane can take 
place either co- or post-translationally, as has been suggested for opsin (Kanner et al., 2002), 
possibly in a C to N-terminal direction (Nilsson et al., 2000). Several factors including the 
hydrophobicity and the length of the amino terminus play a role in its membrane translocation 
efficiency. Statistical analyses have shown that GPCRs without a signal peptide tend to have 
shorter amino termini (40 amino acids on average) than GPCRs with signal sequences (200 
amino acids) (Wallin and von Heijne, 1995). There are, however, exceptions to this rule. For 
example, the human cannabinoid receptor 1 (CB1) has an amino terminus of 116 amino acids 
and lacks a cleavable signal peptide. This receptor shows very poor ER translocation and it was 
shown that introducing a signal sequence or shortening its amino terminus greatly improved its 
stability and cell surface expression (Andersson et al., 2003).  
Evidence has emerged that several GPCRs can exist as dimers (hetero- or homo-dimers) or 
higher ordered oligomers (Breitwieser, 2004; Franco et al., 2003; Milligan et al., 2003) and that 
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this dimerization plays a role in the expression and function of the GPCRs. Interestingly, the 
dimerization of many GPCRs was found to happen as early as the ER and that this dimerization 
was key for cell surface expression (Herrick-Davis et al., 2006; Karpa et al., 2000; Kaykas et al., 
2004; Margeta-Mitrovic et al., 2000). For example, the homodimerization of the β2AR was 
found to be a prerequisite for the targeting of the receptor to the cell surface (Salahpour et al., 
2004). A possible explanation for this prerequisite requirement with some GPCRs was that the 
formation of dimers masks an ER retention signal that exists within the carboxyl terminus of the 
receptor and this would then allow trafficking of the receptor to the cell surface (Margeta-
Mitrovic et al., 2000). 
The appropriate localization of a receptor to the cell surface is essential to the function of a 
GPCR because it makes the receptor accessible to requisite ligands and signal transduction 
machinery. This targeted cell-surface is coordinated by many regulatory factors (reviewed in 
(Wu, 2012)). First, GPCR export to the cell surface is regulated by multiple proteins, such as 
receptor activity modifying proteins (RAMPs), ER chaperones, and accessory proteins. These 
proteins may stabilize receptor conformation, facilitate receptor maturation, and promote 
receptor delivery to the plasma membrane. Second, recent studies have indicated that the exit of 
GPCRs from the ER may be directed by specific motifs embedded within the receptors. Third, 
post-translational modifications, such as N-linked glycosylation, have long been proven to be 
involved in the delivery of some GPCRs to the cell surface. Fourth, GPCR cell-surface targeting 
depends on the microtubule networks and GPCRs may directly interact with tubulin to control 
their cell-surface movement. The functional importance of GPCR localization is emphasized by 
diseases that ensue from receptor mislocalization such as retinitis pigmentosa (RP) (Humphries 
et al., 1992), where there is progressive photoreceptor degeneration and eventual retinal 
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dysfunction due to intracellular accumulation of mutant rhodopsin (reviewed in (Dejneka and 
Bennett, 2001)), and X-linked nephrogenic diabetes insipidus (NDI), which is caused by an 
improper response of the kidney to the antidiuretic hormone arginine vasopressin. This leads to a 
decrease in the ability of the kidney to concentrate urine by removing free water (Oksche and 
Rosenthal, 1998) and results from intracellular accumulation of the V2 vasopressin receptor. 
1.1.9 GPCR lifecycle 
As soon as the GPCR is at the cell surface, it can be activated by ligands that include light-
sensitive compounds, odors, neurotransmitters, ions, chemokines, nucleotides, hormones, and 
growth factors. The classical view of the activation of GPCRs is that upon ligand binding, a 
conformational change is induced in the structure of the GPCR which leads to the activation of 
their respective heterotrimeric guanine-nucleotide binding protein (G protein) by enabling a GTP 
for GDP exchange on the α-subunit of the coupled G protein. These activated G proteins can, in 
turn, stimulate various downstream signaling pathways or effector molecules such as adenlyate 
cyclase before the intrinsic GTPase activity of the α-subunit hydrolyzes the bound GTP to GDP 
and inactivates the G protein. Upon prolonged exposure to ligand, most GPCRs show a rapid 
loss of responsiveness (desensitization). Their signaling is terminated by phosphorylation which 
typically occurs on serine and threonine residues within intracellular domains, typically IC3 or 
the carboxyl terminus. This phosphorylation plays an important role in receptor regulation and 
function. As was first described for rhodopsin, phosphorylation is a crucial mechanism in turning 
off receptor signaling. The phosphorylation that leads to receptor uncoupling from G protein is 
usually catalyzed by members of the GPCR kinase (GRK) family. This phosphorylation modifies 
the intracellular face of the receptor and leads to arrestin recruitment and consequent receptor 
desensitization and internalization by sterically blocking the receptors from coupling to G 
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proteins (Lefkowitz, 1998). Phosphorylation of GPCRs with protein kinase C (PKC) and protein 
kinase A (PKA) has also been reported (Garcia et al., 1998; Lefkowitz et al., 2002; Smith, 1994; 
Smith and Goldin, 1992). 
Fundamental to the process of receptor internalization are 2 families of proteins, the GRKs and 
the β-arrestins, both of which were initially identified in studies of GPCR desensitization and 
which are involved in removal of ligand-activated GPCRs from the plasma membrane. The GRK 
family of kinases is composed of seven members that share significant amino acid and structural 
homology (reviewed in (Ferguson, 2001; Penela et al., 2006)). GRK2 and GRK3 reside in the 
cytosol in the absence of agonist and translocate to the membrane following GPCR stimulation. 
GRK2/3 translocation and membrane localization are mediated in part by their binding to 
heterotrimeric G protein βγ subunits (Pitcher et al., 1992). GRK5 and GRK6, on the other hand, 
are constitutively localized to the plasma membrane. Whereas GRK6 palmitoylation is essential 
for membrane association (Stoffel et al., 1994), localization of GRK5 to the plasma membrane is 
believed to be attributable to an electrostatic interaction between the highly basic carboxyl 
terminus of GRK5 and phospholipids at the plasma membrane (Kunapuli et al., 1994; Premont et 
al., 1994). The β-arrestin proteins exist in 2 isoforms in humans, namely β-arrestin 1 and β-
arrestin 2, both of which show ubiquitous tissue distribution. In addition to their well-described 
role in limiting receptor-G protein interaction, the β-arrestin proteins also serve to both recruit 
and physically bridge the receptor to the endocytic machinery. In addition, the β-arrestin proteins 
themselves are able to interact directly with the essential components of the clathrin-coated 
vesicle (CCV) coat machinery, namely the heterotetrameric AP-2 complex (Laporte et al., 1999), 
as well as clathrin (Goodman et al., 1996), and these interactions are critical both for recruitment 
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of the receptor into clathrin-coated pits as well as for receptor internalization (Doherty and 
McMahon, 2009; Wolfe and Trejo, 2007).  
Internalized receptors can then either traffic to lysosomes for degradation or follow a recycling 
route back up to the cell surface (resensitization; Figure 1.9) (Claing et al., 2002; Gainetdinov et 
al., 2004). Recent work has established that agonist stimulation of the β2-AR promotes direct 
association of the extreme carboxyl terminus of the receptor with the first PDZ domain within 
Na
+
/H
+
-exchanger regulatory factor-1 (NHERF1) (Hall et al., 1998b).  
 
Figure 1.9. Model of the GPCR life cycle. GPCRs are synthesized, folded, and assembled at the 
endoplasmic reticulum (ER). Properly folded receptors are transported from the ER through the 
Golgi complex to the plasma membrane. Upon agonist stimulation, GPCRs bind and activate a G 
protein, which in turn dissociates to impact downstream signaling pathways. Prolonged exposure 
to agonist results in desensitization and internalization of the receptor by phosphorylation and 
arrestin recruitment. (modified from (Stadel et al., 2011)). 
 
 31 
 
Similar associations have been shown to occur for other GPCRs containing sequences that 
conform to the consensus motif D-S/T-X-L, including the purinergic P2Y1 receptor and the 
CFTR (Hall et al., 1998a), whereas other GPCRs such as the parathyroid hormone receptor have 
been shown to interact with both PDZ domains of both NHERF1 and NHERF2. NHERF was 
found to be of critical importance for proper intracellular sorting of the β2-AR (Figure 1.10b). In 
addition to its ability to bind the extreme carboxyl terminus of the β2-AR via its PDZ domain, 
NHERF is able via its ezrin–radixin–moesin (ERM) domain to bind to the actin cytoskeleton 
through association with ERM proteins. Mutations that were generated to disrupt the interaction 
of NHERF with either the β2-AR carboxyl terminus or with ERM proteins lead to significant 
agonist-induced lysosomal degradation of the β2-AR following endocytosis, rather than 
recycling (Figure 1.10b; (Cao et al., 1999)). Another protein found to be critical for receptor 
endocytosis is the N-Ethylmaleimide-Sensitive Fusion Protein (NSF), an ATPase essential for 
many intracellular transport functions (McDonald et al., 1999). Overexpression of NSF in 
HEK293 cells led to enhanced agonist-induced β2-AR internalization and could rescue the 
effects of a β-arrestin1 mutant (S412D) previously shown to function as a dominant negative for 
β2-AR internalization. β2-AR is able, via its extreme carboxyl terminus, to bind directly to NSF 
(Cong et al., 2001). The β2-AR/NSF interaction is agonist dependent and requisite for efficient 
agonist-mediated β2-AR internalization. Importantly, whereas wild-type β2-ARs recycle to the 
cell surface following exposure to the antagonist propranolol, β2-ARs containing mutations in 
their distal carboxyl termini remain sequestered intracellularly, demonstrating the importance of 
the β2-AR/NSF interaction for proper β2-AR recycling. Thus, although it is clear that proteins 
that bind to the extreme carboxyl termini of GPCRs, such as NHERF and NSF, serve to regulate 
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the intracellular sorting of the receptors such as the β2-AR, the extent to which the trafficking of 
other GPCRs is modulated by these or similar unidentified proteins remains to be elucidated. 
Following internalization, GPCRs may be either recycled to the plasma membrane or undergo 
sorting to the endosomal/lysosomal pathway for degradation. Sorting nexin 1 (SNX1) has been 
demonstrated to interact with protease activated receptor 1 (PAR1) in an agonist-dependent 
manner (Wang et al., 2002). Overexpression of a SNX1 carboxyl terminal–deletion mutant did 
not significantly impair agonist-induced PAR1 internalization and accumulation in early 
endosomes but was able to impede endosome to lysosome sorting of PAR1 and thus markedly 
inhibit PAR1 degradation (Wang et al., 2002). Additional studies, in which depletion of 
endogenous SNX1 in HeLa cells via small interfering RNA technology markedly impaired 
agonist-induced PAR1 degradation, further supporting the suggestion that SNX1 plays a role in 
the intracellular trafficking of PAR1 from endosomes to lysosomes (Gullapalli et al., 2006). 
Whether SNX1 or other SNX proteins can mediate the endosomal to lysosomal sorting of 
GPCRs other than PAR1 remains to be determined but is certainly possible given the general 
conservation of trafficking themes shared across members of this large protein family. 
A second class of proteins shown to regulate the movement of GPCRs both during and 
subsequent to endocytosis are the Rab proteins, a family of Ras-like small GTP binding proteins. 
Importantly, different Rab GTPase family members selectively associate with specific 
intracellular structures including both recycling and sorting endosomes, where they mediate 
multiple steps of vesicular membrane trafficking including vesicle budding, docking, and fusion 
(reviewed in (Seachrist and Ferguson, 2003)). Rab5 has been found to play a role in GPCR 
trafficking events associated with GPCR internalization and/or early endosomal formation. 
Multiple additional Rab family members have been implicated in other GPCR-trafficking events, 
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including Rab4 and Rab11 in receptor recycling, and Rab7 in endosomal to lysosomal sorting 
(Dale et al., 2004). 
Another key cellular mediator in the GPCR postendocytic sorting process that was found to bind 
to the carboxyl-terminus of the dopamine receptor D2 (Bartlett et al., 2005), the CB1 receptor 
(Martini et al., 2007) and the δ-opioid receptor (Figure 1.10a; reviewed in (Whistler et al., 2002)) 
is the G-protein-coupled receptor-associated sorting protein (GASP1). For CB1, HEK293 cells 
overexpressing GASP1 displayed reduced lysosomal colocalization compared with cells 
expressing the CB1 receptor alone (Martini et al., 2007). This reduced lysosomal targeting led to 
the recycling and enhanced surface recovery of the receptor following treatment with inverse 
agonist, suggesting that overexpression of GASP1 promoted the redirection of internalized 
receptors to the recycling pathway. The opposite holds true for the δ-opioid receptor (Figure 
1.10a). 
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Figure 1.10 GPCR-interacting proteins can regulate the post-endocytic trafficking of 
GPCRs. Following agonist-induced receptor endocytosis, some GPCRs are targeted for 
proteolytic and/or lysosomal degradation, whereas other GPCRs rapidly recycle back to the 
plasma membrane. (a) The interaction between GPCR-associated sorting protein 1 (GASP1) and 
δ-type opioid receptor (δOPR) promotes the endocytic targeting of agonist-internalized δOPRs to 
lysosomes, where the receptors are degraded. However, in a distinct cellular compartment (or 
distinct cell type) that lacks GASP1, as shown on the left, δOPRs are rapidly recycled back to the 
plasma membrane. (b) By contrast, the interaction between the GPCR-interacting protein Na+–
H+ exchange regulatory factor 1 (NHERF1) and the β2-adrenergic receptor (β2AR) promotes the 
rapid recycling of receptors following agonist-promoted internalization. However, in a distinct 
cellular compartment (or distinct cell type) that lacks NHERF1, as shown on the left, β2ARs are 
preferentially targeted to lysosomes for degradation. (Ritter and Hall, 2009). 
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1.2 Cannabinoid receptors 
The identification of the cannabinoid receptors grew out of a desire to understand the 
psychoactive effects of Δ9-tetrahydrocannabinol (THC), the main psychoactive component of 
Cannabis sativa. To date, two cannabinoid receptors, CB1 and CB2, have been described with 
regard to their primary structure (Figure 1.11), ligand binding properties and signal transduction 
systems (Howlett et al., 2002; Pertwee et al., 1995). The existence of these receptors was 
confirmed when it was shown that cannabinoids decreased cAMP in neuroblastoma cell cultures, 
suggesting the activation of a Gi/o-coupled receptor (Howlett, 1985; Howlett and Fleming, 1984; 
Howlett et al., 1986). Immunohistochemical and radioligand binding methods were also used to 
characterize a receptor that was present in high concentrations in certain brain regions (Devane et 
al., 1988). The cloning of the cannabinoid receptor 1 (CB1) provided the final evidence for its 
existence in 1990 when it was cloned from a cDNA library obtained by sequencing rat cerebral 
cortex (Matsuda et al., 1990). The cloning of the cannabinoid receptor 2 (CB2) followed closely 
thereafter in 1993 and was cloned from the HL60 promyelocytic human leukaemic cell line 
(Munro et al., 1993).  
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Figure 1.11 Schematic representations of the human CB1 and CB2 receptors. Black circles 
represent amino acids common to the two receptors, and white circles different amino acids. 
(Shire et al., 1996) 
 
1.2.1 Tissue distribution of CB1 and CB2 
The physiological distribution of CB1 receptors has been characterized in both rat and human 
brains (Glass et al., 1997; Herkenham et al., 1991a; Herkenham et al., 1991b; Herkenham et al., 
1990b; Mailleux and Vanderhaeghen, 1992; Westlake et al., 1994). CB1 receptor expression was 
detected in regions influencing a number of key functions, including mood, motor coordination, 
autonomic function, memory, sensation and cognition. Electron microscopy studies 
demonstrated CB1 receptors predominantly on presynaptic terminals (Katona et al., 1999; 
Marsicano and Lutz, 1999; Tsou et al., 1999), but they were found also on postsynaptic 
structures and glia (Rodriguez et al., 2001). The presence of CB1 receptors in the hippocampus 
in high density is related to the disruptive effects of cannabinoids on memory and cognition 
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(Herkenham et al., 1991a; Herkenham et al., 1990b). Chronic exposure to THC or marijuana 
extracts were shown to permanently alter the structure and function of the hippocampus (Scallet, 
1991) which is involved in learning and memory processes in both rats and humans. The 
occurrence of CB1 receptors in the basal ganglia and the effects of cannabinoids in these 
structures imply that the endogenous cannabinoids are involved in the fine-tuning of motor 
control. Evidence of decreased CB1 receptor expression and binding has been shown in 
neurodegenerative diseases, such as Parkinson‘s and Huntington‘s (Glass et al., 1993; Richfield 
and Herkenham, 1994; Sanudo-Pena et al., 1998). 
There is also a high density of CB1 receptors in the rat cerebellum (Matsuda et al., 1993) and 
they may have a role in the ataxia, immobility, and catalepsy following acute THC 
administration (Navarro et al., 1998). In contrast, a relatively low density of CB1 receptors is 
found in the human cerebellum and is consistent with the more subtle effects observed in overall 
human motor functioning after marijuana use (Ameri, 1999; Herkenham et al., 1990a). 
The CB1 receptors are perhaps most known for their important role in the central and peripheral 
regulation of food intake, fat accumulation and lipid and glucose metabolism (Svizenska et al., 
2008). Alterations of these functions are associated with CB1 hyperactivity (Gelfand and 
Cannon, 2006) in both central nervous system (CNS) and peripheral tissues (adipocytes, skeletal 
muscle cells, liver, gastrointestinal tract). Stimulation of hypothalamic CB1 receptors interacts 
with neuropeptides regulating energetic homeostasis, food intake and lipogenesis in visceral 
tissues (Cota et al., 2003). Stimulation of CB1 receptors in the accumbens nucleus activates the 
dopaminergic reward pathway and thus the motivation to eat, as well as to smoke or intake drugs 
of abuse (Maldonado et al., 2006).  CB1 receptors are also highly expressed in the areas that are 
involved in pain modulation, including the periaqueductal gray (Tsou et al., 1997) and the dorsal 
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horn of the spinal cord (Farquhar-Smith et al., 2000). More recent evidence has emerged that the 
CB1 receptor is also expressed in a number of peripheral tissues, such as the cardiovascular and 
reproductive systems as well as the gastrointestinal tract (Figure 1.12; (Batkai et al., 2001; Croci 
et al., 1998; Pertwee, 1997; Pertwee, 2001)). 
Determination of the distribution of CB2 receptors has lagged considerably due to the lower 
abundance of CB2 receptors relative to CB1 as well as the difficulty in raising highly selective 
CB2 receptor antibodies (Mackie, 2008). Strong evidence exists of the distribution of CB2 
receptors in peripheral tissues, and particularly in immune tissues such as the spleen, tonsils, 
thymus, mast cells and blood cells (Berdyshev, 2000; Munro et al., 1993; Sugiura and Waku, 
2000; Wilson and Nicoll, 2001). The CB2 receptor was also recently found in the CNS, e.g., in 
rat microglial cells (Ashton et al., 2006) as well as neurons (Gong et al., 2006; Skaper et al., 
1996) under certain conditions (Figure 1.12). 
 
Figure 1.12 Tissue distribution of the human CB1 and CB2 receptors in the body. CB1 
receptors are highly expressed in the hippocampus, basal ganglia, cortex and cerebellum. They 
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are less expressed in the amygdala, hypothalamus, nucleus accumbens, thalamus, 
periapeduncular grey matter and the spinal cord, as well as in other brain areas, mainly in the 
telencephalon and diencephalum. CB1 receptors are also expressed in several peripheral organs. 
Thus, they are present in adipocytes, liver, lungs, smooth muscle, gastrointestinal tract, 
pancreatic ß -cells, vascular endothelium, reproductive organs, immune system, sensorial 
peripheral nerves and sympathetic nerves. The distribution of CB2 receptors is quite different 
and mainly restricted to the periphery in the immune system cells, such as macrophages, 
neutrophils, monocytes, B-lymphocytes, T-lymphocytes and microglial cells. Recently, CB2 
receptor expression has also been shown in skin nerve fibers and keratinocytes, bone cells such 
as osteoblasts, osteocytes and osteoclasts, liver and somatostatin secreting cells in the pancreas. 
The presence of CB2 receptors has also been demonstrated at the CNS, in astrocytes, microglial 
cells and brainstem neurons. (online at http://www.fundacion-canna.es/en/endocannabinoid-
system). 
 
1.2.2 The endocannabinoid system  
The endocannabinoid system is comprised of cannabinoid receptors, their endogenous ligands, 
i.e. endocannabinoids, and the enzymes required for their biosynthesis and degradation (Figure 
1.13; (Freund et al., 2003; Howlett et al., 2002; Mackie, 2006)). Endocannabinoids are so named 
because they were first identified to activate the same receptors that were activated by the main 
psychoactive component of cannabis. Endocannabinoids produced by the brain include 
arachidonoyl ethanolamide (anandamide), 2-arachidonoyl glycerol (2-AG), noladin ether, 
virodhamine, and N-arachidonoyl dopamine (NADA). Unlike many neuromodulators, 
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endocannabinoids are not synthesized in advance and stored in vesicles. Rather, their precursors 
exist in cell membranes and are synthesized and cleaved ―on demand‖ from cell membrane 
arachidonic acid derivatives by specific enzymes such as diacylglycerol lipase (DAGL). 
Depolarization of a postsynaptic neuronal membrane induces membrane-derived 
endocannabinoid production. Endocannabinoids are then capable of activating cannabinoid 
receptors on the membranes of presynaptic neurons resulting in a G protein-dependent reduction 
in neurotransmitter release into the presynaptic cleft. Intracellular endocannabinoid sequestration 
inactivates the cannabinoid receptors. Whether cannabinoid uptake is predominantly an active or 
passive process remains controversial. Hydrophobic endocannabinoids may passively internalize 
through the plasma membrane by means of simple diffusion. However, recent data suggests that 
both the 2-AG and anandamide internalization process is saturable and temperature dependent 
indicating the uptake may be protein-facilitated (reviewed in (Yates and Barker, 2009)). 
Endocannabinoids have a local effect and short half-life before being degraded by enzymes such 
as fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) (Alexander and 
Kendall, 2007; Basavarajappa, 2007; Okamoto et al., 2007; Simon and Cravatt, 2006). The 
concentration of 2-AG in the brain greatly exceeds anandamide levels by upwards of 150 times 
(Dinh et al., 2002). These two endocannabinoids are discussed in more detail in section 1.2.4.  
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Figure 1.13 Molecular basis of endocannabinoid neuromodulatory action. At the presynaptic 
nerve terminal, anandamide and 2-arachidonoylglycerol (2-AG) activate G-protein-coupled CB1 
receptors, modulating neuronal membrane permeability to Ca
2+
 and K
+
 ions and the activity of 
adenylate cyclase (AC), thereby affecting neurotransmitter release or action. Once released by 
the depolarization of neurons, the two compounds, due to their lipophilicity, might behave, like 
other arachidonic acid (AA) derivatives, as autocrine or paracrine signals by acting on the same 
or neighboring neurons or on astrocytes. In the hippocampus, inhibition of AC and subsequently 
cAMP-dependent protein kinase (PKA), can also lead to modulation of synaptic plasticity, for 
example, through increased tyrosine phosphorylation and subsequent activation of focal adhesion 
kinase+ (FAK+). Gs-mediated activation of AC was observed upon Gi/o inhibition with pertussis 
toxin, and concurrent stimulation of D2 and CB1 receptors in striatal slices leads to AC 
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stimulation instead of inhibition. In hippocampal slices, a direct potentiation of NMDA receptors 
by anandamide has also been observed. By acting on CB1 receptor-coupled K
+
 channels, 
anandamide might also directly hyperpolarize smooth muscle cells. Anandamide also affects 
intracellular AA and Ca
2+
 concentrations in astrocytes via pertussis toxin-sensitive mechanisms. 
Abbreviations: AA, arachidonic acid; FAK+, focal adhesion kinase+; PLA2, phospholipase A2; 
THC, Δ9(−)-tetrahydrocannabinol. (Di Marzo et al., 1998). 
 
1.2.3 Structural features of the cannabinoid receptors 
CB1 splice variants. Multiple splice variants of human CB1 are thought to exist in vivo. These 
splice variants vary in the length of their extracellular amino terminus. The first variant to be 
cloned was CB1a in 1995 and was found to lack the first 61 amino acids of the amino terminus 
of CB1 (Shire et al., 1995). The second splice variant to be identified was CB1b which was 
shown to have a deletion of 33 amino acids from the CB1 amino terminus (Ryberg et al., 2005). 
The splice variants CB1a and CB1b lacked an affinity or efficacy for the endogenous 
cannabinoids (Ryberg et al., 2005) and showed only minimal binding to anandamide and 2-
arachidonoylglycerol (Ryberg et al., 2005). The Kendall lab, however, showed that up to 89 
amino acids from the amino terminus of CB1 can be deleted without affecting receptor binding 
to the ligand CP55,940 (Andersson et al., 2003). 
Glycosylation. Glycosylation involves the addition of carbohydrate chains to target proteins. 
These added polysaccharide chains serve various functions including providing structural 
components to the cell wall and extracellular matrix, increasing protein stability at high 
temperatures, directing trafficking of the protein and proper folding and mediating cell signaling 
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(Lodish H, 2000). Within the amino terminus of CB1, there are 3 potential N-linked 
glycosylation sites (N-X-S/T, where X can be any amino acid). In rat brain, about 60-85% of 
cannabinoid receptors were found to be glycosylated. Rat CB1 specific bands were detected at 
52 kDa, 59 kDa and 64 kDa, suggesting that glycosylation occurs at 2 sites based on the size 
differences between molecular weights (Song and Howlett, 1995). In 2003, truncation mutants of 
human CB1 were generated and it was determined by immunoblot analysis that N77 and N83 are 
likely the glycosylation sites (Andersson et al., 2003). The third potential glycosylation site on 
CB1, N113, was ruled out as a glycosylation site when the truncation the first 89 residues of the 
amino terminus and immunoblot analysis revealed a 53 kDa band corresponding to a non-
glycosylated CB1 receptor (Andersson et al., 2003).  
Loop regions. Even though sequence and structure diversity is more prominent in loop regions 
than in transmembrane domains, these loop regions nonetheless play important roles in receptor 
activation, signaling and cellular localization. The NMR solution structures of bovine rhodopsin 
(Yeagle et al., 1997a; Yeagle et al., 2000) intracellular IC1 and IC2 showed that these regions 
adopted a β-turn (Yeagle et al., 1997b) in the middle of each loop and that extracellular EC1, 
EC2 and EC3 regions adopted a helix-turn-helix motif. These regions are important for compact 
packing with TMs and receptor stability. IC3 is the longest loop among all of the loop regions of 
GPCRs. It has been shown to be important in signal transduction including G protein selectivity 
(Eason and Liggett, 1995; Eason and Liggett, 1996; Hallbrink et al., 2001; Jewell-Motz et al., 
1997; Wade et al., 1999) and desensitization and internalization through arrestin binding 
(Bhaskaran et al., 2003; DeGraff et al., 2002; Lee et al., 2000; Peverelli et al., 2008; Schmidlin et 
al., 2003). An NMR study performed on a peptide corresponding to the CB1 IC3 has shown that 
IC3 contains three helical segments (Ulfers et al., 2002). Helical segments are extended from the 
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carboxyl terminal end of TM5 and from the amino terminal end of TM6, respectively (Ulfers et 
al., 2002). Interestingly, the squid rhodopsin crystal structure also revealed intracellular helical 
extensions from both TM5 and TM6, which may contribute to G protein selectivity (Murakami 
and Kouyama, 2008). 
Helix 8 (H8). The cannabinoid receptors also possess an intracellular carboxyl-terminus domain 
(reviewed in (Stadel et al., 2011)). The CB1 carboxyl terminus has 73 residues (Bramblett et al., 
1995) and the CB2 receptor carboxyl terminus has 59 residues (Munro et al., 1993). Although 
the human CB1 and CB2 receptors only differ in their carboxyl terminal length by 14 residues, 
there is no significant homology across these receptor subtypes. H8 (residues 401-412 in CB1) is 
found at the cytoplasmic end of TM7 (reviewed in (Stadel et al., 2011)). H8 has been shown in 
rhodopsin to undergo conformational changes upon receptor activation and this movement is 
believed to unmask critical G protein-binding domains (Abdulaev and Ridge, 1998). More direct 
evidence of the interaction of G-proteins and the carboxyl terminus of CB1 (residues 400-416) 
has been shown following co-immunoprecipitation and suggests that this part of the terminus 
which includes H8 is involved in Gαi3/o recognition, binding and activation (Mukhopadhyay et 
al., 2000). 
Palmitoylation. Residue Cys415 immediately following H8 in CB1 may serve as a potential 
palmitoylation site. Palmitoylation enhances the hydrophobicity of proteins and contributes to 
their membrane association and appears to play significant roles in subcellular trafficking of 
proteins between membrane compartments (Rocks et al., 2005) and protein-protein interactions 
(oyoti Basu, 2004). When mutating this residue to alanine on a cysteine-less CB1 receptor, wild-
type-like ligand binding and G protein activation were observed (Fay et al., 2005) suggesting this 
residue may not be palmitoylated. In contrast, mutating Cys313 or Cys320 in the carboxyl 
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terminus of CB2 resulted in receptors that bound ligand similarly to the wild-type receptor but 
had significantly less ability to reduce cAMP production. This suggests that Cys313 and Cys320 
may indeed be palmitoylation sites (Feng and Song, 2001). The distal region of the carboxyl 
terminus has also been found to impact receptor activation, signaling and subcellular 
localization.  
Conserved motifs and the inactive CB1 model. Despite the lack of cannabinoid receptor 
crystal structures, the β2AR has been used as a template in the creation of homology models of 
CB1 because it shares many structural features with CB1. Both CB1 and the β2AR bind a small 
molecular-weight ligand, possess a disulfide bond within EC2 (Fay et al., 2005; Shire et al., 
1996), lack secondary structure in the amino terminus, and lack the helix kink in TM1. 
Many of the functional motifs that are conserved among most family A GPCRS exist in CB1 and 
CB2. These include the S(N)LAxAD in TM2, E/DRY in TM3, WX(9)P in TM4, CWXP in TM6, 
and NPXXY in TM7. These motifs within the transmembrane helical domain contribute to 
helical stabilization through hydrogen bonding, water-mediated hydrogen bonding, aromatic 
stacking and lipid interactions.  
Several modeling studies of CB1, using both the rhodopsin and β-adrenergic receptors as 
templates, have suggested the presence of the TM1-TM2-TM7 hydrogen bonding network that 
was mentioned earlier as being conserved in rhodopsin (Figure 1.2b). This network involves 
residues Asn134, Asp163 and Asn393 of the CB1 receptor, which are conserved in rhodopsin as 
Asn55, Asp83, and Asn302. Another hydrogen bonding cluster exists in CB1 between TM3 and 
TM5 that includes the interaction between Thr201 and Thr283, and between Thr197 and Tyr275. 
For the helical stability of the inactive CB1 receptor conformation, modeling studies have also 
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revealed two important salt bridges or ionic locks (Salo et al., 2004; Shim, 2009). The first of 
these is the highly conserved TM3-TM6 ionic lock which involves Arg214 of the E/DRY motif 
on TM3 and Glu338 on TM6 of the CB1 receptor. The second ionic lock involves interactions 
between Asp176 on TM2 and Lys192 on TM3. Site-specific mutational studies and molecular 
modeling analyses have indicated that Lys192 on TM3 plays a critical role in ligand binding 
(Chin et al., 1998; Salo et al., 2004; Shim and Howlett, 2006; Song et al., 1999). Thus, Lys192 
likely mediates receptor activity through direct interaction and hydrogen bonding with ligands. 
Aromatic stacking within CB1 has also been shown to exist. Some of the aromatic stacking 
interactions that have been proposed include Tyr215, Phe208, Phe289, Tyr292, Ty2296 ,Trp356, 
Phe170 and Phe200 (McAllister et al., 2003; Shim, 2009; Shim and Howlett, 2006). The 
interaction between Trp356 of the CWXXP motif and Phe200 in the inactive state of the receptor 
is highly conserved throughout family A GPCRs and is believed to also exist within CB1 
(McAllister et al., 2004; Singh et al., 2002). Breaking this interaction upon receptor activation 
was found to change the angle of the proline kink in TM6, which is the basis of the rotamer 
toggle switch and accompanies rigid body movements of TM3 and TM6 (McAllister et al., 2004; 
Nygaard et al., 2009). 
1.2.4 Cannabinoid ligands and receptor activation states  
Interestingly, the cannabinoid receptors exhibit some basal activity (like many non-sensory class 
A GPCRs) indicative of G protein coupling in the absence of agonists (Landsman et al., 1997). 
In transfected HEK293 cells, up to 85% of CB1 receptors were found to be localized to 
endocytic intracellular vesicles with only a small population expressed on the cell surface 
(Leterrier et al., 2004). This cellular distribution of CB1 is consistent with patterns observed in a 
variety of cell types including CHO cells and hippocampal neuronal cells (Martini et al., 2007; 
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Rozenfeld and Devi, 2008). Cannabinoid receptors can be activated by four major chemical 
groups of agonists: classical cannabinoids, nonclassical cannabinoids, aminoalkylindoles and 
eicosanoids ((Pertwee, 2006); Figure 1.14).  
Classical and nonclassical cannabinoids. The classical cannabinoids consist of dibenzopyran 
derivatives and are either plant-derived cannabinoids or synthetic analogues of these. The most 
notable examples are Δ9-tetrahydrocannabinol (THC; derived from Cannabis sativa), Δ8-
tetrahydrocannabinol, or HU210. These ligands have three rings in their structure, one of which 
is a pyran ring along with an alkyl chain on C-3 of the A ring. Nonclassical cannabinoids are 
quite similar in structure to classical cannabinoids but lack a pyran ring and have either two or 
three rings along with the C-3 alkyl chain. Several of the compounds of this group were 
developed by a Pfizer research team. The most widely used of these is CP55940 which has CB1 
and CB2 affinities in the low nanomolar range (Ki= 0.5 nM and 0.69 nM, respectively) and 
exhibits relatively high efficacy at both of these receptor types (reviewed in (Pertwee et al., 
2010)). One of the most investigated pharmacophores is the lipophilic chain or alkyl chain 
projecting from the C-3 of the phenol group common to both classical and nonclassical agonists. 
An extensive study was performed on the length and nature of the side chain of Δ8-
tetrahydrocannabinol that suggested that an alkyl chain methylated at the second carbon retained 
CB1 agonism if the chain was between 3 to 10 carbon atoms in length. Attempts have been made 
to modify the CB1-CB2 selectivity of classical agonists which intrinsically bind both 
cannabinoid receptors by modifying the length of this C-3 side chain. Some evidence suggests 
shortening the side chain can enhance CB2 selectivity (reviewed in (Poso and Huffman, 2008)). 
Removal of the hydroxyl group at the C-1 position could also be used to augment CB2 
selectivity (Huffman et al., 2006) presumably because Lys 192 of CB1 is thought to hydrogen 
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bond to this phenolic hydroxyl group. However, mutation of the corresponding residue in CB2 
(Lys 109) to a residue which precludes hydrogen bonding to the C-1 hydroxyl group did not 
significantly affect CP55940 binding (Tao et al., 1999).  
Aminoalkylindoles. The aminoalkylindole agonist was developed by Sterling Research after 
observations were made that certain aminoalkylindoles were able to inhibit adenylyl cyclase by 
activating G proteins. The structure of WIN 55212-2 is completely different than any of the other 
compound groups. Like CP55940, it exhibits relatively high efficacy at CB1 and CB2 receptors 
(Ki= 1.89 nM and 0.28 nM, respectively) but has a slightly greater affinity for CB2 than CB1 
receptors (Chin et al., 1999; Song et al., 1999). This selectivity was studied by creating a 
chimeric cannabinoid receptor and swapping TM3 of CB1 with the corresponding domain of 
CB2. This resulted in enhanced WIN55212-2 binding affinity to CB2. A mutagenesis study 
performed by Song and colleagues (Song et al., 1999) suggested that a Phe present in TM5 of 
CB2 corresponding to a Val residue in CB1 confers the selectivity of the compound. Molecular 
modeling of CB2 points to Phe197 as being able to form an aromatic stacking interaction with 
the indole ring of WIN55212-2, an interaction lacking with CB1‘s corresponding Val residue.  
Endocannabinoids. The two most common and investigated members of the endogenous, lipid-
derived agonists have been anandamide and 2-AG (Figure 1.14). Anandamide binds somewhat 
more selectively to CB1 than to CB2 receptors (61 nM and 279 nM, respectively). 2-AG has 
been found to possess affinity for CB1 and CB2 receptors (58.3 nM and 145 nM, respectively) 
similar to those of anandamide but to exhibit higher CB1 and CB2 efficacy than anandamide 
(Pertwee et al., 2010). Other endocannabinoids also include 2-arachidonoyl glyceryl ether 
(noladin either) (Fezza et al., 2002), N-arachidonyldopamine (NADA) as well as O-arachidonoyl 
ethanolamine (virodhamine) (Porter et al., 2002). Because these ligands are substrates for 
 49 
 
enzymes such as fatty acid amide hydrolase (FAAH), an enzyme typically present in membrane 
preparations, a C-2 methylated anandamide, known as methanandamide, was created to 
circumvent FAAH. Methanandamide binds CB1 with an affinity comparable to that of 
anandamide but the added methylate precludes its hydrolysis by FAAH (Pertwee et al., 2010). 
Inverse Agonists. Inverse agonists of the CB1 receptor have attracted considerable attention in 
drug discovery because of their ability to regulate appetite and manage substance addiction 
(Janero, 2012; Janero and Makriyannis, 2009; Silvestri and Di Marzo, 2012a). The first specific 
cannabinoid inverse agonist to be developed was the diarylpyrazole, SR141716A (rimonabant) 
(Rinaldi-Carmona et al., 1994) and was the only CB1 inverse agonist to be approved and briefly 
clinically marketed in Europe for the control of obesity (Moreira and Crippa, 2009). It was 
removed from use shortly after due to its severe neuropsychiatric side effects including mood-
depressant actions (Despres et al., 2005; Traynor, 2007). SR141716A is a highly potent and 
selective CB1 ligand that blocks and reverses CB1-mediated effects both in vitro and in vivo 
(Howlett et al., 2002; Pertwee, 1999; Pertwee, 2005b) and binds to CB1 with Ki= 1.8 nM. Three 
analogs of SR141716A that have also been used to block CB1-mediated effects are AM251 (Ki= 
7.49 nM), AM281 (Ki= 12 nM) and LY320135 (Ki= 141 nM), each with less affinity for CB1 
(Pertwee et al., 2010). The structures of these compounds are shown in Figure 1.14. The most 
notable CB2-selective inverse agonists are the Sanofi-Aventis diarylpyrazole, SR144528 (Ki= 
0.28 nM) (Rinaldi-Carmona et al., 1998a) and 6-iodopravadoline (AM630; Ki= 31.2 nM) (Ross 
et al., 1999). Both compounds bind with much higher affinity to CB2 than to CB1 receptors. 
These inverse agonists produce inverse cannabimimetic effects by reducing the constitutive 
activity of CB2 receptors.  
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Antagonists. VCHSR (Figure 1.14), an antagonist analog of SR141716A lacking hydrogen 
bonding potential at the C-3 substituent displayed no inverse agonism in cells expressing the 
wild-type CB1 receptor HURST 2006 (Hurst et al., 2006). Interestingly, VCHSR bound the 
wild-type cannabinoid receptor and the K192A receptor with affinities similar to that of 
SR141716A. Further synthesis of SR141716A analogs was studied to determine if the 
carboxamide group or the piperidine nitrogen of the C-3 substituent of SR141716A were 
necessary for its high affinity binding to the cannabinoid receptor. These analogs lacked 
hydrogen bonding potential at either of the two positions. The results demonstrated that the 
carboxamide group rather than the amide nitrogen of the C-3 substituent of SR141716A likely 
hydrogen bonds with Lys192. Molecular modeling studies suggest that the carboxamide group of 
SR141716A forms a hydrogen bond with Lys 192 in an inactive receptor, explaining the loss of 
inverse agonism when a hydrogen bond between Lys 192 and SR141716A is precluded.  
As previously mentioned, the alkyl chain of cannabinoid receptor agonists has been shown to 
play a role in the efficacy of the ligand. Shortening the alkyl chain of Δ8-tetrahydrocannabinol to 
two carbons, with a dimethyl group on the first carbon, resulted in the compound JWH179 that 
bound CB1, but failed to exhibit a functional response (Huffman et al., 2003). Besides shortening 
the chain, the addition of a triple bond, as in O-2050, renders it less flexible and has been shown 
to abolish agonism (Gardner and Mallet, 2006). Taken together these results suggest a flexible 
alkyl chain on classical and nonclassical cannabinoid receptor agonists longer than two carbons 
is a prerequisite for receptor activation.  
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Figure 1.14 Cannabinoid receptor ligands.  Structures of common CB1 and CB2 agonists, 
antagonists, and inverse agonists.  Ligands which are thought to selectively bind CB1 or CB2 
have either a ―CB1‖ or ―CB2‖ adjacent to their structures, respectively.   
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CB1 active state model. The inactive states of GPCRs have been shown to possess many 
structural similarities. However, when the receptor is activated by structurally distinct ligands 
with various potencies, the receptor may adopt multiple activation conformations with diversity 
in ligand binding site interactions. Many studies on Class A GPCRs indicate that the ligand 
binding pocket is primarily within the core of the helical bundle of the receptors. This is unlike 
class B or C GPCRs that bind glycoprotein hormones or neurotransmitters through their 
extracellular region. Based on molecular modeling studies of CB1, it is believed that there is a 
primary hydrophobic binding pocket, mainly formed by TM3, TM5, TM6 and TM7 (Figure 
1.15). The key residues of this pocket are Phe189, Phe200, Trp279,Leu276, Tyr275, Lys192, 
Pro358, Ile353, Trp356, Leu359, Ser383, Cys386, Leu387 and Leu360 (Gonzalez et al., 2008; 
Montero et al., 2005; Padgett et al., 2008; Salo et al., 2004; Shim and Howlett, 2006). Residues 
Ile175 and Asp176 at the end of TM2 of CB1 have been determined to play a role in transmitting 
a signal across the receptor following ligand binding (Kapur et al., 2008). The single-site 
mutations of both of these residues resulted in a significant decrease in inverse agonist 
SR141716A binding affinity (Kapur et al., 2008).  
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Figure 1.15 Docking conformations of the cannabinoid ligand. The key residues forming the 
primary binding pocket for anandamide, CP55940, WIN55212-2, and SR141716A are illustrated 
in green. The ligand is colored as follows: gray is carbon, red is oxygen, blue is nitrogen and 
green is chlorine. (modified from (Salo et al., 2004)). 
 
Residues L207 and T210 in TM3 have also been implicated in cannabinoid receptor activation 
(D'Antona et al., 2006a; D'Antona et al., 2006b). A L207A mutant displayed increased basal 
levels of cAMP production and increased constitutive activity. Upon treatment of L207A with 
SR141716A, the basal levels of cAMP were decreased, ruling out the possibility that this mutant 
coupled to Gi and instead showing that this mutant constitutively couples to Gs. Interestingly, 
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upon treatment of L207A with the agonist CP55940, cAMP levels were also reduced. This 
finding suggests that CP55940 alters the structure of the L207A receptor shifting it from a Gs to 
a Gi favoring conformation. The study also showed that the noncovalent interactions of L207 
and T210 also keep the receptor in the constitutively active R' state. 
Mutations of residue T210 in TM3, to produce T210I and T210A, created the CB1 receptor in 
active and inactive states, respectively (D'Antona et al., 2006a). CB1 with the T210I mutation 
had an increased affinity for agonist while at the same time reducing affinity for inverse agonist. 
Pretreatment of T210I with guanosine-5‘-O-(3-thiotriphosphate) (GTPS) significantly 
attenuated CP55940 binding. In addition, T210I displayed enhanced thermal lability over wild-
type which provided further evidence that the T210I mutation increased CB1 constitutive 
activity. Molecular modeling performed with both the L207A and T210I mutant receptors 
suggest the mutation disrupts the highly conserved TM3-TM6 ionic lock between Arg214 of the 
E/DRY motif in TM3 and Asp338 in TM6. In contrast, CB1 with the T210A mutation decreased 
the constitutive activity of the CB1 receptor (D'Antona et al., 2006a). The mutant receptor 
exhibited enhanced affinity for inverse agonists and decreased agonist affinity. The mutation 
significantly reduced CP55940 binding sensitivity to GTPS suggesting an attenuation in G 
protein coupling and increased the thermal stability of T210A over wild-type CB1. These results 
suggest that residue T210 of TM3 is critical for regulating the equilibrium between the inactive 
state and the active state of the receptor.  
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1.2.5 Signaling of the cannabinoid receptors 
Both CB1 and CB2 receptors couple primarily to and signal through the pertussis toxin (PTX)-
sensitive inhibitory Gi/o proteins (Howlett et al., 2002). The activation of these inhibitory G 
proteins by CB1 has been functionally linked to the inhibition of adenylate cyclase (Slipetz et al., 
1995) and the cAMP pathway. Due to the decrease of cAMP accumulation, cAMP-dependent 
protein kinase (PKA) is inhibited by CB1 activation. In the absence of cannabinoids, PKA 
phosphorylates and inhibits the A-type and inwardly rectifying K
+
 channels (Howlett, 2005), 
thereby reducing outward potassium current. However, when cannabinoids are present, PKA 
phosphorylation of the channel is reduced and leads to an enhanced outward potassium current.   
CB1 activation has also been shown to be associated with the inhibition of N- and P/Q-type 
voltage-dependent Ca
2+
 channels  (Howlett, 2005). Based on these findings, it has been 
suggested that cannabinoids suppress neuronal excitability and play a role in regulating 
neurotransmitter release. The CB1 receptor has also been linked to the activation of mitogen-
activated protein kinases (MAPKs), including extracellular signal-regulated kinase-1 and -2 
(ERK1/2), p38 MAPK, and c-Jun N-terminal kinase (JNK) (Ahn et al., 2012; Bouaboula et al., 
1996; Turu and Hunyady, 2010). The CB1 receptor can also interact with other partners such as 
β-arrestins, adaptor protein AP-3, GPCR-associated sorting protein 1 (GASP1) and the adaptor 
protein FAN to control receptor signaling or trafficking (reviewed in (Howlett et al., 2010; Smith 
et al., 2010)). Other events following CB1 receptor activation include activation of focal 
adhesion kinase and the expression of immediate early genes (Bouaboula et al., 1995; Howlett 
and Fleming, 1984; Mackie and Hille, 1992; Mackie et al., 1995). 
Stimulation of CB2 has similar consequences in that CB2 is also coupled to Gi proteins and 
therefore inhibits adenylyl cyclase and the cAMP pathway in various types of cells (Howlett, 
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2005). This decreased cAMP production results in less activation of cAMP-dependent protein 
kinase (PKA), culminating in inhibition of A-type potassium channels and inhibition of some 
gene expression. CB2 stimulation can also result in the activation of AKT/protein kinase B 
which are involved in stimulating cell survival, migration and growth. It also stimulates MAPK 
cascades (i.e. Raf, MEK1/2 and ERK1/2) and can involve inwardly rectifying potassium 
channels as a signaling mechanism (Ho et al., 1999; McAllister et al., 1999). Since CB2 
receptors are mainly located in immune cells, one of their functions in the immune system is the 
modulation of cytokine release. The activation of B- and T-cell CB2 receptors by cannabinoids 
leads to the inhibition of adenylyl cyclase in these cells and to a reduced response to immune 
challenge (Condie et al., 1996). 
1.2.6 Allosteric modulators of CB1 
The discovery of a potential allosteric site on CB1 has generated significant interest, due to the 
anticipated therapeutic potential of allosteric-based drugs. A few compounds have been 
identified as allosteric modulators of the CB1 receptor including ORG27569, ORG29647, 
ORG27759, and PSNCBAM-1 (Horswill et al., 2007; Price et al., 2005) (Figure 1.16). As 
positive allosteric modulators, these compounds were found to increase the binding of the CB1 
agonist [
3
H]CP55940 in membranes from cells expressing the CB1 receptor. Intriguingly, these 
studies suggested that these compounds also concurrently antagonized CP55940-induced 
signaling by inhibiting [
35S]GTPγS binding and reducing the Emax value in the mouse vas 
deferens assays (Price et al., 2005). The prototypical CB1 allosteric modulator is ORG27569 
(Figure 1.16).  
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Figure 1.16 Structures of CB1 allosteric modulators. CB1 allosteric modulators enhance the 
affinity of certain cannabinoid receptor agonists while decreasing their ability to transduce a 
signal. 
 
Not only has this modulator exhibited paradoxical effects of increasing the equilibrium binding 
of CP55940 while at the same time antagonizing its G protein-mediated efficacy, but it was also 
shown to decrease the binding of the inverse agonist [
3
H]SR141716A to CB1 in both mouse 
brain membranes (Price et al., 2005) and in HEK293 membranes (Ahn et al., 2012). Despite this 
antagonizing effect on CP55940-induced G protein activation, the Kendall lab showed (Ahn et 
al., 2012) that upon co-treatment of HEK cells with CP55940 and ORG27569, a robust 
acceleration in the internalization process of the CB1 T210A (inactive) receptor occurred. High 
levels of receptor internalization began at 10 min and plateaued by 20 min, compared to the 
internalization upon treatment with CP55940 alone which plateaued at 40 min. Additionally, 
ORG27569 was found to play a role in cellular signaling. The CB1 wild-type receptor displayed 
CP55940-stimulated JNK phosphorylation with a peak at 5 min. This effect was blocked by 10 
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μM SR141716A, indicating that the JNK phosphorylation is CB1-mediated. However, in 
agreement with the [
35S]GTPγS binding data, ORG27569 abrogated the JNK phosphorylation 
induced by CP55940. These data (Ahn et al., 2012) suggest that JNK phosphorylation is only G 
protein-dependent via CB1 consistent with a previous report by Rueda and colleagues (Rueda et 
al., 2000). Moreover, the signaling pathway involving ERK1/2 which has been demonstrated to 
occur both G protein-dependently and G protein-independently by the μ-opioid receptor (Zheng 
et al., 2008), angiotensin AT1A receptor (Kendall et al., 2011), and parathyroid hormone 
receptor (Gesty-Palmer et al., 2006) was investigated. CP55940 induced a time-dependent 
stimulation of ERK1/2 with a maximum phosphorylation at 5 min. Interestingly, ORG27569 (10 
μM) alone caused a significantly higher increase in transient ERK1/2 phosphorylation at 5 min 
compared with the stimulation by CP55940 alone in cells expressing the CB1 wild-type receptor. 
When the cells were co-treated with ORG27569 and CP55940, a peak at 5 min was also 
observed that was somewhat diminished relative to ORG27569 alone, perhaps reflecting some 
competition between G protein-mediated and G protein-independent pathways (Ahn et al., 2012; 
Baillie et al., 2013). In addition, ORG27569 treatment alone also caused MEK1/2 and Src 
phosphorylation, components of the upstream MAPK pathway, to peak at 5 min and then 
diminish after 10 min (Ahn et al., 2013). CP55940 treatment alone resulted in MEK1/2 
phosphorylation but interestingly failed to induce Src phosphorylation. Src phosphorylation is a 
necessary step in the activation of various mitogenic signaling pathways activated by GPCRs. It 
has been shown that non-receptor tyrosine kinases from the Src family are recruited to GPCRs 
via β-arrestin interactions (Barlic et al., 2000; Imamura et al., 2001).  
Using a combination of computational methods together with mutagenesis, synthesis and 
pharmacological studies, one hypothesis regarding the ORG27569 binding site is that it is 
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located in the TM3-6-7 region of the CB1 receptor, partially overlapping the SR141716A 
binding site. This is consistent with equilibrium binding assays that suggest ORG27569 displaces 
SR141716A (Shore et al., 2014). The indole ring of ORG27569 was found to form several 
aromatic stacks with Phe379, placing a significant amount of ORG27569‘s steric bulk against the 
EC of TM6. This tight packing against TM6 is hypothesized to prevent TM6 from undergoing 
the necessary conformational changes required upon activation by an agonist, i.e. the ―tripping‖ 
of the toggle switch within the orthosteric binding pocket that allows TM6 to flex in the CWXP 
hinge region and break the ―ionic lock‖ between Arg135 and Glu134 at the intracellular end of 
the receptor. The ORG27569 indole ring also forms an aromatic stacking interaction with 
Phe268 an EC2 loop residue, which is believed to move down towards the TM core during 
receptor activation; this movement of EC2 places Phe268 in close proximity to CP55940. The 
aromatic stacking interaction of ORG27569 with Phe268 may sterically block this movement. 
This correlation between a conformational change in the EC2 loop and receptor activation has 
been observed for other numerous GPCRs. For example, the results of NMR studies have 
suggested that upon activation, rhodopsin‘s EC2 loop undergoes a necessary conformational 
change that is coupled to the breaking of the intracellular ―ionic lock‖ (Ahuja et al., 2009). 
Additionally, the ORG27569 piperidine nitrogen forms an important hydrogen bond with 
Lys192, which was previously shown to be important for SR141716A‘s inverse agonism (Hurst 
et al., 2002). It is believed that with these interactions, ORG27569 promotes an intermediate 
conformation of the CB1 receptor (i.e. a conformation that is in between inactive and active) that 
accounts for its enhanced binding to agonist but its inability to signal in G protein-mediated 
pathways.  
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The indole-2-carboxamide class of compounds, to which ORG27569 belongs, have been noted to 
have great potential as CB1 allosteric modulators (Ahn KH et al., 2013; Piscitelli et al., 2012). It 
was previously noted that indole-2-carboxamides with lower alkyl group substitutions at C3 of 
the indole ring impact orthosteric ligand binding (Piscitelli et al., 2012). Thus, two novel 
structural analogs of ORG27569, ICAM-a and ICAM-b, were synthesized and studied by the 
Kendall lab (Ahn KH et al., 2013). In ICAM-b, the C3 alkyl chain was elongated from an ethyl 
to a n-pentyl group in comparison with ORG27569. In ICAM-a, only the nitrogen of the indole 
ring was methylated in comparison with ORG27569 (Figure 1.17). Although both compounds 
enhanced the level of specific [
3
H]CP55,940 binding, ICAM-b showed a more drastic effect than 
ICAM-a. ICAM-b also exhibited a high cooperativity for CP55,940, evident from a moderate KB 
value of 470 nM and a remarkably high α value of 17.6. Consistent with previous allosteric 
modulators, ICAM-b inhibited CP55,940-induced [
35
S]GTPS binding in a concentration-
dependent manner evident by a progressive decrease in Emax values with an increasing 
concentration of ICAM-b for the CB1 receptor. In the same study (Ahn KH et al., 2013), it was 
demonstrated that β-arrestin 1, but not β-arrestin 2, is key for ICAM-b-induced ERK1/2 
phosphorylation. 
Given the vital role of CB1 in the CNS and its potential therapeutic value, the development of its 
allosteric modulators with distinct therapeutic properties resulting from receptor-selectivity and 
signaling-pathway-selectivity provides a promising avenue by which the current obstacles in 
cannabinoid-based drug discovery such as on- and off-target side effects can be overcome.  
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Figure 1.17 Novel indole-2-carboxamide analogs of ORG27569. In ICAM-b, the C3 alkyl 
chain was elongated from an ethyl to an n-pentyl group in comparison with ORG27569. In 
ICAM-a, only the nitrogen of the indole ring was methylated in comparison with ORG27569. 
 
1.2.7 Functional selectivity of the cannabinoid receptors 
Studies have reported agonist-specific differences in potency and/or efficacy towards activation 
of different G protein species upon CB1 receptor activation. For CB1 receptor-catalyzed 
activation of Gi, HU210, WIN55,212, and anandamide all elicited maximal activation, whereas 
Δ9-THC (56 ± 6%) caused only partial Gi activation. In contrast, only HU210 effected maximal 
CB1 stimulation of Go, with anandamide, WIN55,212-2, and Δ9-THC all stimulating between 60 
and 75% compared with HU210. These data demonstrate that different agonists induce different 
conformations of the CB1 receptor, which in turn can distinguish between different G proteins 
(Glass and Northup, 1999). Other studies also demonstrated the concept of functional selectivity 
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at the CB1 cannabinoid receptor by co-immunoprecipitation studies that revealed that WIN 
55,212-2 activates all subtypes of Gi proteins (Gi1, Gi2, Gi3) while the unrelated cannabinoid 
ligand, desacetyllevonantradol, activates Gi1 and Gi2 while acting as an inverse agonist with 
respect to Gi3 coupling (Mukhopadhyay and Howlett, 2005). Extending this concept to other 
types of G protein, agonist-selective regulation of Gs (Bonhaus et al., 1998) and Gq by 
WIN55,212 (Lauckner et al., 2005) coupling to the CB1 cannabinoid receptor have been 
reported. A mutagenesis study further supporting this model was performed. The intracellular 
carboxyl-terminal H8 of the CB1 cannabinoid receptor deviates from the highly conserved 
NPXXY(X)5,6F GPCR motif, possessing a Leu instead of a Phe. The study compared the signal 
transduction capabilities of CB1 with those of an L7.60F mutation and an L7.60I mutation that 
mimics the CB2 sequence. The two mutant receptors differed from wild type in their ability to 
regulate G-proteins in the [
35
S]GTPS binding assay. Hence it demonstrated that the Leu in the 
NPXXY(X)5,6L in H8 contributes to maximal activity of the CB1 receptor and thus provides a 
molecular basis for the differential coupling observed with chemically different agonists (Anavi-
Goffer et al., 2007). 
Further investigations via biochemical studies directly compared agonist efficacies and potencies 
at different levels of downstream signaling cascades. By comparing the transcriptional regulation 
achieved by HU210 and CP55,940, Bosier et al. reported these ligands to have different effects 
on the expression of tyrosine hydroxylase in a model of neuroblastoma cells (Bosier et al., 2007): 
while both ligands inhibited CRE-dependent gene transcription, CP55,940 acted as an antagonist 
of the AP-1-dependent gene transcription, whereas HU210 behaved as a full agonist (Bosier et 
al., 2008a). In addition, it was demonstrated that among the different MAPK family members, 
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HU210 was more efficacious in increasing ERK1/2 phosphorylation, while CP55,940 displayed 
a higher efficacy to activate JNK (Bosier et al., 2008b).  
While we know that β-arrestins are involved in the desensitization and internalization of the CB1 
receptor as scaffolding proteins (Breivogel and Childers, 2000; Daigle et al., 2008; Jin et al., 
1999; Kouznetsova et al., 2002), there has been evidence that β-arrestins can also act as signaling 
molecules independent of G proteins. The signaling discussed earlier by ORG27569 on the CB1 
receptor was reported by the Kendall lab (Ahn et al., 2013) to be mediated specifically by β-
arrestin 1 in a G protein-independent manner. siRNA knockdowns of β-arrestin 1 resulted in 
abolishing ERK1/2, MEK1/2 and Src phosphorylation when treated with ORG27569 but had no 
significant effect on CP55940-induced phosphorylation. Knockdowns of β-arrestin 2, on the 
other hand, had no effect on the signaling of either compound, but did dramatically attenuate the 
internalization of CB1 following CP55940 treatment, co-treatment with ORG27569 and 
CP55940 and treatment with ORG27569 alone (Ahn et al., 2013). These observations provided 
the first evidence of signaling-pathway-selective allosteric modulation via CB1. 
Interestingly, CB2 ligands show significant functional selectivity. For example, it was found that 
endocannabinoids activated distinct signaling pathways with varied rank order potencies in 
Chinese hamster ovary (CHO) cells transfected with CB2 receptors (Shoemaker et al., 2005). 
The endocannabinoid, 2-AG, was most potent in activating the ERK1/2-MAPK pathway but 
higher concentrations were needed to inhibit adenylyl cyclase and induce calcium transients. On 
other hand, noladin ether displayed higher potency in inhibiting adenylyl cyclase as compared to 
activating ERK1/2 and calcium transients. An even more extreme example of functional 
selectivity occurs for several commonly used CB2 agonists. Certain CB2 agonists (e.g., the 
aminoalkylindoles) inhibit adenylyl cyclase and activate ERK1/2, but failed to induce CB2 
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internalization or inhibition of voltage sensitive calcium channels in AtT20 cells (Atwood et al., 
2012). This striking functional selectivity of CB2 receptor agonists enriches the possibilities for 
developing drugs targeting CB2 receptors (Atwood et al., 2012; Han et al., 2013). Arrestin-
biased signaling has been found to produce useful therapeutic effects for other GPCR‘s (Wisler 
et al., 2007). To date no CB2 arrestin-biased agonists have been described, so it will be 
interesting to screen the rich repertoire of CB2 ligands synthesized to determine if arrestin-biased 
signaling exists for CB2 ligands. 
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CHAPTER 2 
Allosteric modulators of the cannabinoid receptor 1 (CB1) 
Parts of this chapter have been incorporated from published material (Mahmoud, M.M., Ali, H.I., 
Ahn, K.H., Damaraju, A., Samala, S., Pulipati, V.K., Kolluru, S., Kendall, D.A., Lu, D. 
"Structure–Activity Relationship Study of Indole-2-carboxamides Identifies a Potent Allosteric 
Modulator for the Cannabinoid Receptor 1 (CB1)." Journal of Medicinal Chemistry 56(20) 
(2013): 7965-7975). Compound synthesis was done by our collaborators from Dr. Dai Lu‘s lab. 
 
This chapter deals with the identification of novel allosteric modulators of the CB1 receptor and 
the optimization of both their potency and efficacy, which are two independent parameters 
contributing to the pharmacological profile of allosteric modulators. The ubiquitous distribution 
of GPCRs in general and their involvement in virtually all physiological processes makes them 
extremely attractive targets for drug development. Modulation of interactions between activated 
GPCRs and their intracellular signal transducers, such as heterotrimeric G-proteins or kinases, is 
an attractive, yet largely unexplored, paradigm for the treatment of certain diseases. The 
importance of the regulation of cellular functions has been a topic of increased interest in the 
hopes of regulating downstream signaling for the treatment of a plethora of associated diseases 
such as congenital diseases due to constitutively active GPCRs, as well as tumors where GPCRs 
are often overexpressed. The multiple potential advantages that allosteric modulators present 
compared to orthosteric drugs have made them the focus of drug development efforts. In 
particular, the greater ease of achieving higher selectivity for the target because of the higher 
heterogeneity of the allosteric binding sites. A few compounds have been identified as allosteric 
modulators of the CB1 receptor and we demonstrate the ability to use these compounds to fine-
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tune and specifically target downstream signaling pathways. Therefore, developing new 
modulators and understanding their regulation of receptor activity will contribute to our 
understanding of the ligand-specific modulation of CB1 receptor activity.
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2.1 Abstract 
The cannabinoid CB1 receptor is involved in complex physiological functions. The 
discovery of CB1 allosteric modulators generates new opportunities for drug discovery targeting 
the pharmacologically important CB1 receptor. 5-chloro-3-ethyl-N-(4-(piperidin-1-
yl)phenethyl)-1H-indole-2-carboxamide (ORG27569; 1) represents a new class of indole-2-
carboxamides that exhibit allostery of CB1. To better understand the structure-activity 
relationships (SAR), a group of indole-2-carboxamide analogs were synthesized and assessed for 
allostery of the CB1 receptor. We found that within the structure of indole-2-carboxamides, the 
presence of the indole ring is preferred for maintaining the modulator‘s high binding affinity for 
the allosteric site, but not for generating allostery on the orthosteric site. However, the C3 
substituents of the indole-2-carboxamides significantly impact the allostery of the ligand.  A 
robust CB1 allosteric modulator 5-chloro-N-(4-(dimethylamino)phenethyl)-3-pentyl-1H-indole-
2-carboxamide (11j; LDK1240) was identified. It showed an equilibrium dissociation constant 
(KB) of 167.3 nM with a markedly high binding cooperativity factor (=16.55) and potent 
antagonism of agonist-induced GTPγS binding.  
 
2.2 Introduction 
The endocannabinoid system is composed of at least two G-protein coupled receptors 
(GPCRs), CB1 and CB2, a group of endogenous lipid ligands and several catabolic and anabolic 
enzymes that are involved in the biosynthesis and degradation of the endogenous ligands 
(Battista et al., 2012). The CB1 receptors are mainly found on neurons of the central and 
peripheral nervous system (Herkenham et al., 1990b) where they attenuate neurotransmitter 
release. CB1 receptors are also present at much lower concentrations in some peripheral tissues, 
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including spleen, tonsil, reproductive organs, endocrine glands, arteries, bone marrow, lungs and 
heart (Galiegue et al., 1995a; Gerard et al., 1991a; Straiker et al., 1999). Consistent with its 
widespread distribution, the CB1 receptor regulates a wide variety of physiological functions 
including neuronal development, neuromodulatory processes, energy metabolism, 
cardiovascular, respiratory as well as reproductive functions (Howlett et al., 2004; Mackie, 2006; 
Pertwee, 2006). In addition, it also modulates cell proliferation, motility, adhesion and apoptosis 
(Guzman et al., 2002; Rajesh et al., 2008). 
Like many GPCRs, the CB1 receptor displays a multiplicity of intracellular signal 
transduction mechanisms. It preferentially couples to Gi/o type G proteins while its interaction 
with Gs (Glass and Felder, 1997) or Gq (Lauckner et al., 2005) is also possible. Activation of the 
CB1 receptor primarily leads to the inhibition of adenylyl-cyclase thereby reducing cAMP levels 
in cells. The CB1 receptor also modulates the activation of mitogen-activated protein kinases 
(MAPKs), including extracellular signal-regulated kinase-1 and -2 (ERK1/2), p38 MAPK, 
p42/p44 MAPK and c-Jun N-terminal kinase (JNK) (Turu and Hunyady, 2010). Additionally, 
CB1 can negatively couple to N- and P/Q-type voltage-gated Ca
2+
 channels and positively 
couple to A-type and inwardly rectifying K
+
 channels (Howlett, 2005). CB1 also interacts with 
non-G protein partners such as -arrestins, adaptor protein AP-3, GPCR-associated sorting 
protein 1 (GASP1) and the adaptor protein FAN to control receptor signaling or trafficking 
(Howlett et al., 2010; Smith et al., 2010). 
The activation of the CB1 receptor by endogenous and exogenous agonists such as 
anandamide and (-)-9-tetrahydrocannabinol (9-THC) has been linked to a wide range of 
pharmacological effects (Pertwee, 1999). Growing evidence suggests that the CB1 receptor 
exists in multiple active conformations, each of which may display distinct abilities to regulate 
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individual signaling pathways (Hudson et al., 2010). Thus, the assumption that there is only one 
active conformation of the CB1 receptor is overly simplistic and is inadequate to explain all 
cannabinoid-mediated responses. Recently, several small molecules (Figure 2.1) have been 
identified as allosteric modulators of the CB1 receptor. The representative members include  
ORG27569 (1) (Price et al., 2005), (1-(4-chlorophenyl)-3-(3-(6-(pyrrolidin-1-yl)pyridin-2-
yl)phenyl)urea (2, PSNCBAM-1) (Horswill et al., 2007), 3-(4-chlorophenyl)-5-(8-methyl-3-p-
tolyl-8-azabicyclo[3.2.1]octan-2-yl)isoxazole (3, RTI-371) (Navarro et al., 2009) and the 
endogenous ligand (5S,6R,7E,9E,11Z,13E,15S)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoic acid 
(4, lipoxin A4) (Pamplona et al., 2012). The identification of these ligands indicates the existence 
of allosteric site(s) on the CB1 receptor and suggests new opportunities for fine-tuning the 
signaling pathways of the CB1 receptor. 
 
 
Figure 2.1 Structures of representative allosteric modulators of the CB1 receptor 
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Indole-2-carboxamide 1 (ORG27569) was the first allosteric modulator identified for the 
CB1 receptor. It increases specific binding of the tritium labeled CB1 agonist 2-[(1R,2R,5R)-5-
hydroxy-2-(3-hydroxypropyl)cyclohexyl]-5-(2-methyloctan-2-yl)phenol ([
3
H]CP55,940) but 
decreases the binding of the tritium labeled CB1 inverse agonist 5-(4-chlorophenyl)-1-(2,4-
dichloro-phenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide ([
3
H]SR141716A) in 
membranes from cells expressing the CB1 receptor. Despite acting as an enhancer of agonist 
binding, it acts as an inhibitor of agonist-induced Gi protein coupling (Ahn et al., 2012; Price et 
al., 2005). It was further demonstrated that the ORG27569-induced conformational change of the 
CB1 receptor leads to cellular internalization of the receptor and downstream activation of ERK 
signaling (Ahn et al., 2012), both of which have been conventionally recognized as the 
consequences of CB1 receptor activation.  More recent studies showed that the ORG27569-
induced activation of ERK1/2 signaling is Gi-independent (Ahn KH et al., 2013; Baillie et al., 
2013) and mediated by -arrestins (Ahn et al., 2012). Hence, ORG27569 not only acts as an 
allosteric agonist which is able to induce receptor internalization and ERK1/2 phosphorylation 
on its own, but also functions as an antagonist of CB1 agonist-induced [
35S]GTPγS binding. This 
supports the notion that allosteric modulators can selectively regulate the functions of the CB1 
receptor. Consequently, more functionally-defined pharmacological effects can be achieved for 
the physiologically and pharmacologically important CB1 receptors. Along with ORG27569, a 
few other indole-2-carboxamides (Ahn KH et al., 2013; Piscitelli et al., 2012; Price et al., 2005) 
have also shown allosteric modulation of the CB1 receptor. To study the structure-activity 
relationships (SAR) of this class of compounds, we synthesized a series of analogs of 
ORG27569 with the general structure shown in Figure 2.2, and individual structures shown in 
Figures 2.3 and 2.4.  
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Figure 2.2 General structures of indole- and benzofuran-2-carboxamide analogs.  
 
Previous results from us (Ahn KH et al., 2013) and others (Piscitelli et al., 2012) 
indicated that the alkyl substituents at the C3 position have a profound influence on the ligand‘s 
allostery. For instance, replacing compound ORG27569‘s C3 ethyl group with a n-pentyl group 
led to the enhancement of the allosteric effects, which is reflected by an improvement in the 
cooperativity factor  from 6.95 (1; ORG27569) to 17.6 (11a; ICAM-b) (Ahn KH et al., 2013). 
The α cooperativity factor is a value that quantifies the magnitude by which the affinity of one 
ligand is changed by the other ligand when both are bound to the receptor simultaneously to form 
the ternary complex. When α is 1.0, the test modulator does not affect the binding of the 
orthosteric ligand. If α is less than 1.0, the test modulator reduces orthosteric ligand binding 
(negative allosteric modulation on orthosteric ligand binding). If α is greater than 1.0, the 
modulator increases orthosteric ligand binding (positive allosteric modulation) (Christopoulos 
and Kenakin, 2002). This prompted us to continue the investigation of the C3 substituents. 
Therefore, alkyl groups of different lengths, a cyclic ring and an aromatic ring were introduced at 
the C3 position to elucidate the SAR. Since we previously found that 11a (ICAM-b) displayed a 
remarkably enhanced binding cooperativity factor   (Ahn KH et al., 2013), we chose to use it as 
X
R1
Cl O
HN R2
 X = NH, O
Bicyclic aryl side
Amide side
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a template to vary the amines of the amide side, with the aim of improving the affinity of the 
allosteric modulator to its allosteric site, which is denoted by its equilibrium dissociation 
constant (KB) (Christopoulos and Kenakin, 2002). The above efforts yielded compounds 11b-
11k (Figure 2.3, Table 2.1, Table 2.2 and Table 2.4). Next, to elucidate the significance of the 
indole ring in the indole-2-carboxamide structure, we replaced the indole ring of 11a (ICAM-b) 
with other bicyclic aromatic rings such as the benzofuran ring. This effort led to the compounds 
represented by the structure 13a-13d (Figure 2.4, Table 2.3 and Table 2.4). 
 
N
H
Cl
COOEt
N
H
Cl
COOEt
R
O
RCOCl
N
H
Cl
COOEt
R
N
H
Cl
COOH
N
H
Cl
R1
11a-l
5 7a-f 8a-f
9a-f
a: R= n-C4H9
b: R= Ph 
c: R= c-hexyl
d: R= n-C6H13
e: R= n-C8H17  
f:  R= CH3
10a-f
O
HN Y
a: R1 = n-C5H11, Y = (CH2)2, R2 = N-piperidinyl
b: R1 = Ph, Y = (CH2)2, R2 = N-piperidinyl
c: R1 = CH2Ph, Y = (CH2)2, R2 = N-piperidinyl
d: R1 = CH2-c-hexyl, Y = (CH2)2, R2 = N-piperidinyl
e: R1 = n-C7H15, Y = (CH2)2, R2 = N-piperidinyl
f:  R1 = n-C9H19, Y = (CH2)2, R2 = N-piperidinyl
g: R1 = n-C5H11, Y = CH2, R2 = N-piperidinyl
h: R1 = n-C5H11, Y = (CH2)2, R2 = N-morpholinyl
i:  R1 = n-C5H11, Y = (CH2)2, R2 = Phenoxyl
j:  R1 = n-C5H11, Y = (CH2)2, R2 = N(CH3)2
k: R1 = n-C5H11, Y =CH(CH2OH)CH2, R2 = N(CH3)2
l:  R1 = CH2CH3, Y = (CH2)2, R2 = N(CH3)2
R2
H2N Y R2
R
(i)
(ii)
(iii) (iv)
(6a-f)
a: Y = (CH2)2, R2 = N-piperidinyl
b: Y = CH2, R2 = N-piperidinyl
c: Y = (CH2)2, R2 = N-morpholinyl
d: Y = (CH2)2, R2 = Phenoxyl
e: Y = (CH2)2, R2 = N(CH3)2
f:  Y = CH(CH2OH)CH2, R2 = N(CH3)2
10a-f6-9
 
Figure 2.3 Syntheses of indole-2-carboxamide analogs (11a-l). Reagents and Conditions: (i) 
AlCl3, 1,2-dichloromethane, reflux, 2-3 h; (ii) (Et)3SiH, CF3COOH, 0 

C - rt, 4-12 h; (iii) NaOH, 
EtOH, reflux, 2 h; (iv) BOP, DIPEA, DMF, rt, 4-12 h. 
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2.3 Materials and Methods 
Chemistry. The syntheses of the indole-2-carboxamide analogs (11) were achieved through the 
methods illustrated in Figure 2.3.  
The C3 substituents were introduced through acylation of the commercially available 
ethyl 5-chloroindole-2-carboxylate (5) by Friedel-Crafts reaction catalyzed by aluminum 
chloride. Acylation of 5 with the selected acyl chloride (6) provided the desired 3-acyl-5-
chloroindole-2-carboxylates (7). Reduction of the carbonyl group of 7 by triethylsilane generated 
the C3 alkylated 5-chloroindole-2-carboxylates (8), which were then hydrolyzed in basic 
conditions to yield the key intermediate acids (9). The final compounds (11a-11l) were prepared 
by coupling commercially available amines (10a-f) with the indole-2-carboxylic acids (9a-f) and 
commercially available 5-chloro-3-phenyl-2-carboxylic acid individually in the presence of BOP 
and diisopropylethyl amine (DIPEA) in anhydrous DMF at room temperature. Similarly, 
benzofuran-2-carboxamides (13a-d) were prepared according to the methods depicted in Figure 
2.4.   
O
Cl
COOH
R1
12
+
H2N
R2
a: R1 = H
b: R1 = Et
10
a: R2 = N-piperidinyl
e: R2 = N(CH3)2
O
Cl
R1
O
HN
R2
13
a: R1 = H; R2 = N-piperidinyl
b: R1 = Et; R2 = N-piperidinyl
c: R1 = Et; R2 = N(CH3)2
d: R1 = H: R2 = N(CH3)2
(i)
 
Figure 2.4 Syntheses of benzofuran-2-carboxamide analogs 13a-d.
 
Reagents and Conditions: 
(i) BOP, DIPEA, DMF, rt, 4-12 h.  
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The commercially available 5-chlorobenzofuran-2-carboxylic acid 12a (AlfaAesar, Ward 
Hill, MA) or 5-chloro-3-ethyl-benzofuran-2-carboxylic acid 12b (Princeton BioMolecular 
Research, Monmouth Junction, NJ) was coupled with selected amines (10a or 10e) in the 
presence of BOP and DIPEA in anhydrous DMF at room temperature to provide the desired 
benzofuran-2-carboxamides (13a-13d). Most of the final compounds of the 11 and 13 series had 
acceptable solubility in organic solvents and were therefore purified through chromatography. 
However, compounds 11b, 11c and 11d had very poor solubility in most of the common organic 
solvents, such as acetone, ethyl acetate, tetrahydrofuran, dichloromethane, diethyl ether, ethanol 
and methanol. They were therefore purified using a combination of trituration, recrystallization 
and chromatography as detailed in the synthesis section.  
Compounds. Tested compounds (11a-11l and 13a-13d) were synthesized for this study except 
1, which was purchased from Tocris Bioscience (Minneapolis, MN). Compounds 11a (Price et 
al., 2005) and 11l (Piscitelli et al., 2012) have previously been reported and were used in this 
study for comparison.  
CB1 Expression and Membrane Preparation. HEK293 cells were maintained in Dulbecco‘s 
modified Eagle‘s medium supplemented with 10% fetal bovine serum and 3.5 mg/ml glucose at 
37 °C in 5% CO2. For transient receptor expression, HEK293 cells were plated at 800,000 
cells/100-mm dish on the day prior to transfection. The cells were transfected using the calcium 
phosphate precipitation method (Chen and Okayama, 1987). 24 h post-transfection, membranes 
of transfected cells were prepared as described previously (Ahn et al., 2009a). 
Radioligand Binding Assay. Membranes from HEK293 cells expressing the CB1 wild-type 
receptor were prepared as previously described (Ahn et al., 2009a). In assays used to determine 
the cooperativity between allosteric and orthosteric ligands, approximately 4 µg of membrane 
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was incubated at 30 °C for 60 min with a fixed tracer ([
3
H]CP55,940; 147.9 Ci/mmol, 
PerkinElmer Life Sciences (Boston, MA)) concentration typically at its Kd (2.5 nM) which was 
determined from a saturation binding isotherm. Binding assays were performed with at least nine 
concentrations of unlabeled allosteric compound (ranging between 100 pM and 100 µM) as 
described previously (Ahn et al., 2012). Nonspecific binding was determined in the presence of 1 
µM unlabeled CP55,940. Reactions were terminated by adding 250 µL of TME buffer 
containing 5% BSA followed by filtration with a Brandel cell harvester through Whatman GF/C 
filter paper. Radioactivity was measured using liquid scintillation counting. The total assay 
volume and the amount of membrane samples were adjusted to avoid ligand depletion by 
keeping the bound ligand less than 10% of the total.  
GTPγS Binding Assay. GTPS binding assays were performed as described previously (Ahn et 
al., 2012). Briefly, 7.5 µg of membranes were incubated for 60 min at 30°C in a total volume of 
200 µL GTPS binding assay buffer (50 mM Tris-HCl, pH 7.4, 3 mM MgCl2, 0.2 mM EGTA, 
and 100 mM NaCl) with unlabeled CP55,940 (at least nine different concentrations were used 
ranging between 100 pM and 100 µM), 0.1 nM [
35
S]GTPS (1250 Ci/mmol; PerkinElmer Life 
Sciences, Boston, MA), 10 µM GDP (Sigma, St. Louis, MO), and 0.1% (w/v) BSA in the 
absence and presence of varying concentrations of the allosteric compounds as indicated. The 
basal GTPS binding was measured in the absence of orthosteric ligand and with 5 µM GDP to 
increase the window of basal activity. Nonspecific binding was determined with 10 µM 
unlabeled GTPS (Sigma, St. Louis, MO). The reaction was terminated by rapid filtration 
through Whatman GF/C filters. The radioactivity trapped in the filters was determined by liquid 
scintillation counting.  
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Ligand and GTPγS Binding Data Analysis. All ligand binding assays and GTPS binding 
assays were carried out in duplicate. Data are presented as the mean ± S.E. value or the mean 
with the corresponding 95% confidence limits from at least three independent experiments. The 
interactions between the orthosteric radiolabeled agonist [
3
H]CP55,940 and the test modulators 
were analyzed using Prism 6.0 (GraphPad Software Inc., San Diego, CA) according to the 
following allosteric ternary complex model of interaction (Price et al., 2005). 
𝑌 =
 A 
 A + 
𝐾A 1 +  B 𝐾B  
 1 + 𝛼 B 𝐾B  
 
 
      
      Equation 1. 
Where Y denotes the specific bound orthosteric ligand divided by the total concentration of 
orthosteric ligand [A]. [B] denotes the concentration of the allosteric ligands. KA and KB are 
equilibrium dissociation constants for their respective ligands, and α is a cooperativity factor that 
quantifies the allosteric interaction in terms of magnitude and direction between the two ligands 
when they simultaneously occupy the receptor. When α is 1.0, the tested modulator does not 
change orthosteric ligand binding. If α is less than 1.0, the tested modulator reduces orthosteric 
ligand binding (negative allosteric modulation on orthosteric ligand binding). If α is greater than 
1.0, the modulator increases orthosteric ligand binding (positive allosteric modulation). For this 
analysis, the value of [A] was kept constant and was the average of radioactive orthosteric ligand 
concentration employed in the binding assays. KA was also fixed as a constant and was 
determined from previous CP55,940 saturation binding assays, whereas values of α and KB were 
determined by nonlinear regression. 
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Synthesis. All chemical reagents and solvents were purchased from Sigma-Aldrich Chemical 
Company unless specified otherwise and used without further purification. All anhydrous 
reactions were performed under a static argon atmosphere in dried glassware using anhydrous 
solvents. Organic phases in work up were dried over anhydrous Na2SO4, and removed by 
evaporation under reduced pressure. The crude compounds were purified by a Combiflash Rf 
chromatography system (Teledyne Technologies, Inc, Thousand Oaks, CA) unless specified 
otherwise. Purities of the intermediates were established by Thin-layer Chromatography (TLC), 
melting point,
 1
HNMR, and mass spectrometry. Analytical Thin-layer Chromatography (TLC) 
was run on pre-coated silica gel TLC aluminum plates (Whatman

, UV254, layer thickness 250 
µm), and the chromatograms were visualized under ultraviolet (UV) light. Melting points were 
determined on a capillary Electrothermal

 melting point apparatus and are uncorrected. 
1
HNMR 
spectra of intermediates were recorded on a Bruker Avance DPX-300 spectrometer operating at 
300 MHz. 
1
HNMR spectra of final compounds were recorded on a Bruker AV-500 spectrometer 
operating at 500 MHz. All NMR spectra were recorded using CDCl3 or DMSO-d6 as solvent 
unless otherwise stated and chemical shifts are reported in ppm (parts per million) relative to 
tetramethylsilane (TMS) as an internal standard. Multiplicities are indicated as br (broadened), s 
(singlet), d (doublet), t (triplet), q (quartet), m (multiplet), bs (broadened singlet) and coupling 
constants (J) are reported in hertz (Hz). Low resolution mass spectra were performed at the 
School of Chemical Sciences, University of Illinois at Urbana-Champaign. The purity of each 
tested compound was analyzed by combustion elemental analysis and was confirmed to be 
greater than 99%. Corresponding combustion elemental analysis was conducted in Roberson 
Microlit laboratories  (Madison, NJ). The specific details for the synthesis of each compound can 
be found in the original publication.  
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2.4 Results and Discussion 
To investigate the allostery of the newly synthesized compounds for the CB1 receptor, 
we evaluated each compound‘s binding cooperativity factor α to quantify the magnitude of the 
allosteric effect on orthosteric ligand binding. Some of the compounds that showed α values 
comparable to that of ORG27569 were selected for further testing their capability to modulate 
the agonist CP55,940-induced G protein coupling.  Additionally, to evaluate the effectiveness of 
the modulator binding to the allosteric site, their equilibrium dissociation constants KB were also 
determined. The  and KB values were analyzed according to the allosteric ternary complex 
model ((Price et al., 2005); See equation (1) in experimental section).  
The results for compounds with structural variation at the C3 position are shown in Table 
2.1. We found that replacing the C3 alkyl group of ORG27569 with a phenyl ring completely 
abolished the allosteric effect of the ligand (11b (LDK1225) compared to previously tested 
ORG27569 (Ahn et al., 2012) and 11a (ICAM-b) (Ahn KH et al., 2013)), whereas a benzyl 
group at C3 was somewhat tolerated but with a significantly increased KB value indicative of 
lower affinity (11c; LDK1230). Replacing the phenyl ring of the benzyl group in ligand 11c 
(LDK1230) with a cyclohexyl group (11d; LDK1232) further increased KB although allosteric 
modulatory effects were retained. These data suggest that aliphatic or aromatic rings on the C3 
alkyl group significantly decrease the affinity of the allosteric ligand. Therefore, linear alkyl 
chains as C3 substituents were employed for further exploration. The C3-n-heptyl (11e; 
LDK1218) and C3-n-nonyl (11f; LDK1219) analogs of ORG27569 were synthesized. Although 
11e and 11f displayed appreciable KB values, the  values substantially decreased relative to 11a 
(ICAM-b), suggesting that a C3-n-pentyl is optimal for maximum allosteric modulatory effects.  
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Table 2.1 Allostery of indole-2-carboxamide analogs 11a-f 
N
H
Cl O
HN
R1
N
 
Cmpd R
1
 KB (nM)
a
 b [35S]GTPS bindingc 
1
d 
Et 217.3 (170.3-277.2) 6.95 Antagonizing 
11a
e 
n-C5H11 469.9 (126.2-1750) 17.60 Antagonizing 
11b Ph ND 1.0 - 
11c CH2Ph 1067 (347.3-3344) 11.37 - 
11d CH2-c-hexyl 2408 (570.2-8151) 9.84 - 
11e n-C7H15 651.2 (81.51-5203) 7.38 - 
11f n-C9H19 259.7 (87.56-770) 6.80 Antagonizing 
a 
KB: equilibrium disassociation constant. 
b : binding cooperativity factor between CP55,940 and the tested allosteric 
modulators.  
c 
Effects on CP55,940-induced [
35S]GTPγS binding in the presence of allosteric 
modulator. 
d
 Data cited for 1 (ORG27569) is from our earlier report and given for comparison 
(Ahn et al., 2012). 
e
 Data cited for 11a (ICAM-b) is from our earlier report and given for comparison 
(Ahn KH et al., 2013). 
ND: no detectable modulation of [
3
H]CP55,940 binding using up to 32 µM of test 
compound. 
- : not performed. 
 
Overall, this series of analogs indicates that the type and size of the substituents at the C3 
position of indole-2-carboxamides have a critical role in the allosteric effects on the CB1 
receptor. Our results support the hypothesis of the presence of a hydrophobic sub-pocket in close 
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proximity of the C3-position of ORG27569 when it is bound to the allosteric site. This sub-site 
could only be occupied by linear alkyl groups but not cyclic structures.   
 
Table 2.2. Allostery of indole-2-carboxamide analogs 11g-k 
N
H
Cl O
HN R2
 
Cmpd R
2
 KB (nM)
a
      b [35S]GTPS bindingc 
11a
d 
N
 
469.9 (126.2-1750) 17.06 Antagonizing 
11g N
 
ND 1.0 - 
11h N O
 
508.4 (96.34-2683) 10.0 Antagonizing 
11i O
 
2335 (695.3-7542) 13.15 - 
11j N
 
167.3 (23.39-1197) 16.55 Antagonizing 
11k 
N
OH
 
1018 (81.51-5203) 13.27 - 
a 
KB: equilibrium disassociation constant. 
b: binding cooperativity factor between CP55,940 and the tested allosteric 
modulators.  
c 
Effects on CP55,940-induced GTPγS binding in the presence of allosteric modulator. 
d
 Data cited for 11a (ICAM-b) is from our earlier report and given for comparison 
(Ahn KH et al., 2013). 
ND: no detectable modulation of [
3
H]CP55,940 binding using up to 32 µM of test 
compound. 
- : not performed. 
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Among the C3-alkyl analogs of ORG27569, the previously tested compound 11a (ICAM-
b) (Ahn KH et al., 2013) exhibited the most robust allostery (=17.6) of the CB1 receptor. In an 
earlier communication, we reported that 11a (ICAM-b) promoted the phosphorylation of CB1 
downstream effectors ERK1/2 in a Gi-independent but -arrestin-1 mediated manner (Ahn KH et 
al., 2013). Although a markedly high  factor was achieved, 11a (ICAM-b) exhibited moderately 
weak affinity for CB1, as reflected by its relatively high KB value (469.9 nM). Hence, this 
compound was selected for further modification on the amide side with the aim of exploring 
SAR and improving the affinity to the allosteric site on CB1. This effort led to the synthesis of 
the compounds presented in Table 2.2.  
When a methylene group of the ethylene linker between the piperidinylphenyl group and 
the amide bond was removed, it resulted in complete elimination of the allostery of the ligand 
(11g vs 11a). This indicates that the substituted phenyl ring on the amide side must be separated 
from the amide bond by at least a 2-carbon linkage. This ethylene moiety was therefore retained 
for the rest of this series of compounds (11h-11k). When the piperidinyl group was replaced by a 
structurally related but more hydrophilic morpholinyl group (11h), the KB value increased and 
the cooperativity factor  decreased. This suggests that the hydrophilic substitution on the amino 
group decreased the affinity of the ligand for the allosteric site and reduced the allosteric 
modulation of the orthosteric site. Replacing the piperidinyl group with a phenoxy group (11i) 
resulted in a significant increase in the KB value, but the high binding cooperativity () was 
retained. Next, swapping the cyclic piperidinyl group with an acyclic dimethyl amino group on 
the phenyl ring led to 11j (LDK1240) which exhibited the most robust allostery (KB = 167.3 nM; 
= 16.55) reported so far for the CB1 receptor. A low KB value and a high  factor, as achieved 
in 11j, are significant and indicate the low concentration of compound 11j that is needed to 
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achieve the increase in affinity this allosteric modulator has on CP55,940 binding; i.e. a smaller 
concentration of 11j (compared to all CB1 allosteric modulators) is needed to achieve its robust 
allosteric effect on agonist binding. This is a key factor that is taken into consideration in 
therapeutic drug treatments. Moving forward to introduce a hydroxymethyl group at the  
position of the ethylene linker of 11j (LDK1240) reduced its affinity, but a relatively good 
binding cooperativity ( value) was maintained (11k; LDK1243). Overall, in this series of 
compounds, we found that structural modifications on the amide side generally do not 
significantly affect the cooperativity factor , whereas the influence on the KB of the allosteric 
modulators is much more profound. 
To date, the majority of structural modifications on ORG27569 have been focused on the 
substitution of the indole ring (Ahn KH et al., 2013; Price et al., 2005) and the variation of the 
amide side (Piscitelli et al., 2012). To unveil the importance of the indole ring on the KB and  
values, we synthesized several benzofuran-2-carboxamides and compared them with their 
indole-2-carboxamide counterparts. The results are shown in Table 2.3.  
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Table 2.3. Allostery of indole-/benzofuran-2-carboxamide analogs (11l and 13a-d) 
X
Cl O
HN R2
R1
 
Cmpd X R
1
 R
2
 KB (nM)
a
 b [35S]GTPS bindingc 
1
d 
NH Et N
 
217.3 (170.3-277.2) 6.95 Antagonizing 
11l
e 
NH Et N
 
207.4 (155.9-2759) 19.68 - 
13a O H N
 
ND 1.0 - 
13b O Et N
 
2594 (1005-6696) 18.04 Antagonizing 
13c O Et N
 
627.1 (151.5-2596) 11.59 - 
13d O H N
 
ND 1.0 - 
a 
KB: equilibrium disassociation constant. 
b : binding cooperativity factor between CP55,940 and the tested allosteric modulators.  
c 
Effects on CP55,940-induced GTPγS binding in the presence of allosteric modulator. 
d
 Data cited for 1 is from our earlier report and given for comparison (Ahn et al., 2012). 
e
 Compound 11l was reported earlier (Piscitelli et al., 2012) but was synthesized here and 
pharmacologically characterized for comparison with other analogs under the same 
conditions. 
ND: no detectable modulation of [
3
H]CP55,940 binding using up to 32 µM of test 
compound. 
- : not performed. 
 
We learned that replacing the indole ring of ORG27569 with a benzofuran ring (13b; 
LDK1210) resulted in a significant loss of the affinity of the ligand (KB = 2594 nM), however, 
the binding cooperativity with the orthosteric ligand was markedly enhanced (13b vs 
ORG27569). Similarly, replacing the indole ring of a potent CB1 allosteric modulator reported 
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earlier (11l) (Piscitelli et al., 2012) with a benzofuran ring (13c; LDK1238) led to a 3-fold 
increase in KB while the high binding cooperativity (=11.59) was well-preserved. These results 
suggest that the bicyclic aryl moiety (i.e. the indole ring, Figure 2.2) significantly impacts the 
ligand‘s affinity compared to its impact on the binding cooperativity. The indole ring, therefore, 
accounts more for the ligand‘s capability to bind to the allosteric site, but is less influential on the 
ligand‘s capability to modulate the orthosteric site.  In the benzofuran-2-carboxamides, removal 
of the C3 alkyl group (i.e. 13c vs 13d) eliminated the allosteric effects completely. 
To further characterize the nature of the compounds that show positive allosteric 
modulation on the binding of the CB1 orthosteric agonist [
3
H]CP55,940, compounds 11f 
(LDK1219), 11h (LDK1231), 11j (LDK1240) and 13b (LDK1210) were chosen for their strong 
allosteric properties (i.e. low KB value or high α value)  as representatives from each series of 
analogs and further tested for their effects on CP55,940-induced and basal G protein coupling 
using a [
35S]GTPγS binding assay. Figure 2.5 shows that 11f, 11h, 11j and 13b decrease agonist-
induced G protein coupling to the CB1 receptor in a concentration-dependent manner similar to 
the effects exhibited by the previously reported ORG27569, 2 (PSNCBAM-1), 11a (ICAM-b) 
and 4 (Lipoxin A4) (Ahn KH et al., 2013; Ahn et al., 2012; Horswill et al., 2007; Pamplona et 
al., 2012; Price et al., 2005). Remarkably, compound 11j exhibited a robust inhibitory effect in 
CP55,940-induced GTPS binding (Figure 2.5C) evident by a progressive decrease in the Emax 
values with an increasing concentration of 11j (LDK1240). For example, at 0.1 µM of 11j, the 
CP55,940-induced [
35
S]GTPS binding was substantially reduced (Emax = 53.4 ± 3.1 fmol/mg) 
compared with that in the absence of 11j (Emax = 113.0 ± 2.6 fmol/mg) while compounds 11f, 
11h and 13b exhibited comparable levels of reduction at 3.2 µM and higher (Emax = 61.4 ± 2.0, 
58.2 ± 1.07 and 59.5 ± 1.4 fmol/mg, respectively; Figure 2.5A, B and D). Treatment with 1 µM 
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of 11j showed complete inhibition of CP55,940-induced [
35
S]GTPS binding (Emax = 36.04 ± 2.0 
fmol/mg) while at least 10 µM of 11f, 11h and 13b was needed to achieve a similar effect. 
Because of the robust allostery that compound 11j displayed, the basal levels of G protein 
coupling in the absence of CP55,940 (Figure 2.5E) were also examined. Compound 11j also 
antagonized the basal level of [
35
S]GTPS in a concentration-dependent manner. Treatment with 
10 µM of 11j resulted in complete inhibition of this basal activity. While this pattern of G 
protein coupling is consistent with an inverse agonist‘s profile in its ability to inhibit basal and 
CP55,940-induced GTPS binding, when collectively taken with its enhancement of the 
orthosteric agonist CP55,940 binding, it indicates that these compounds are allosteric modulators 
that are likely able to selectively regulate the functions of the CB1 receptor. To date, compound 
11j (LDK1240) is the most effective allosteric antagonist of CB1 G protein coupling and 
surpasses both ORG27569 and 11a (ICAM-b) which we also found inhibited G protein coupling 
at 3.2 µM (Ahn KH et al., 2013; Ahn et al., 2012). Moreover, this pattern is consistent with the 
robust allostery of compound 11j as reflected by its binding parameters (Table 2.2).  
A recent study of the CB1 receptor explored the mechanism of action of ORG27569 
using a site-directed fluorescence labeling approach (Fay and Farrens, 2012). The results showed 
that the agonist CP55,940 induces a movement in the cytoplasmic end of TM6, which 
accompanies G protein coupling. Upon co-treatment with ORG27569, this agonist-induced 
movement is blocked. This state of CB1 may explain how ORG27569 and its analogs can elicit 
differential effects on CB1 agonist affinity and efficacy (i.e. a positive allosteric modulator of 
binding but an antagonist of G protein coupling activity).  
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Figure 2.5 Dose-response curves for CP55,940-induced [
35S]GTPγS binding to human 
embryonic kidney (HEK293) cell membranes expressing the CB1 wild-type receptor in the 
absence and  presence of compounds 11f (A), 11h (B), 11j (C) and 13b (D) at the indicated 
concentrations. The basal level of [
35S]GTPγS binding was also measured in the absence of any 
orthosteric ligand and the inhibition of it was tested at the indicated concentration of compound 
11j (E). Data are presented as specific binding of GTPγS to the membranes. Non-specific 
binding was determined in the presence of 10 μM unlabeled GTPγS. Each data point represents 
the mean ± S.E. (error bars) of at least three independent experiments performed in duplicate. 
Statistical significance of the differences in each concentration of 11j compared to basal (i.e. no 
ligand) in (E) was assessed using one-way analysis of variance and Bonferroni‘s post-hoc test; 
***, p < 0.005. The dotted line in (E) indicates the level of non CB1-mediated GTPγS binding 
obtained from [
35S]GTPγS binding to the mock-transfected membrane sample. 
 
2.5 Summary 
We synthesized a group of analogs of the CB1 allosteric modulator ORG27569 to 
understand the structure activity relationship of indole-2-carboxamides in allosteric modulation 
of the CB1 receptor. Within the structure of indole-2-carboxamides, the presence of the indole 
ring seems to be more influential on the ligand‘s binding affinity (KB) to the allosteric site than 
on the binding cooperativity () between the allosteric site and the orthosteric site. The C3 alkyl 
groups on the indole-2-carboxides profoundly impacted the allostery of the ligand. Through 
structural modification, we identified a robust CB1 allosteric modulator 11j (LDK1240) which 
showed an equilibrium dissociation constant KB of 167.3 nM with a markedly high binding 
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cooperativity factor (=16.55) and potent inhibition of GTPγS binding. Although a small 
binding constant KB for the allosteric modulator is not necessary for maximum binding 
cooperativity with the CB1 orthosteric ligand, CB1 modulators with high binding affinities to the 
allosteric site and high cooperativity towards the orthosteric site are desirable for therapeutic 
applications.  
 
2.6 Supporting Information  
Details of synthesis and compound characterization of intermediates 7a-f to 9a-f can be found in 
the supporting information for the associated paper. This material is available free of charge via 
the internet at http://pubs.acs.org. 
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Table 2.4. A guide to compound names and numbers 
 Compd. Chemical Name 
ORG27569 1 5-chloro-3-ethyl-N-(4-(piperidin-1-
yl)phenethyl)-1H-indole-2-carboxamide 
ICAM-b 11a 5-chloro-3-pentyl-N-(4-(piperidin-1-
yl)phenethyl)-1H-indole-2-carboxamide 
LDK   
1225 11b 5-chloro-3-phenyl-N-(4-(piperidin-1-
yl)phenethyl)-1H-indole-2-carboxamide 
1230 11c 3-benzyl-5-chloro-N-(4-(piperidin-1-
yl)phenethyl)-1H-indole-2-carboxamide 
1232 11d 5-chloro-3-(cyclohexylmethyl)-N-(4-(piperidin-
1-yl)phenethyl)-1H-indole-2-carboxamide 
1218 11e 5-chloro-3-heptyl-N-(4-pipridin-1-
yl)phenethyl)-1H-indole-2-carboxamide 
1219 11f 5-chloro-3-nonyl-N-(4-pipridin-1-
yl)phenethyl)-1H-indole-2-carboxamide 
1221 11g 5-chloro-3-pentyl-N-(4-(piperidin-1-yl)benzyl)-
1H-indole-2-carboxamide 
1231 11h 5-chloro-N-(4-morpholinophenethyl)-3-pentyl-
1H-indole-2-carboxamide 
1224 11i 5-chloro-3-pentyl-1H-indole-2-carboxylic acid 
[2-(4-phenoxy-phenyl)-ethyl]-amide 
1240 11j 5-chloro-N-(4-(dimethylamino)phenethyl)-3-
pentyl-1H-indole-2-carboxamide 
1243 11k 5-chloro-N-(1-(4-(dimethylamino)phenyl)-3-
hydroxypropan-2-yl)-3-pentyl-1H-indole-2-
carboxamide 
1202 13a 5-chloro-N-(4-(piperidin-1-
yl)phenethyl)benzofuran-2-carboxamide 
1210 13b 5-chloro-3-ethyl-N-(4-(piperidin-1-
yl)phenethyl)benzofuran-2-carboxamide 
1238 13c 5-chloro-N-(4-(dimethylamino)phenethyl)-3-
ethylbenzofuran-2-carboxamide 
1239 13d 5-chloro-N-(4-
(dimethylamino)phenethyl)benzofuran-2-
carboxamide 
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2.7 Conclusions and Future Directions 
The results from this study along with another indole-2-carboxamide study published 
from our lab (Khurana et al., 2014) elucidated key structural requirements of indole-2-
carboxamides for allosteric modulation of the CB1 receptor. The critical structural factors 
include (see Figure 2.2): (1) the chain length of the C3-alkyl group is critical with n-propyl being 
preferred for allosteric modulation of orthosteric ligand binding and n-hexyl being preferred for 
enhancing affinity of the allosteric modulator to the CB1 receptor, (2) an electron withdrawing 
group needs to reside at the C5 position of the indole ring (Figure 2.2), (3) the linker between the 
amide bond and the phenyl ring B (Figure 2.2) must be an ethylene group whereas shortening or 
elongating the linker abolishes allosteric effects, and (4) the substituent on the phenyl ring B 
explicitly influences both the binding to the allosteric site and the binding cooperativity with the 
orthosteric ligand, with the N,N-dimethyl amino group being preferred over the piperidinyl 
functionality of the prototypical CB1 allosteric modulator ORG27569. These SAR studies will 
guide the future design and synthesis of more potent CB1 allosteric modulators based on the 
indole-2-carboxamide scaffold.  
In recent years, drug discovery targeting allosteric sites of GPCRs has gained momentum 
(Muller et al., 2012). This approach offers a number of potential advantages over drugs targeting 
the orthosteric site, such as improved selectivity across receptor subtypes and the capability to 
maintain the spatial and temporal signaling profile of the endogenous ligand. The nature of 
biased signaling of some CB1 allosteric modulators such as 1 (ORG27569) (Ahn et al., 2012; 
Baillie et al., 2013), 11a (ICAM-b) (Ahn KH et al., 2013), and 4 (Lipoxin A4) (Figure 2.1) 
(Pamplona et al., 2012) suggested a possibility to selectively regulate specific functions of the 
CB1 receptor and this may be therapeutically beneficial. The activation and inactivation of the 
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CB1 receptor have been linked to therapeutic implications for many diseases such as drug 
addiction, anxiety, depression, obesity, neurodegeneration, cancer and inflammation. ORG27569 
has been the prototype to date for allosteric modulators of the CB1 receptor. Growing evidence 
indicates that ORG27569 (Ahn et al., 2012; Baillie et al., 2013) and its analogs (Ahn KH et al., 
2013) are functionally positive allosteric modulators of the CB1 receptor although they 
antagonize Gi-protein coupling activity to CB1. This class of compounds may selectively 
transduce the orthosteric agonist signals through the ERK1/2 phosphorylation pathway. Very 
recently, Pamplona et al demonstrated using in vivo experiments that the CB1 positive allosteric 
modulator Lipoxin A4 is protective against -amyloid-induced neurotoxicity (Pamplona et al., 
2012). The therapeutic potential of indole-2-carboximides represented by ORG27569 as 
neuroprotective agents remains to be explored. 
Future optimization of the allosteric modulators presented in this chapter, to increase 
their binding affinity to CB1, reflected by a decreased KB, while also maintaining a high binding 
cooperativity factor, is desirable for therapeutic applications. In addition, expanding the SAR 
studies for other scaffolds that have shown promise as allosertic modulators, including the 
diarylurea backbone of 2 (PSNCBAM-1) or the 3-phenyltropane backbone of 3 (RTI-371) (see 
Figure 2.1 for structures) will broaden possibilities and will aid in the future design and synthesis 
of more robust allosteric modulators and increase our understanding of ligand-specific 
modulation of the pharmacologically and physiologically vital CB1 receptor.  
It would also be of great interest to perform in vivo studies of the indole-2-carboxamide 
compounds, namely compound 11j (LDK1240), that have a higher binding affinity to CB1 than 
ORG27569 and also a higher cooperativity factor. The question of whether the actions of these 
allosteric modulators, that have been characterized in vitro, translate to the whole animal is 
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crucial to their benefit in therapeutics. An in vivo study (Horswill et al., 2007) of 2 (PSNCBAM-
1; Figure 2.1) showed that in an acute rat feeding model, PSNCBAM-1 decreased food intake 
and body weight. A more recent study (Gamage et al., 2014) investigated the effects of 
compound 1 (ORG27569) in a well-established mouse behavioral assay. The study showed that 
similar to the orthosteric CB1 inverse agonist rimonabant (SR141716A), ORG27569 reduced 
food intake. The study also questioned whether the anorectic effect presented by ORG27569 
occurred independently of the CB1 receptor (Gamage et al., 2014) and was non CB1-mediated 
since their results showed that ORG27569 did not elicit CB1-mediated effects alone and lacked 
efficacy in altering antinociceptive, cataleptic, and hypothermic actions of the orthosteric 
agonists anandamide, CP55,940, and Δ9-tetrahydrocannabinol. These findings question the utility 
of ORG27569 as a ‗gold standard‘ CB1 allosteric modulator and underscore the need for the 
development of other CB1 allosteric modulators, such as those presented in this chapter, with 
pharmacology that translates from the molecular level to the whole animal. 
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CHAPTER 3 
Novel Cannabinoid CB1 Receptor Inverse Agonists from the class of 
Benzyhydryl Piperazine Analogs 
Parts of this chapter have been incorporated from published material (Mahmoud, M.M, 
Olszewska, T., Liu, H., Shore, D.M., Hurst, D.P., Reggio, P.H., Lu, D., and Kendall, D.A. (4-
(Bis(4-fluorophenyl)methyl)piperazin-1-yl)(cyclohexyl)methanone hydrochloride (LDK1229): A 
New Cannabinoid CB1 Receptor Inverse Agonist from the class of benzhydryl piperazine 
analogs. Molecular Pharmacology, 87(2) (2015): 197-206). Compound synthesis and receptor 
modeling were done by our collaborators from the Lu lab and the Reggio lab, respectively. 
 
This chapter involves the characterization of 30 new compounds (for structures and chemical 
names see Tables 3.5-3.7) from the class of benzhydryl piperazine analogs as inverse agonists of 
the CB1 receptor. SR141716A, the first potent inverse agonist of CB1 was used for the treatment 
of smoking cessation, obesity and associated metabolic disorders. However, limited use in 
Europe revealed that this drug induced significant psychiatric side-effects, namely anxiety and 
depression and it was, therefore, withdrawn from the market. The design for an inverse agonist 
that can avoid such adverse side effects has been an ongoing effort in the field. The research 
presented here aims at furthering our understanding of the ligand-specific modulation of CB1 
receptor activity. Developing drugs that act in slightly different ways than classical drugs at the 
CB1 receptor would be a potential option to overcome the problems that have beset current 
endocannabinoid drugs. For instance, the non-psychomimetic major cannabis constituent, 
cannabidiol (CBD), has been suggested to be capable of antagonizing CB1 and CB2 receptor 
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agonists at reasonably low concentrations (Zuardi, 2008). In spite of its low affinity for CB1 
(Ki> 4000nM) and CB2 receptors (Ki > 2000 nM), CBD has shown several potential therapeutic 
properties, including antidepressive, anxiolytic (Crippa et al., 2004), antipsychotic (Zuardi et al., 
2006),  anti-diabetes (Weiss et al., 2006) and motor diseases effects (Zuardi et al., 2009). Thus, 
the objective of this chapter is to optimize CB1 inverse agonists that reduce the potential 
psychiatric side-effects of the classical CB1 receptor antagonists, such as rimonabant. This is 
done by optimizing the binding of the inverse agonists, i.e. high affinity, and to also develop 
peripherally restricted CB1 inverse agonists that do not produce undesired central nervous 
system side effects. These novel drugs can then be used to further our understanding of the 
ligand-specific modulation of CB1 receptor activity. 
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3.1 Abstract 
Some inverse agonists of the cannabinoid CB1 receptor have been demonstrated to be anorectic 
antiobesity drug candidates. However, the first generation of CB1 inverse agonists, represented 
by rimonabant (SR141716A), otenabant and taranabant, are centrally active with a high level of 
psychiatric side effects. Hence, the discovery of CB1 inverse agonists with a chemical scaffold 
distinct from these holds promise for developing peripherally active CB1 inverse agonists with 
fewer side effects. We present here the binding data for 30 new compounds from the class of 
benzhydryl piperazine analogs. From these, we characterized the CB1 inverse agonist (4-(Bis(4-
fluorophenyl)methyl)piperazin-1-yl)(cyclohexyl)methanone hydrochloride (LDK1229). This 
compound binds to CB1, more selectively than CB2, with a Ki value of 220 nM. Comparable 
CB1 binding was also observed by analogs 1-(Bis(4-fluorophenyl)methyl)-4-cinnamylpiperazine 
dihydrochloride (LDK1203) and 1-(Bis(4-fluorophenyl)methyl)-4-tosylpiperazine hydrochloride 
(LDK1222) which differed by the substitution on the piperazine ring where the piperazine of 
LDK1203 and LDK1222 are substituted by an alkyl group and by a tosyl group, respectively. 
LDK1229 exhibits efficacy comparable to SR141716A in antagonizing the basal G protein 
coupling activity of CB1 as indicated by a reduction in GTPS binding. Consistent with inverse 
agonist behavior, increased cell surface localization of CB1 upon treatment with LDK1229 was 
also observed. Although docking studies showed that LDK1229 forms similar interactions with 
the receptor as SR141716A, the benzhydryl piperazine scaffold is structurally distinct from the 
first generation CB1 inverse agonists; it offers new opportunities for developing novel CB1 
inverse agonists through optimization of molecular properties such as the polar surface area and 
hydrophilicity, to reduce the central activity observed with SR141716A. 
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3.2 Introduction 
The cannabinoid receptors are members of the class A superfamily of G protein coupled 
receptors (GPCRs). The cannabinoid receptor 1 (CB1) is present in high abundance throughout 
the central nervous system (Howlett, 1995) but is also expressed in a number of peripheral 
tissues, such as the cardiovascular and reproductive systems as well as the gastrointestinal tract 
(Batkai et al., 2001; Croci et al., 1998; Engeli et al., 2005), and is involved in substance 
addiction, chronic pain,  memory and metabolic and inflammatory disorders (Howlett et al., 
2004; Mackie, 2006; Pertwee, 2006). A second subtype of the cannabinoid receptors, the 
cannabinoid receptor 2 (CB2), is predominantly found in immune cells and non-neuronal tissues 
(Galiegue et al., 1995b) and is implicated in a variety of modulatory functions, including 
immune suppression, induction of apoptosis, and induction of cell migration (Basu and Dittel, 
2011). 
The CB1 receptor preferentially couples to the Gi/o type of G proteins (Howlett and 
Fleming, 1984) and has been functionally linked to the inhibition of adenylate cyclase (Slipetz et 
al., 1995) and the activation of mitogen-activated protein kinases (MAPKs), including 
extracellular signal-regulated kinase-1 and -2, p38 MAPK, and c-Jun N-terminal kinase (Ahn et 
al., 2012; Bouaboula et al., 1996; Turu and Hunyady, 2010). In addition, it is associated with the 
inhibition of N- and P/Q-type voltage-dependent Ca
2+
 channels and the stimulation of A-type 
and inwardly rectifying K
+
 channels (Howlett, 2005).  
As is common for many GPCRs (De Lean et al., 1980), the CB1 receptor may exist in 
multiple activation states that are promoted by its binding to different ligands. Upon binding to 
receptor agonists, such as the endogenous arachidonylethanolamide and 2-arachidonyl glycerol, 
or the synthetic agonists CP55,940 and WIN55,212-2, the active form of the receptor 
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predominates. Interestingly, the CB1 receptor possesses agonist-independent constitutive or basal 
activity which can be inhibited by inverse agonists (Pertwee, 2005a). This ligand-independent 
activity led to a receptor model that accounts for multiple activation states (Gether and Kobilka, 
1998; Ghanouni et al., 2001) with distinct biochemical characteristics, including extent and 
selectivity of G protein or β-arrestin coupling (Kenakin, 1995).  
Inverse agonists of the CB1 receptor have attracted considerable attention in drug 
discovery because of their ability to regulate appetite and manage substance addiction (Janero, 
2012; Janero and Makriyannis, 2009; Silvestri and Di Marzo, 2012b). Consequently, 
considerable effort has been invested in discovering compounds that can regulate the constitutive 
activity of the CB1 receptor. However, SR141716A (rimonabant) (Rinaldi-Carmona et al., 1994), 
the only CB1 inverse agonist to be briefly clinically marketed in Europe for the control of obesity 
(Moreira and Crippa, 2009), was removed from use due to its severe neuropsychiatric side 
effects including mood-depressant actions (Despres et al., 2005; Traynor, 2007). The first 
generation of CB1 inverse agonists are commonly derived from diaryl analogs of pyrazole (e.g. 
SR141716A) or pyrazole bioisosteres such as imidazole, triazole, thiazole and pyrazoline (Lange 
and Kruse, 2005; Lange and Kruse, 2008; Muccioli and Lambert, 2005). However, most of these 
are brain penetrant due to their physicochemical nature (Chorvat, 2013) and will likely generate 
unwanted side effects in the central nervous system.  In an effort to develop new CB1 inverse 
agonist scaffolds, we analyzed the common pharmacophore of this class of compounds that was 
proposed by Lange et al (Lange and Kruse, 2005). This showed that the biaryl groups connecting 
to a central heteroaromatic ring are pivotal in forming aromatic stacking interactions with CB1 
receptors (McAllister et al., 2004; Shim et al., 2012). This brought our attention to the 
benzhydryl piperazine scaffold, which exhibits a similar structure to the common pharmacophore 
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of CB1 inverse agonists in lieu of the biaryl heteroaromatic ring moiety. Hence, we synthesized a 
group of benzhydryl piperazine analogs, and demonstrated that some of the synthesized analogs, 
LDK1203, LDK1222 and LDK1229, exhibited inverse agonist binding profiles for the CB1 
receptor. In addition to its binding profile to the CB1 receptor, LDK1229‘s inverse agonism is 
evident from its effect on basal as well as agonist-induced G protein coupling, and its impact on 
the internalization and cell surface expression of CB1. Docking and mutational studies using a 
model of the inactive CB1 receptor showed that LDK1229 forms interactions with the receptor 
consistent with inverse agonist SR141716A. Discovering new and improved means for inhibiting 
the activity of CB1 is critical for understanding the constitutive activity of CB1 and for 
developing new therapeutic agents for treating substance addiction and disorders associated with 
CB1 activity. 
 
3.3 Materials and Methods 
Synthesis. The benzhydryl piperazine analogs LDK1203, LDK1222 and LDK1229 were 
synthesized by alkylation, tosylation and acylation of the 1-(4,4′-difluorobenzhydryl)piperazine 
(Figure 3.1A). The employed 1-(4,4′-difluorobenzhydryl)piperazine (III) was prepared by 
monoalkylation of piperazine with 4,4′-difluorobenzhydryl chloride (II) that was obtained by 
halogenation of 4,4′-difluorobenzhydryl methanol (I) with oxalyl chloride as previously reported 
(Weïwer et al., 2012). The obtained free bases of the benzhydryl piperazine analogs were then 
converted to their corresponding hydrochloric salts by reacting with an ethereal solution of HCl. 
The chemical identity of the newly synthesized compounds is as follows: LDK1203 is 1-(Bis(4-
fluorophenyl)methyl)-4-cinnamylpiperazine dihydrochloride, LDK1222 is 1-(Bis(4-
fluorophenyl)methyl)-4-tosylpiperazine hydrochloride and LDK1229 is (4-(Bis(4-
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fluorophenyl)methyl)piperazin-1-yl)(cyclohexyl)methanone hydrochloride. The structure 
confirmation data for the free bases of LDK1203, LDK1222 and LDK1229 can be found in the 
original publication. 
Plasmid Construction. All mutants were generated by site-directed mutagenesis (QuickChange; 
Stratagene, La Jolla, CA) using the human CB1 cDNA cloned into pcDNA3.1 as a template, 
according to the manufacturer‘s instructions. All mutations were confirmed by DNA sequencing. 
CB1 Expression and Membrane Preparation. Human embryonic kidney 293 (HEK293) cells 
were maintained in Dulbecco‘s modified Eagle‘s medium supplemented with 10% fetal bovine 
serum and 3.5 mg/ml glucose at 37°C in 5% CO2. For transient expression of the receptors, 
HEK293 cells were seeded at 800,000 cells/100-mm dish on the day prior to transfection and 
transfected with 5-10 µg of the wild type or mutant human CB1 receptor cloned into pcDNA3.1 
using the calcium phosphate precipitation method (Chen and Okayama, 1987). At 24 h post-
transfection, membranes of transfected cells expressing either the wild-type or mutant receptors 
were prepared as described previously (Ahn et al., 2009a).  
Radioligand Binding Assay. In the homologous and heterologous competition binding 
experiments, approximately 7.5 g of wild-type CB1, CB2 or mutant CB1  membrane was 
incubated at 30°C for 60 min with a fixed tracer ([
3
H]CP55,940, 141.2 Ci/mmol, 
[
3
H]SR141716A, 56 Ci/mmol, or [
3
H]WIN55,212-2, 52.2 Ci/mmol, PerkinElmer Life Sciences 
(Boston, MA)) concentration typically at its Kd, which was determined from saturation binding 
isotherms (see results for details). Binding assays were performed with at least nine 
concentrations of unlabeled competitor ligand (ranging between 100 pM and 100 M) as 
described previously (Ahn et al., 2012). Nonspecific binding was determined in the presence of 1 
M unlabeled CP55,940, SR141716A or WIN55,212-2. Reactions were terminated by adding 
 100 
 
300 L of TME buffer containing 5% BSA followed by filtration with a Brandel cell harvester 
through Whatman GF/C filter paper. Radioactivity was measured by liquid scintillation counting. 
The total assay volume and the amount of membrane samples were adjusted to avoid ligand 
depletion by keeping the bound ligand less than 10% of the total.  
GTPγS Binding Assay. GTPS binding assays were performed as described previously (Ahn et 
al., 2012). Briefly, 7.5 g of membranes were incubated for 60 min at 30°C in a total volume of 
200 L GTPS binding assay buffer (50 mM Tris-HCl, pH 7.4, 3 mM MgCl2, 0.2 mM EGTA, 
and 100 mM NaCl) with unlabeled test compounds as indicated, 0.1 nM [
35
S]GTPS (1250 
Ci/mmol; PerkinElmer Life Sciences, Boston, MA), 3 M GDP (Sigma, St. Louis, MO), and 
0.1% (w/v) BSA. 3 M GDP was used to increase the window of basal activity. Nonspecific 
binding was determined with 10 M unlabeled GTPS (Sigma, St. Louis, MO). The reaction was 
terminated by rapid filtration through Whatman GF/C filters. The radioactivity trapped in the 
filters was determined by liquid scintillation counting.  
Confocal Microscopy and Image Quantification. HEK293 cells were transfected with the CB1 
receptor carboxyl terminally fused to GFP using Lipofectamine (Invitrogen) according to the 
manufacturer‘s instructions. The CB1-GFP expressing cells were seeded onto 35-mm glass-
bottomed dishes (Matek, MA) pre-coated with poly-D-lysine. Cells were treated with different 
compounds for various lengths of time and then washed twice with PBS, followed by fixation 
with 4% paraformaldehyde for 10 min at room temperature. Images were acquired using a Leica 
confocal laser scanning microscope and detection of GFP was carried out following excitation at 
488 nm. Quantification of the fluorescence intensity was achieved by using the Quantitative 
Imaging of Membrane Proteins (QuimP) software (http://go.warwick.ac.uk/bretschneider/quimp) 
(Bosgraaf et al., 2009; Dormann et al., 2002), a set of plug-ins for the open source program 
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ImageJ (http://rsb.info.nih.gov/ij/). The Boa plug-in was used to detect the cell surface and 
checked against the cell edge in the transmitted image of each cell. The Ana plugin was then 
used to read the cell contours produced by the Boa plugin and compute the ratio of fluorescence 
intensity on the cell surface to the average intensity of the cell interior fluorescence. The results 
are representative of at least four independent transfections and 6 different images for each 
condition. Untransfected cells exhibited no apparent fluorescence under the experimental 
conditions that were used. The parameters for all of the acquired images and their consequent 
analysis were kept constant throughout. 
Ligand and GTPγS Binding Data Analysis. All ligand binding assays and GTPγS binding 
assays were carried out in duplicate. Data are presented as the mean ± S.E. value or the mean 
with the corresponding 95% confidence limits from at least three independent experiments. Ki 
values were calculated using the Cheng-Prusoff equation (Cheng and Prusoff, 1973) based on Kd 
values obtained from saturation binding analyses. The binding constants for the wild-type and 
mutant receptors were compared using analysis of variance (ANOVA) followed by Bonferroni‘s 
post hoc test for significance. p values of <0.05 were considered to be statistically significant. 
 
Computational Methods 
Conformational Analysis of LDK1229. To generate a library of low-energy conformers of 
LDK1229, the Spartan Conformation Distribution protocol was used (Wavefunction, Inc., Irvine, 
CA). In this protocol, the algorithm systematically searches through all rotatable bonds and ring 
conformations (e.g. alternate chair conformations for flexible rings). The energy of each 
conformer generated was calculated using the Merck Molecular Force Field (MMFF94S). This 
calculation yielded 68 unique conformations of LDK1229. The geometry and energy of these 68 
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conformations was refined by performing ab initio HF-6-31G* energy minimizations on each 
conformer. To calculate the difference in energy between the global minimum energy conformer 
and its final docked conformation, rotatable bonds in the global minimum energy conformer 
were driven to their corresponding value in the final docked conformation and the single-point 
energy of the resultant structure was calculated at the HF 6-31G* level. 
Template Rationale. Our CB1 inactive state model was initially constructed by using the 2.8 Å 
x-ray crystal structure of bovine rhodopsin (Rho) as a template (Palczewski et al., 2000). We 
chose rhodopsin for several reasons: (1) Rhodopsin has an intact ―ionic lock‖ (R3.50214-
E/D6.30
338
), which is the hallmark of the Class A GPCR Inactive state. (2) The cannabinoid 
receptors and rhodopsin have very hydrophobic binding pockets. Crystal structures reveal that 
the N-terminus of rhodopsin/opsin is closed over the binding pocket, preventing access from the 
extracellular milieu (Palczewski et al., 2000; Park et al., 2008; Scheerer et al., 2008b). It is very 
likely that CB1, with its 112 residue N-terminus, is also closed off to the extracellular milieu. 
Instead, rhodopsin/opsin have been reported to have lipid portals that are used for entry and exit 
via the lipid bilayer for 11-cis-retinal/trans-retinal as they are shuttled into and out of the receptor 
(Hildebrand et al., 2009). There is evidence from simulations (Hurst et al., 2010) and from 
experimental covalent labeling studies (Pei et al., 2008; Picone et al., 2005) that the cannabinoid 
receptors also possess a portal between TMH6 and TMH7 through which ligands enter. (3) In 
addition, the cannabinoid receptors and rhodopsin share an unusual, GWNC motif sequence 
motif at the extracellular (EC) end of TMH4. Here a Trp forms an aromatic stacking interaction 
with Y5.39
275
. This interaction influences the EC positions of TMH3-4-5. 
CB1 Inactive State Model. A sequence alignment between the sequence of the human CB1 
receptor (Gerard et al., 1991b) and the sequence of bovine rhodopsin was constructed, using 
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highly conserved residues as an alignment guide; in addition, the hydrophobicity profile of the 
sequence was also considered when constructing the sequence alignment. Residues in the bovine 
rhodopsin structure were then mutated to those of human CB1. The Monte Carlo/simulated 
annealing technique Conformational Memories was used to sample the conformational space of 
TMH6 (Barnett-Norris et al., 2002); this is because TMH6 is known to undergo a functionally-
necessary conformational change upon G protein-mediated signaling. For the inactive state 
model, the chosen TMH6 conformer was one that enabled the formation of a salt bridge between 
the highly conserved TMH6 residue D6.30
338
 and the highly conserved TMH3 residue R3.50
214
. 
This salt bridge (also termed the ―ionic lock‖) has been shown to be important in maintaining the 
inactive state in the β2 adrenergic (Ballesteros et al., 2001) and 5HT-2 receptors (Visiers et al., 
2002). Extracellular and intracellular loops were added to the model using Modeller (Marcu et 
al., 2013). SR141716A was docked (within the TMH3-4-5-6 region) in this CB1 inactive state 
model and the energy of the complex was minimized, as previously described (Hurst et al., 
2006).  
Glide Docking of LDK1229 at the CB1 Receptor (Inactive Conformation). The docking 
program, Glide (version 5.7, Schrödinger, LLC, New York, NY, 2011), was used to explore 
possible receptor binding modes of LDK1229. First, the SR141716A-CB1 binding site was 
chosen as a starting point for Glide docking studies because of the similar pharmacology 
between SR141716A and LDK1229. Second, LDK1229 displaces SR141617A in competitive 
binding experiments, suggesting some commonality between their binding sites. Thus, Glide was 
used to generate a grid centered on the center-of-mass of our previously reported binding site for 
SR141716A at the CB1 receptor (Hurst et al., 2002; McAllister et al., 2004; McAllister et al., 
2003). The grid dimensions were 26 Å x 26 Å x 26 Å; this grid size allowed Glide to thoroughly 
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explore the receptor for possible binding site(s). In addition, the results of previously reported 
mutagenesis and synthetic studies suggest that SR141716A forms an important interaction with 
K3.28
192
 that is necessary for its ability to act as an inverse agonist of G protein-mediated 
signaling (Hurst et al., 2006; Hurst et al., 2002). Therefore, Glide was required to dock 
LDK1229 in such a way so that it formed a hydrogen bond with K3.28
192
. The only other 
constraint used was the requirement that LDK1229 must be docked within the exploration grid. 
Standard precision was selected for the docking setup. 68 conformations of LDK1229 were 
flexibly docked using Glide. The best Glide dock was chosen for subsequent calculations. The 
chosen Glide dock was minimized, using the minimization protocol, described below. 
Receptor Model Energy Minimization Protocol. The energy of the LDK1229-CB1 complex, 
including loop regions, was minimized using the OPLS 2005 force field in Macromodel 9.9 
(Schrödinger, LLC, New York, NY, 2011). An 8.0-Å extended non-bonded cutoff (updated 
every 10 steps), a 20.0-Å electrostatic cutoff, and a 4.0-Å hydrogen bond cutoff were used in the 
calculation. The minimization was performed in two stages. In the first stage, the TMH backbone 
was frozen; this constraint was used to preserve secondary structure while allowing the ligand 
and TMH side chains to relax. In addition, loop residues were frozen, until they could be 
minimized using an appropriate dielectric (in the next stage of the minimization). No constraints 
were placed on the ligands during this stage. The minimization consisted of a conjugate gradient 
minimization using a distance-dependent dielectric of 2.0, performed in 1000-step increments 
until the bundle reached the 0.05 kJ/mol gradient. In the second stage of the calculation, the 
helices and ligand were frozen, but the loops were allowed to relax. The generalized 
Born/surface area continuum solvation model for water as implemented in Macromodel was 
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used. This stage of the calculation consisted of a Polak–Ribier conjugate gradient minimization 
in 1000-step increments until the bundle reached the 0.05 kJ/mol gradient. 
3.4 Results 
Chemistry. The free base forms of LDK1203, LDK1222 and LDK1229 were synthesized 
according to the scheme illustrated in Figure 3.1A, then purified by Combiflash chromatography 
followed by conversion to hydrochloric salts to increase shelf life and aqueous solubility. 
Confirmation data for their structure by mass spectroscopy and 
1
H NMR are presented in 
Materials and Methods. Representative first generation inverse agonists, Rimonabant, Otenabant, 
Taranabant and Ibipinabant are shown for comparison (Figure 3.1B). 
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Figure 3.1 Compound structures. (A) Synthesis of benzhydryl piperazine analogs LDK1203, 
LDK1222 and LDK1229. a) Oxalyl chloride, DCM, cat. DMF; b) Piperazine, CH3CN; c) 3-
Bromo-1-phenyl-1-propene, K2CO3, DMF; d) TsCl, DIPEA, DCM; e) Cyclohexanecarbonyl 
chloride, DIPEA, DCM; f) 1.0 M HCl in ether. (B) Representative members of the first 
generation of CB1 inverse agonists are shown for comparison. 
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LDK1229 and its Analogs Exhibit Inverse Agonist Binding Profiles. To elucidate the 
nature of these new compounds, we performed ligand binding studies using membrane 
preparations from HEK293 cells transfected with CB1. All three compounds competed with 
CP55,940 and SR141716A, an agonist and inverse agonist of CB1, respectively. Using 
[
3
H]CP55,940 (Kd = 2 nM) as a tracer, LDK1203, LDK1222 and LDK1229 bound wild-type 
CB1 with Ki values of 260 nM, 331 nM and 220 nM, respectively. Similarly while using 
[
3
H]SR141716A as a tracer (Kd = 5 nM), the compounds also bound with comparable affinities 
(Ki = 297 nM, 366 nM and 246 nM, respectively; Tables 3.1-3.3). The structures of LDK1203 
and LDK1222 differed from LDK1229 by the substitution groups on the piperazine ring where 
the piperazine ring of LDK1203 was substituted by an alkyl group and the piperazine of 
LDK1222 was substituted by a tosyl group. 
Since LDK1229 exhibited the strongest binding affinity among the compounds, it was 
further investigated for its capability to bind CB1 receptors in the active and inactive states to 
confirm its nature as a CB1 inverse agonist. The CB1 receptor in the active and inactive states can 
be readily mimicked by our previously engineered mutant CB1 receptor models (T210I and 
T210A) (D'Antona et al., 2006a). CB1 with the T210I mutation was shown to adopt a fully active 
form in comparison with the CB1 wild-type. In contrast, CB1 with the T210A mutation adopts an 
inactive state. A GPCR in its active state displays enhanced affinity towards agonists but 
decreased affinity towards inverse agonists, whereas the inactive state of the receptor exhibits the 
opposite binding properties such that inverse agonists show higher binding affinity than agonists 
(Cotecchia et al., 1990; D'Antona et al., 2006a; McWhinney et al., 2000; Wade et al., 2001). 
Hence, our mutant CB1 receptor models provide ideal tools to evaluate the inverse agonism of 
LDK1229. 
  
 
 
Table 3.1 LDK1203 and LDK1222 binding to the wild-type CB1 receptor. 
 vs. [
3
H] CP55,940  vs. [
3
H] SR141716A 
 
Ki (nM)
a
  Ki (nM) 
 
CP55,940 LDK1203 LDK1222 
 
 
SR141716A LDK1203 LDK1222 
CB1 wild-type 2.56 (1.45-4.51)
b
 260 (80.7-837) 331 (177-619)  5.23 (3.29-8.32)
b
 297 (192-458) 366 (144-928) 
a
Data are the median and corresponding 95% confidence limits of three independent experiments performed in duplicate. Ki 
values were determined from competition binding assays using [
3
H] CP55,940 or [
3
H] SR141716A as tracers at their 
respective Kd values as described in Results.  
b
Binding values are from Ahn et.al., 2009 for comparison. 
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As expected for an inverse agonist, using [
3
H]SR141716A as the tracer, the binding 
affinity of LDK1229 to the inactive T210A receptor was enhanced (Ki = 68 nM) relative to its 
affinity to the wild-type CB1 receptor (Ki = 246 nM; Table 3.2). A comparable trend is observed 
with the inverse agonist, SR141716A, that binds T210A with the highest affinity (Ki = 1.47 nM), 
and progressively weaker affinity for the wild-type CB1 (Ki = 5.23 nM), and then the T210I 
receptor (Ki = 14.7 nM). The ratio of binding affinity for the wild-type receptor relative to the 
mutant receptor for LDK1229 and SR141716A also reflects the preference of these two 
compounds for the inactive T210A receptor (Table 3.2).  
 
Table 3.2 LDK1229 binding to the T210A, wild-type and T210I CB1 receptors using 
[
3
H]SR141716A as a tracer. 
 
Ki (nM)
a
 
 
SR141716A Ki ratio  
(wild-type : mutant) 
LDK1229 Ki ratio  
(wild-type : mutant) 
CB1 T210A 1.47 (1.14-1.90) 4:1 67.4 (34.7-131) 3:1 
CB1 wild-type 5.23 (3.29-8.32)
b
 1:1 246 (164-367) 1:1 
CB1 T210I 14.7 (9.61-23.1) 1:3 NB
c
 - 
a
Data are the median and corresponding 95% confidence limits of three independent experiments 
performed in duplicate. Ki values were determined from competition binding assays using 
[
3
H]SR141716A as tracers at its respective Kd values as described in Results.  
b
Binding values are from Ahn et al. 2009 for comparison. 
 cNB: no binding using up to 32 μM of LDK compound. 
 
Using [
3
H]CP55,940 as the tracer, and examining binding of the agonist CP55,940, the 
pattern is reversed (Table 3.3); CP55,940 binds T210A most weakly and then progressively 
exhibits enhanced affinity for the wild-type CB1 and the T210I receptors. This is consistent with 
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its agonist properties. In contrast, LDK1229 binds CB1 wild-type more tightly than the T210I 
receptor consistent with inverse agonist binding profiles (D'Antona et al., 2006a). For the 
constitutively active T210I receptor, a large decrease in the binding affinity of LDK1229 
compared to the binding affinity of the agonist CP55,940 (5831 nM versus 0.835 nM) is 
observed. The ratio of binding affinity for the wild-type receptor relative to the mutant receptor 
for LDK1229 and CP55,940 is also given for comparison (Table 3.3). At the extremes, when 
using [
3
H]CP55,940 as a tracer, we cannot detect any specific binding with T210A, nor when 
using [
3
H]SR141716A as a tracer can we detect any specific binding with T210I, up to 32 µM of 
LDK1229. Taken together these data suggest that LDK1229‘s increased binding affinity to 
T210A over wild-type and its decreased binding affinity to T210I result from the compounds‘ 
inverse agonist mode of action. 
 
Table 3.3 LDK1229 binding to the T210A, wild-type and T210I CB1 receptors using [
3
H]CP55,940 
as a tracer. 
 
Ki (nM)
a
 
 
CP55,940 Ki ratio  
(wild-type : mutant) 
LDK1229 Ki ratio  
(wild-type : mutant) 
CB1 T210A 7.00 (2.59-18.9) 1:3 NB
c
 - 
CB1 wild-type 2.56 (1.45-4.51)
b
 1:1 220 (106-457) 1:1 
CB1 T210I 0.835 (0.542-1.29) 3:1 5831 (907-7510) 1:27 
a
Data are the median and corresponding 95% confidence limits of three independent experiments 
performed in duplicate. Ki values were determined from competition binding assays using 
[
3
H]CP55,940 as tracer at its respective Kd values as described in Results.  
b
Binding values are from Ahn et al. 2009 for comparison. 
cNB: no binding using up to 32 μM of LDK compound. 
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LDK1229 Inhibits Basal and Agonist-induced G Protein Coupling in a 
Concentration-dependent Manner. Given the inverse agonist properties observed in the 
binding profile of LDK1229 to the wild-type and mutant CB1 receptors, [
35S]GTPγS binding 
assays were performed in its presence. This assay monitors the level of G protein activation by 
determining the extent of binding of the nonhydrolyzable GTP analog to Gα subunits. We 
investigated the effects of LDK1229 on the basal G protein coupling activity levels of the wild-
type CB1 receptor (Figure 3.2A). Interestingly, using 1 M of LDK1229 in the absence of 
CP55,940 substantially reduced the basal level of [
35S]GTPγS binding from 110 fmol/mg to 70 
fmol/mg. We also evaluated its impact on agonist CP55,940-induced [
35S]GTPγS binding in the 
presence of various concentrations of LDK1229. We observed a progressive decrease in the 
specific GTPS binding with increasing concentration of LDK1229 up to 32 μM for the CB1 
wild-type receptor (Figure 3.2B).  
Like LDK1229, LDK1203 produced an antagonizing effect on the basal and the agonist-
induced levels of [
35S]GTPγS and is included for comparison (Figure 3.2). The antagonizing 
effect is consistent with the properties of an inverse agonist that promotes the inactive form of 
the receptor and suggests that this compound inhibits G protein coupling. 
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Figure 3.2 Effect of LDK1229 and LDK1203 on the stimulation of [
35
S] GTPS binding to 
HEK293 cell membranes expressing the CB1 wild-type receptor. (A) The basal level of [
35
S] 
GTPS binding was measured for the CB1 wild-type receptor. The stimulatory effect of 
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CP55,940 and the inhibitory effects of SR141716A, LDK1229 and LDK1203 on [
35
S] GTPS 
binding were measured at the indicated concentrations. Statistical significance of the differences 
compared to basal was assessed using one-way analysis of variance and Bonferroni‘s post hoc 
test: *p < 0.05, **p < 0.01, and ***p < 0.001. (B) The inhibitory effects of both LDK1229 and 
LDK1203 on CP55,940-induced [
35
S] GTPS binding in membrane preparations. Statistical 
significance of the differences compared to 0.1µM CP55,940 alone was assessed using one-way 
analysis of variance and Bonferroni‘s post hoc test: †p < 0.05, ††p < 0.01, and †††p < 0.001. 
Data are presented as specific binding of GTPS to the membranes. Nonspecific binding was 
determined in the presence of 10 µM unlabeled GTPS. Each data point represents the mean ± 
S.E. (error bars) of at least 3 independent experiments performed in duplicate. The dotted line 
indicates the level of non CB1-mediated GTPS binding obtained from GTPS binding to the 
mock-transfected membrane sample. 
 
LDK1229 Promotes Cell Surface Expression of the CB1 Receptor. Upon prolonged 
exposure to an agonist, GPCRs become desensitized and subsequently internalize in the cell. 
Inverse agonists, however, act in the opposite manner by promoting GPCR localization to the 
cell surface (Marion et al., 2004; Rinaldi-Carmona et al., 1998b). To assess the effect of 
LDK1229 on CB1 cellular localization, we determined the cellular response of CB1 upon 
LDK1229 treatment using confocal microscopy of cells expressing GFP-tagged CB1 receptors. 
Previous observations (Leterrier et al., 2004; Martini et al., 2007; Rozenfeld and Devi, 2008) 
indicate that CB1 is partially constitutive and that much of the wild-type CB1 receptor (~85%) is 
localized on intracellular vesicles. Using the CB1-GFP chimera expressed in HEK293 cells and 
treated with vehicle alone (0.03% DMSO), we found that about 15% of CB1 is present at the 
 114 
 
plasma membrane but that the pattern of receptor fluorescence within the cells was 
intracellularly punctate, suggesting that a substantial proportion of receptors is internalized 
consistent with its basal activity (Figure 3.3). Treatment with 0.1 µM of the agonist CP55,940 
resulted in a further shift toward internalization and a punctate appearance of the CB1-GFP 
receptor within the cells (data not shown). In contrast, treatment with 1 µM SR141716A or 10 
μM LDK1229 resulted in approximately 20% cell surface localization evident within 3 h and an 
increase to about 65% of cell surface localization after 5 h (Figure 3.3B). This is strikingly 
different from the cell surface localization of 13% for basal cells at 5 h. Taken together, these 
data further support the inverse agonist activity of LDK1229. 
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Figure 3.3 The effect of LDK1229 on the internalization of the CB1 receptor. (A) HEK293 
cells expressing the CB1-GFP receptor were incubated with vehicle alone (0.03% DMSO), 0.5 
µM SR141716A or 10 µM LDK1229. SR141716A is shown for comparison. (B) Quantification 
of CB1 receptors on the cell surface. The QuimP software with plug-ins was used as described in 
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Materials and Methods. Images are representative of at least four independent transfections. The 
scale bar is 5 µm. 
 
LDK1229 Docked in the CB1 receptor (Inactive) Model. Since LDK1229 exhibited the 
strongest binding affinity among the compounds, Glide docking studies were performed and 
suggest that LDK1229 binds in the TMH3-4-5-6 region of CB1. This is the same region that 
forms the binding site for SR141716A at CB1.  Figure 3.4A and 3.4C illustrate SR141716A 
(shown in cyan) docked in the CB1 inactive state model. The hydrogen bonding interaction is 
consistent with our prior CB1 mutant cycle studies which indicated that the amide oxygen of 
SR141716A interacts directly with K3.28
192
. This interaction is critical for the inverse agonist 
properties of SR141716A (Hurst et al., 2006; Hurst et al., 2002).  
 At its binding site, SR141716A also forms several aromatic-stacking interactions. First, 
the SR141716A dichlorophenyl ring forms aromatic T-stacks with F3.36
200
 and W5.43
279
 (shown 
in orange, see Figure 3.4A). In addition, the SR141716A chlorophenyl ring forms off-set parallel 
aromatic stacks with Y5.39
275
 and W5.43
279
 (shown in orange); In addition, SR141716A forms 
hydrophobic interactions with W6.48
356
. These aromatic interactions are consistent with our 
prior mutagenesis studies (McAllister et al., 2004; McAllister et al., 2003) which indicated that 
SR141716A interacts within an aromatic microdomain in CB1, which comprised of F3.36
200
,
 
Y5.39
275
, W5.43
279
 and W6.48
356
.
  
Finally, SR141716A forms hydrophobic interactions with 
L3.29
193
, V3.32
196
, and L6.51
359
 (shown in lime, see Figure 3.4C). In the ligand-free CB1 
receptor, the F3.36
200
/W6.48
356
 aromatic stacking interaction is instrumental to the maintenance 
of the CB1-inactive state (McAllister et al., 2004). The binding of SR141716A stabilizes the 
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F3.36
200
/W6.48
356
 aromatic stacking interaction through the formation of an extensive network 
of aromatic stacks within the ligand-receptor complex (Shim et al., 2012). 
Figures 3.4B and 3.4D illustrate the final docked conformation of LDK1229 (shown in 
lavender) in the CB1 inactive state model (Data Supplement).  Like SR141716A, the LDK1229 
amide oxygen forms a hydrogen bond with K3.28
192
 (shown in yellow). The geometry of this 
hydrogen bond is not optimal, however, because the hydrogen bond distance is longer than found 
for SR141716A (2.8 Å vs. 2.6 Å) and because the hydrogen bond angle deviates more from 
linearity than that formed with SR141716A (157° vs. 171°). This suggests that the interaction 
between LDK1229 and K3.28
192
 is weaker than the interaction between SR141716A and 
K3.28
192
. The importance of this difference between SR141716A and LDK1229 is discussed in 
more detail below. 
 Like SR141716A, LDK1229 also docks in the CB1 TMH3-4-5-6 aromatic microdomain, 
but the geometry of its interactions differ somewhat from SR141716A.  The fluorophenyl ring of 
LDK1229 forms aromatic T-stacking interactions with W6.48
356
 and W5.43
279
 (shown in orange, 
see Figure 3.4 (B)). In addition, the other fluorophenyl ring of LDK1229 forms off-set parallel 
aromatic stacking interactions with Y5.39
275
 and W5.43
279
 (shown in orange). However, 
LDK1229 does not form an aromatic stacking interaction with F3.36
200
.  This is due to a 
difference in how the two compounds are oriented within the receptor. Finally, LDK1229 also 
forms several hydrophobic interactions with residues F3.36
200
 (shown in orange), L3.29
193
, 
V3.32
196
, and L6.51
359
 (shown in lime). 
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Figure 3.4 Model of LDK1229 docked in the inactive CB1 receptor model. (A) and (C) 
illustrate SR141716A (shown in cyan) docked in the CB1 inactive state model. (B) and (D) 
illustrate the final docked conformation of LDK1229 (shown in lavender) in the CB1 inactive 
state model. Hydrogen bonds are shown in yellow, aromatic microdomain residues are shown in 
orange, and hydrophobic interactions are shown in lime. 
 
Mutational Analysis of Computationally Predicted Residues in the LDK1229 
binding pocket. To test the LDK1229 binding-site hypothesis generated by the receptor model, 
selective mutation of key residues in the CB1 receptor were generated. The K3.28
192
A, 
W5.43
279
A, W6.48
356
A, or C7.42
386
M mutant CB1 receptors were generated. Our results showed 
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that the K3.28
192
A mutant receptor resulted in total ablation of [
3
H]CP55,940 binding at wild-
type CB1 and that this residue is critical for CP55,940 binding consistent with previous data 
(Song and Bonner, 1996). Therefore, competition binding assays on the K3.28
192
A mutant were 
performed using [
3
H]WIN55,212-2 as a tracer since [
3
H]WIN55,212-2 binding to the K3.28
192
A 
mutant was not significantly different than its binding to the wild-type receptor (Kd = 8.6 nM 
versus Kd = 4.5 nM). Competition binding analysis revealed that the binding of LDK1229 (Ki = 
1316 nM) was affected 6-fold by this mutation compared to wild-type (Ki = 324 nM; Table 4) 
suggesting that this residue may be important for a hydrogen bonding interaction with LDK1229.  
These results alone cannot tell us the specific region on LDK1229 with which K3.28
192
 interacts, 
but modeling studies reported here suggest that K3.28
192  
hydrogen bonds with the carboxyl 
oxygen of LDK1229.  The K3.28
192
A  mutation results reported here are consistent with previous 
CB1 K3.28
192
A mutation studies which showed that K3.28
192
A is an important interaction site 
(Hurst et al., 2002) for the carboxamide oxygen of SR141716A (Hurst et al., 2006). 
Saturation (equilibrium) binding analysis for [
3
H]CP55,940 at the other three mutant 
receptors, W5.43
279
A, W6.48
356
A, and C7.42
386
M, showed that the affinity parameters obtained 
for the mutant receptors were not significantly different from the Kd at the wild-type CB1 
receptor (Kd for mutants = 6 nM, 4 nM, and 3 nM respectively) suggesting these receptors were 
properly folded. Therefore, competition binding assays on these mutants were performed using 
[
3
H]CP55,940 as a tracer. The W5.43
279
A mutation had the most profound effect on LDK1229 
binding compared to any of the other mutations and showed only 39% displacement of 
[
3
H]CP55,940 when using 32 µM of LDK1229. This result is consistent with the modeling 
studies that suggest that W5.43
279
A is central in the formation of the aromatic T-stacking 
interactions with the two fluorophenyl rings in LDK1229. The W6.48
356
A mutant affected 
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LDK1229 binding by 9-fold (Ki = 1987 nM) and the C7.42
386
M mutant by 5-fold (Ki = 1010 nM; 
Table 3.4). The result for the W6.48
356
A mutation further supports the modeling results which 
suggest that this mutation participates in direct aromatic stacking interactions with one of the 
fluorophenyl rings of LDK1229 consistent with prior studies (McAllister et al., 2003). As shown 
in Table 4, we found here that enlarging the residue at position 7.42 via the C7.42
386
M mutation 
results in a 5-fold loss in affinity for LDK1229 consistent with previous studies by Farrens and 
colleagues (Fay et al., 2005). Taken together, the results of all mutation studies are consistent 
with the modeling results reported here, specifically that LDK1229 occupies the same general 
binding region as SR1417167A.  
Table 3.4. LDK1229 binding to the wild-type or mutant CB1 receptors using 
[
3
H]CP55,940 or [
3
H]WIN55,212-2 as a tracer. 
 
 
Ki 
a
 
  [
3
H]CP55,940 
Receptor  nM Ki ratio  
(wild-type : mutant) 
CB1 wild-type  220 (106-457) 1:1 
K3.28
192
A  1316 (1115-1626)
b
 1:4
b
 
W5.43
279
A  ND
c
 - 
W6.48
356
A  1987 (895-2736) 1:9 
C7.42
386
M  1010 (832-1154) 1:5 
a
Data are the median and corresponding 95% confidence limits of three independent 
experiments performed in duplicate. Ki values were determined from competition binding 
assays using [
3
H]CP55,940 as tracer at its respective Kd values as described in Results.  
b
Binding was performed with [
3
H]WIN55,212-2 as a tracer. LDK1229 binding to CB1 wild-
type using [
3
H]WIN55,212-2 as a tracer yielded a Ki= 324 nM (205-524).  
c
ND: not detectable; 39% displacement at 32 µM. 
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LDK1229 has Diminished Activity for CB2. Based on both binding and functional data, 
LDK1229 showed some selectivity for the CB1 receptor over the CB2 receptor (Figure 3.5). This 
is evident by LDK1229‘s 3-fold reduced binding affinity (Ki= 633 nM; Figure 3.5A) to the CB2 
receptor compared to the CB1 receptor (Ki= 220 nM; Table 3.3) using [
3
H]CP55,940 as a tracer. 
This selectivity is also evident by the small magnitude of the reduction in basal and agonist-
induced G protein coupling using CB2. Using 1 M of LDK1229, in the absence of CP55,940, 
only reduced the basal level of [
35S]GTPγS binding from 95 fmol/mg to 88 fmol/mg (Figure 
3.5B) compared to the 2-fold decrease observed with CB1 (Figure 3.2A). We also observed a 
small decrease in the CP55,940-induced [
35S]GTPγS binding with an increasing concentration of 
LDK1229 (Figure 3.5B) with up to 32 μM of LDK1229 (to 110 fmol/mg from the original 120 
fmol/mg). The CB2 selective inverse agonist SR144528 (Rinaldi-Carmona et al., 1998a) 
antagonized the basal level of [
35S]GTPγS binding and is shown for comparison. We also found 
that LDK1229 can dock in the CB2 inactive state model but in a higher energy conformation 
(data not shown).  This is likely the origin of the 3-fold loss of affinity at CB2. 
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Figure 3.5 The binding parameters of LDK1229 and LDK1203 to CB2. (A) Binding of 
LDK1229 and LDK1203 to CB2 wild-type receptors and (B) their effect on the stimulation of 
[
35
S] GTPS binding. Statistical significance of the differences (*compared to basal, †compared 
to 0.1µM CP55,940 alone) was assessed using one-way analysis of variance and Bonferroni‘s 
post hoc test: *p < 0.05, **p < 0.01, and ***p < 0.001; †p < 0.05, ††p < 0.01, and †††p < 0.001. 
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3.5 Discussion and Future Directions 
In an effort to develop new modulators of the CB1 receptor, we synthesized a group of 
about 30 benzhydryl piperazine analogs (see Tables 3.5-3.7) including the compounds 
LDK1203, LDK1222 and LDK1229 and describe their inverse agonist properties in this study. In 
addition to their inverse agonist binding profiles to the CB1 receptor and their preference to bind 
the inactive T210A CB1 receptor over the constitutively active wild-type CB1 or fully active 
T210I receptor (Tables 3.2-3.3), the inverse agonism exhibited by LDK1229 was also evident 
from its antagonistic effect on basal and agonist-induced G protein coupling (Figure 3.2), and its 
ability to increase the CB1 localization to the cell surface (Figure 3.3). LDK1229 exhibited a 
lower affinity for the CB2 receptor, with relative selectivity for the CB1 receptor of 3-fold. 
Because the CB1 receptor is constitutively active both in-vitro and in-vivo (Landsman et al., 
1997; Meschler et al., 2000), discovering new and improved means for inhibiting the activity of 
the receptor is therapeutically useful and relevant for modulating activity of the CB1 receptor 
system in the brain. 
Our results show that the benzhydryl piperazine analogs represented by LDK1229 behave 
as inverse agonists of the CB1 receptor. Structurally, the benzhydryl piperazine analogs are 
distinct from the first generation of CB1 inverse agonists, which generally possess nitrogen-
containing 5- or 6-member aromatic rings as their central connecting units (Chorvat, 2013; 
Lange and Kruse, 2005; Vemuri et al., 2008). In contrast, benzhydryl piperazine analogs have a 
central core of piperazine, which is non-aromatic and possesses basic amino group(s). A 
pharmacophore model of the first-generation of CB1 inverse agonists was proposed, (Lange and 
Kruse, 2005) of which the biaryls (e.g. SR141716A) form favorable aromatic stacking 
interactions with two sub pockets surrounded by residues Y5.39
275
-W4.64
255
-F5.42
278
 and 
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residues W5.43
279
-F3.36
200
-W6.48
356
 of CB1. The central core (e.g. pyrazole in SR141716A) 
then connects to a lipophilic moiety through a hydrogen bond acceptor (e.g. the carbonyl of 
SR141716A). The hydrogen bond acceptor stabilizes the D6.58
366
-K3.28
192
 salt bridge in the 
inactive state of the CB1 receptor. The lipophilic moiety (e.g. the methylene groups of piperidine 
ring in SR141716A) fits in a pocket formed by V3.32
196
-F2.57
170
-L7.43
387
 and M7.44
384
 of the 
CB1 receptor (Lange and Kruse, 2005). In spite of the structural difference between our 
benzhydryl piperazine analogs and the first generation of CB1 inverse agonists, docking 
SR141716A and LDK1229 into the CB1 inactive state model suggest that both compounds bind 
in similar receptor regions and form similar interactions with the receptor. This is also consistent 
with the results of competitive displacement assays that suggest LDK1229 displaces 
SR141716A, implying an overlapping binding site. However, the results of the docking studies 
suggest one major difference between SR141716A and LDK1229; the geometry of the 
SR141716A hydrogen bond with K3.28
192
 is much better than that of LDK1229.  
Conformational analysis of LDK1229 suggests that it does not have the conformational freedom 
to adopt a conformation that would allow it to improve its hydrogen bond geometry. In addition, 
the extra ring hydrogen (cyclohexyl ring vs. piperidine ring) introduced in LDK1229 forces the 
ligand to position itself differently.
  
Together,
 
these effects lead to a less favorable hydrogen bond 
with K3.28
192
. This is consistent with the results of the binding experiments that show that 
SR141716A has a higher affinity for CB1 than does LDK1229. Notably, LDK1229 exhibits an 
efficacy comparable to SR141716A in antagonizing basal GTPS binding to the CB1 receptor 
although it shows a weaker binding affinity to the receptor (Table 2, Table 3 and Figure 2). One 
advantage of the benzhydryl piperazine analogs is that the piperazine ring provides two amino 
groups that can be readily used in further derivatization. This opens up rich opportunities for 
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structural modifications that may lead to the improvement of the pharmacokinetic properties of 
the drug molecules, such as their lipophilicity and polar surface area, which are critical factors 
influencing the brain barrier-penetration of these compounds.  
Evidence has begun to emerge on the involvement of the endocannabinoid system in the 
regulation of metabolism in several peripheral organs crucial to energy storage and utilization 
(Di Marzo and Matias, 2005; Silvestri et al., 2011). Elevated peripheral endocannabinoid levels 
and increased CB1 expression in these tissues have been observed in several studies of obese 
mice (Pagotto et al., 2006)  as well as obese humans compared to leaner controls (Engeli et al., 
2005). In light of the above, it has proven difficult to diminish the adverse central nervous 
system effects of brain-penetrant CB1 inverse agonists (Jones, 2008). Not surprisingly, 
significant effort has been put forth to develop CB1 neutral antagonists (Janero, 2012) or 
peripherally restricted CB1 inverse agonists (Chorvat, 2013; Silvestri and Di Marzo, 2012b) that 
do not produce undesired central nervous system side effects.  LDK1229 suggests a new lead for 
developing novel CB1 inverse agonists and is attractive for the design and synthesis of 
peripherally active CB1 inverse agonists, a class of potential therapeutic agents for the treatment 
of obesity and other related metabolic syndromes. In general, there are several strategies to 
reduce a ligand‘s permeability to the blood brain barrier (BBB) (Clark et al., 2005). These 
include increasing H-bonding capacity, molecular weight (MW) and polar surface area (PSA) as 
well as introducing acidic functional groups or increasing hydrophilicity. In comparison with the 
conventional scaffold of CB1 inverse agonists (i.e. biaryl substituted heteroaromatic ring), the 
benzhydryl piperazine scaffold offers two basic nitrogen atoms, which provide extra 
opportunities to increase the overall H-bonding capability. Additionally, the two basic nitrogen 
functionalities, are considerably easy to modify to introduce various substitutions so that the MW 
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and PSA properties can be readily manipulated to gain suitable pharmacokinetic (PK) properties 
that reduce BBB penetration. Hence, this scaffold enriches the chances for PK-driven drug 
optimization to achieve the desired peripheral restriction of CB1 inverse agonists. 
In a preliminary attempt, we designed and synthesized 3 compounds, LDK1270, 
LDK1273, and LDK1276, to be peripherally active (Tables 3.5-3.7). Although LDK1270 and 
LDK1273 showed no detectable binding with up to 32 µM of LDK compound, LDK1276 
showed promise in its ability to partially displace (41% displacement) the inverse agonist [
3
H] 
SR141716A when using 32 µM of LDK1276 in the presence of 5 nM of [
3
H] SR141716A. The 
hydrophilic nature of these compounds (see structures in tables 3.5-3.7) may be the cause of their 
inability to penetrate the HEK293 membrane preparations and bind CB1 to fully displace the 
inverse agonist SR141716A.  
While the three peripherally active compounds identified thus far are previews of an early 
effort, they provide information on chemical templates and strategy—knowledge that can be of 
value for a new lead for optimizing and developing novel CB1 inverse agonists. The potential 
ability of these agents to treat obesity and other related metabolic syndromes in a unique and 
specific fashion versus available therapies makes the design of peripherally active compounds an 
enticing approach.  
 The modeling hypothesis presented in this manuscript proposes that the interaction of 
LDK1229 with the binding pocket of CB1 differs from the binding of SR141716A. This would 
suggest that the mode of action for the two inverse agonists is possibly different. Future studies, 
including the downstream signaling effects of LDK1229 compared to those of SR141716A, 
would provide more insight into whether LDK1229 will avoid the adverse side effects presented 
by SR141716A. In vivo animal studies of LDK1229 or its analogs will also give us more insight 
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into the physiological effects this inverse agonist presents in animal models. Another important 
avenue for future research will be to test LDK1229 against the endogenous endocannabinoids, 
and see whether they can compete with 2-AG and AEA and whether they are true inverse 
agonists in vivo for the confirmation of these results and their further characterization in the 
brain and clarification of their functional and therapeutic significance. 
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Table 3.5. Binding of benzhydryl piperazine analogs (entry numbers 1-12) to the wild-type 
CB1 receptor. 
2HCl
N N
F
F
R1
 
Entry LDK R
1
 vs. [
3
H] CP55940 
nM 
vs. [
3
H] 
SR141716A 
nM 
1 1203 
 
259.9 (80.7-837.4) 296.8 (192.4-458.1) 
2 1204 
N
 
NB NB 
3 1205 OCH3
 
1312 (700-2457) - 
4 1206 CF3
 
2035 (518.1-7992) - 
5 1207 
 
746.2 (362.7-1535) - 
6 1208 
OCH3
OCH3
 
1589 (1061-2378) - 
7 1209 F
 
1853 (1154-2976) - 
8 1211 
OCH3
OCH3
OCH3
 
686.5 (435.9-1081) - 
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9 1233 
H3CO OCH3
OCH3
 
1313 (855.4-1520) - 
10 1234 
H3CO
OCH3
 
768 (227.2-2596) - 
11 1270* N
O
N  
NB NB 
12 1276* S
O
N NCH3
O
 - partial
#
 
NB: no detectable binding with up to 32 mM of LDK compound. 
ND: not determined. 
* designed to be peripherally active. 
#
41% displacement was observed at 32 mM of LDK1276 in presence of 2 nM of [
3
H] 
SR141716A. 
- : not performed. 
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Table 3.6 Binding of benzhydryl piperazine analogs (entry numbers 13-25) to the wild-type 
CB1 receptor. 
F
N
F
N R
2
ClH
 
Entry LDK R
2
 vs. [
3
H] CP55940 
nM 
vs. [
3
H] SR141716A 
nM 
13 1213 
O
 
644.2 (365-1137) - 
14 1214 
O
Cl
 
269.5 (176.8-410.8) - 
15 1215 
O
OCH3
 
1070 (692.5-1653) - 
16 1216 
O
 
725.5 (213.3-2276) - 
17 1217 
O
 
464.9 (156.7-1380) - 
18 1222 
S
O
O
CH3
 
330.8 (176.6-619.1) 365.7 (144.1-928.2) 
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19 1223 
 
530 (141.1-1991) - 
20 1227 S
O
O
 
276.8 (91.4-838.2) - 
21 1228 
S
O
O
O
 
355.8 (156.9-806.6) - 
22 1229 
O
 
219.7 (105.6-457) 245.5 (164.2-367.1) 
23 1271 
NH
O
 
232.7 (148.7-364.1) 232.8 (127.6-425) 
24 1275 
S
N
OO
 
252.1 (107-593.9) 292.8 (147.1-582.7) 
25 1277 
O
N
 
- 1077 (589.7-1968) 
- : not performed. 
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Table 3.7 Binding of benzhydryl piperazine analogs (entry numbers 26-29) to the wild-type CB1 
receptor. 
N N R
3
F
F  
Entry LDK R
3
 vs. [
3
H] CP55940 
nM 
vs. [
3
H] SR141716A 
nM 
26 1212 
O
 
1076 (643.2-1801) - 
27 1272^ N
O
N  
NB NB 
28 1273* 
N
+
N N
O
F
F
N
+
 
NB NB 
29 1274 N
O
O 
NB NB 
^compound LDK1272 is the free base form of LDK1270. 
NB: no detectable binding with up to 32 mM of LDK compound. 
* designed to be peripherally active.  
- : not performed. 
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CHAPTER 4 
Site-specific Incorporation of the Unnatural, Photo-cross-linking 
Amino Acid p-benzoyl-L-phenylalanine (pBpa) into the 
Cannabinoid Receptor CB2 
4.1 Abstract 
Many of the intracellular loops of GPCRs, including the carboxyl terminus, have been implicated 
in the regulation of receptor activation, signaling, and subcellular localization as well as the 
binding and dynamic recruitment of numerous proteins. However, studies thus far on interactions 
between the receptor and binding partners have mostly been restricted to peptides corresponding 
to regions of GPCRs and in vitro assays. Although we have learned extensively from these, 
predictions and extrapolation of data to the full-length receptor without really knowing how its 
presence may alter the structures, orientations and membrane interactions of the intracellular 
loops have been necessary. Incorporating p-benzoyl-L-phenylalanine (pBpa), an unnatural amino 
acid with photo-cross-linking properties, into the full length CB2 receptor under its native 
cellular conditions will enable us to identify the binding partners of CB2 in situ either by mass 
spectrometry (MS) or by western blotting with antibodies to the putative binding partner. This 
technique has been used in bacterial cells but has only recently been applied to mammalian cells. 
In this chapter, we piloted and optimized the technique and show the successful incorporation of 
this unnatural amino acid into different sites on the CB2 receptor. The data presented here lays 
the foundation for the application of this technique to delineating the binding partners of CB2, 
and can also be used as a basis for other GPCR model systems. It will also aid in the 
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understanding of the ligand-dependent modulation of receptor activity. Different ligands produce 
different downstream signaling patterns and therefore recruit different binding partners for the 
different processes or pathways each ligand activates. We hope that this technique will help to 
delineate some of these details so that they can be used to ultimately design drugs that can fine-
tune and regulate a GPCR and select the signaling pathway that produces the desired therapeutic 
effect while maintaining the least number of side effects. 
 
4.2 Introduction  
GPCRs associate with a plethora of interacting partners such as G proteins, GRKs, arrestins and 
many more accessory proteins (reviewed in (Brady and Limbird, 2002; Ritter and Hall, 2009)). 
In some cases these proteins can directly mediate receptor signaling, whereas in other cases they 
act as scaffolds to modulate G protein-mediated signaling. 
G proteins. A myriad of studies involving chimeric substitutions, various mutational 
approaches, and the use of synthetic peptides have been performed to define the structural 
determinants of GPCRs in the interactions with G proteins. The studies have established the 
pivotal roles of the second (IC2) and the third intracellular (IC3) loops plus, in some receptors, 
the proximal part of the carboxyl-terminus in G protein coupling (reviewed in (Strader et al., 
1994; Wess, 1998)). Moreover, numerous studies have established the pivotal role of IC2 in 
determining receptor and G protein coupling and interaction (Burstein et al., 1998; Fernandez 
and Puett, 1997; Wess et al., 1997). Replacement of the entire IC2 of the bradykinin B2 receptor 
with the E2 prostaglandin receptor resulted in a cAMP-generating receptor, which indicated the 
importance of this domain for Gs coupling and activation (Pal-Ghosh et al., 2003). For the AT1 
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angiotensin receptor (Gáborik et al., 2003), the IC2 domain appears to have a direct role in 
agonist-induced G protein coupling. The role of IC2 was further substantiated by Brann and co-
workers (Burstein et al., 1998), who developed a random mutagenesis approach for their study of 
muscarinic receptor coupling. In IC2 of the M5 muscarinic receptor, they found that substitution 
of residues clustering on one side of a presumed IC2 α-helix extending from TM3 caused 
constitutive activation, while substitutions of residues clustering on the opposite side of the helix 
compromised G protein coupling. Taken together, the data suggest that the residues on the 
constitutively activating side were critical for maintaining the receptor in an inactive state, 
whereas the residues on the opposing side were important for G protein activation (Burstein et 
al., 1998). It was therefore inferred that IC2 could act as a switch that enables G protein coupling 
(Burstein et al., 1998).  
In addition, the crystal structures of GPCRs provide us with information on the relationship 
between the structure and function of a GPCR. Recent crystallographic studies have suggested 
that G protein activation requires a conformation change in IC2 (Rasmussen et al., 2011; 
Scheerer et al., 2008a). The recent β2AR-Gs crystal structure showed receptor residues Thr 68 
and Asp 130 interacting with the IC2 helix of the β2AR via Tyr 141, positioning the helix so that 
Phe 139 (IC2) of the receptor docks into a hydrophobic pocket on the G protein surface, thereby 
structurally linking receptor–G protein interactions with the highly conserved E(D)RY motif of 
the β2AR (Rasmussen et al., 2011).   
In a recent cannabinoid receptor study (Zheng et al., 2013), the substitution of IC2 of CB2 with 
the corresponding region of CB1 displayed a two-fold increase in basal activity as compared to 
the wild-type, suggesting the possible role of IC2 in the interaction of CB2 with G proteins. The 
chimeric mutant with a replacement of both the IC2 and carboxyl-terminal tail with the 
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corresponding regions of CB1 led to a switch of G protein coupling from Gi to Gs. These results 
indicate that the IC2 of CB2 is likely to play a key role in the specificity of G protein coupling in 
coordination with the carboxyl-terminal tail (Zheng et al., 2013).  
GRKs and β-arrestins. At the receptor level, GRKs phosphorylate agonist-activated 7TM 
receptors on serine and threonine residues located in the carboxyl-terminal tail region or on the 
third cytoplasmic loop. β-arrestin is recruited with high affinity to agonist-occupied, GRK-
phosphorylated receptors, and ultimately sterically inhibits G protein coupling (Shenoy and 
Lefkowitz, 2003). The carboxyl termini of GPCRs have been implicated in the binding and 
dynamic recruitment of numerous proteins as well as the regulation of receptor activation, 
signaling, and subcellular localization. For CB1, significant structure within its carboxyl-
terminus has been elucidated (Ahn et al., 2009b) and interactions of accessory proteins with this 
region have been found to be critical for mediating key points of the receptor life cycle (Figure 
4.1; reviewed in (Stadel et al., 2011)).  
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Figure 4.1. Schematic diagram of the carboxyl terminus of the human CB1 receptor 
showing the proposed structural and functional domains. The NPXXY motif, helix 8, and 
helix 9 are highlighted in cyan, purple and green respectively. Potential phosphorylation sites are 
indicated by red filled circles and the TM7 NPXXY motif by turquoise filled circles.  
For CB2, very little information is known regarding the functional domains within IC2, IC3 and 
the carboxyl-terminus to which accessory proteins are recruited. Therefore, an understanding of 
the extent to which the CB2 cellular fate is governed by these domains is still in its infancy. It is 
important to elucidate the CB2 protein binding partners, domains they interact with, and under 
what circumstances. Knowledge of these binding partners opens up avenues by which receptor 
activity can be fine-tuned and regulated. 
To explain the molecular mechanisms underlying cell activities it is important to analyze the 
network of interactions between molecules in their native cellular context. Methods involving 
co-immunoprecipitation with tagged proteins can isolate the protein complexes that actually 
form in cells. However, for these methods to be effective, the complexes must be stable and 
cannot dissociate during cell extraction. Moreover, it is possible to capture nonspecific 
interacting partners in immunoprecipitation complexes. Cross-linkers, which can be incorporated 
into proteins as amino acids with photo-reactive linkers in their side-chain moieties (Brunner, 
1993) are therefore an important tool in stabilizing such complexes. One such photo-reactive 
amino acid is p-Benzoyl-L-phenylalanine (pBpa) (Figure 4.2a). Upon excitation at 350-365nm, 
the benzophenone group of pBpa reacts with nearby C-H bonds forming a covalent bond with its 
bound biomolecule (Figure 4.2b; (Dorman and Prestwich, 1994)). Because the pBpa is 
incorporated into the amino acid sequence of the protein, its location within the protein is known 
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and therefore gives much information regarding the location of the bound cross-linked 
biomolecule. 
 
Figure 4.2. pBpa cross-linking (a) Chemical structure of pBpa; (b) Illustration of a photo-cross-
link between pBpa and a bound protein upon excitation with 365nm light. (c) Snake diagram of 
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CB2 with the sites in IC2, IC3 and the carboxyl-terminus that were separately replaced with 
pBpa in blue. SOURCE: images (a) and (b) are modified from (Hino et al., 2005). 
The Kendall lab has previously used this photo-cross-linking method for purified proteins and in 
bacterial cells (Wang et al., 2004; Yu et al., 2013) and it has now been adapted to mammalian 
cells (Hino et al., 2005). In 2011, Sakmar and co-workers (Grunbeck et al., 2011) employed an in 
situ photocrosslinking approach by incorporating the unnatural amino acids p-Azido-l-
phenylalanine (AzF) and p-acetyl-l-phenylalanine (AcF) to study the binding interactions of 
inhibitor T140 specific for CXC chemokine receptor 4 (CXCR4). This receptor is important in 
directed cell migration, cancer metastasis, and HIV entry. They tested eight amino acid positions 
at the receptor interface and mapped a unique UV-light-dependent crosslink in vivo—the site of 
specific interaction between CXCR4 residue 189 and T140 (HIV-1 co-receptor blocker). 
Similarly, Becker and co-workers (Huang et al., 2008) used pBpa to probe the potential binding 
site of the pheromone receptor Ste2 (a yeast GPCR). They were able to identify positive 
crosslinks as potential binding sites for its natural peptide α-factor ligand (Huang et al., 2008). 
These first experiments fully confirmed that site-specific unnatural amino acid insertion within 
the receptor is an invaluable noninvasive tool to study the mechanisms and dynamics of GPCR 
ligand binding and signal transmission.  
To delineate the sites on the CB2 receptor that interact with different proteins, pBpa was 
incorporated into different sites on IC2, IC3 and the carboxyl-terminus of CB2 individually 
(Figure 4.2c) based on the importance of these regions in CB1 and other class A GPCRs. This 
technique enables us to observe the in situ crosslinking of the full-length CB2 in its native 
environment under defined conditions to identify its binding partners and their site of interaction. 
The genetic encoding of this non-natural amino acid in mammalian cells requires a bacterial pair 
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of an amber suppressor tRNA and an aminoacyl-tRNA synthetase (aaRS) specific to the non-
natural pBpa (Hino et al., 2006). We therefore used an exogenous tRNA-aaRS pair specific to 
pBpa (Figure 4.3) to translate this amino acid in place of the amber codons. The tRNA used is 
only recognized by the Eco-pBpaRS (Figure 4.3a) but not recognized by any endogenous 
mammalian cell amino acyl-tRNAs (aaRS). The Bst-sup-tRNA (Figure 4.3b) used will suppress 
the phenotypic ―stop‖ signal of the amber codons and become charged with pBpa by the action 
of the Eco-pBpaRS. The pcDNA4/TO vector that incorporated this tRNA-aaRS pair uses the 
complete cytomegalovirus promoter (PCMV) to promote high expression levels as well as 
control elements from the bacterial tetracycline operon (TetO2) to give flexibility to transcription 
control. It also includes zeocin (ZeoR) and ampicillin (AmpR) antibiotic resistance genes that 
will allow for effective selection of the properly transfected HEK293 mammalian cells. Using 
site directed mutagenesis, we introduced an amber stop codon (UAG), one at a time, into several 
locations along IC2, IC3 and the carboxyl-terminus substituting for naturally occurring 
phenylalanine or other bulky hydrophobic residues when possible (Figure 4.2c). It is anticipated 
that substitutions at the heart of any binding site could disrupt interactions but regions 
immediately flanking binding sites would lead to successful cross-linking. We show here pilot 
and optimization studies of the successful incorporation of pBpa into different sites on the CB2 
receptor. The data presented here lays the foundation for the application of this technique to 
delineating the binding partners of CB2, and can also be used as a basis for other GPCR model 
systems.  
 141 
 
 
 
Figure 4.3. Map of the plasmids needed for pBpa incorporation. (a) Eco-pBpaRS plasmid 
encoding the pBpa synthetase; (b) Bst-suppressor tRNA pBR322 encoding the ‗stop‘ codon 
suppressor tRNA; (c) pcpBpaRS plasmid encoding both the suppressor tRNA and the pBpa 
synthetase 
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4.3 Materials and Methods 
Materials. pBpa was purchased from Bachem AG (Bubendorf, Switzerland). The anti-
hemagglutinin antibody was from Roche Diagnostics (Indianapolis, IN). The horse-radish 
peroxidase-conjugated anti-mouse IgG was from Genscript (Piscataway, NJ). 
Plasmids. The tRNA-aaRS pairs necessary for the genetic encoding of non-natural amino acids 
have been developed from naturally occurring tRNA and aaRS species (Chin et al., 2003) and 
were a generous gift from the Yokoyama lab at RIKEN Genomic sciences center in Japan (Hino 
et al., 2006). The naturally occurring Escherichia coli tyrosyl-tRNA synthetase (E.coli TyrRS) 
was engineered to only recognize pBpa and is known as the Eco-pBpa tRNA synthetase (Kiga et 
al., 2002). This synthetase was cloned into the MCS site of a pcDNA4/TO plasmid (Eco-
pBpaRS; Figure 4.3a) under the tetracycline-regulated CMV promoter, and the Zeocin resistant 
gene under the SV40 promoter.  
The amber suppressor tRNA was derived from Bacillus stearothermophilus tRNA and nine 
tandem copies of it were cloned into the MCS site of pBR322. Each of the nine tRNA genes has 
the internal promoter that works in mammalian cells (Bst-sup-tRNA pBR322; Figure 4.3b) (Hino 
et al., 2006). This tRNA is only recognized by the Eco-pBpaRS but not recognized by any 
endogenous mammalian cell amino acyl-tRNAs (aaRS). In addition, another plasmid, pcpBpaRS 
(Figure 4.3c), was constructed and carries both the pBpaRS gene under the tetracycline-regulated 
CMV promoter, together with the nine tandem copies of the sup-tRNA gene and the Zeocin 
resistant gene under the SV40 promoter. Two versions of the pBpaRS synthetase were used, one 
with an HA tag and one without. 
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Site-directed mutagenesis. The wild-type CB2 gene in a pcDNA3.1 vector was mutagenized 
using the QuickChange site-directed mutagenesis kit, to generate a series of clones with 
individual amber codons in CB2 at position 137 in IC2, positions 231 and 227 in IC3 and 
positions 317, 337 and 346 of the CB2 carboxyl terminus. 
Transfection. HEK293 cells were seeded into 6-well plates with 1x10
5
 cells/well on the day 
prior to transfection. The cells were maintained in about 2 ml/well of DMEM growth medium 
supplemented with 10% FBS and 3.5 mg/ml glucose at 37
o
C in 5% CO2. Transfection was 
carried out using the Lipofectamine 2000 reagent (Invitrogen; according to manufacturer‘s 
protocol) in the Gibco OptiMEM growth medium (Invitrogen). The HA tagged CB2 receptor 
plasmid was used at a concentration of 0.2 µg/well (whether it was wild-type CB2 or it contained 
an amber mutant codon). The CB2 amber mutant gene plasmid was mixed with the suppresser 
tRNA plasmid (Bst-sup-tRNA/pBR322) and the synthetase plasmid (EcopBpaRS (no HA tag)) 
in one condition (3 plasmids total) and with the combination plasmid (pcpBpaRS (no HA tag)) in 
another condition (2 plasmids total). In the pilot studies, the plasmids coding for the tRNA-aaRS 
pair were used at concentrations ranging from 0.2-5 µg. Four hours after transfection, the 
transfection medium was replaced with DMEM (supplemented with 10% FBS and 3.5 mg/ml 
glucose) containing pBpa at a concentration of 0.5 mM and was incubated at 37
o
C for 36-40h for 
proper pBpa incorporation. To prepare 15 ml of the DMEM medium containing pBpa at the final 
concentration of 0.5 mM, 2 mg of pBpa were dissolved in 300 µl 1 M HCl, and immediately 
added to 13.5 ml of the DMEM pre-warmed at 37 °C. The pH of this medium was adjusted to 
7.2 with 1 M NaOH and the final volume to 15 ml with sterile water. Finally, the medium was 
filtered through a 0.22 µm filter connected to a syringe for sterilization. Because pBpa is light 
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sensitive, most experimental steps involving the preparation or following the addition of pBpa to 
the media were carried out in low to no light conditions.  
During the 4h transfection incubation, the mutant CB2 gene, the gene encoding pBpaRS and the 
suppressor tRNA will begin to be expressed. Because pBpaRS does not recognize any amino 
acid except pBpa, if the medium is not supplemented with pBpa, only the gene products 
truncated at the amber position will be expressed (see results). 
UV Photo-cross-linking. Approximately 30 h after pBpa was added to the media (during the 36-
40h pBpa incorporation incubation), the media was supplemented with 10 µM SR144528, a CB2 
inverse agonist. After 8 h, the cells were washed with ice-cold PBS and treated with CP55,940 
for 1min, 5min and 20min and washed again. The culture dishes containing these cells in PBS 
were then irradiated with a Spectroline Built-in-Ballast UV lamp (model BIB-150P, 365nm) for 
30sec, 1min, 5min and 15min.  
Western Blotting. Following the 36-40h incubation in pBpa-containing media (and after 
treatment with the CB2 inverse agonist SR144528 and/or the agonist CP55940 for some of the 
samples), the cells were solubilized and lysed in 200 µl/well of ice-cold Cell Lytic M reagent 
(Sigma) (plus 1% Triton X-100, and 1% protease inhibitor cocktail). Samples were subjected to 
SDS-polyacrylamide gel electrophoresis in 7.5% gels, and proteins were transferred onto 
polyvinylidene fluoride (PVDF) membranes. After blocking with 5% nonfat milk (Bio-Rad), the 
membrane was incubated for 1 h with the anti-hemagglutinin (anti-HA) primary antibody 
(1:4000). The membranes were washed with PBS, and then they were incubated with the horse-
radish peroxidase anti-mouse secondary antibody (1:6000) for 1 h at room temperature. The 
specific immunoreactive proteins were detected using the SuperSignal West Femto 
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Chemiluminescent Substrate System (Thermo Fisher Scientific, Rockford, IL) following the 
manufacturer‘s protocol and visualized on x-ray film.  
Initial Membrane Solubilization. Crude cell membranes expressing CB1 (tagged with c-myc, 
Flag or HA) were used. Briefly, HEK293 cells were plated with 1x10
6
 cells/100-mm dish on the 
day prior to transfection. The cells were maintained in DMEM growth medium supplemented 
with 10% FBS and 3.5 mg/ml glucose at 37
o
C in 5% CO2. 24 hours after transfection (refer to 
Chapters 2 and 3 for calcium phosphate transfection method) cells were harvested and 
resuspended in PBS. The cells were then centrifuged at 500 x g for 5 minutes. The supernatant 
was discarded and the cell pellet was resuspended in 1ml PBS and centrifuged again in a 
swinging bucket microcentrifuge at 500 x g for 5 min. The supernatant was once again discarded 
and the cell pellet was resuspended in 250 µl of 1x KHD lysis buffer (50 mM Tris-HCl, pH 7.6, 
1 mM EDTA, 150 mM NaCl, 10% protease inhibitor cocktail) per 100-mm dish. The samples 
were then sonicated and centrifuged at 21,000 x g for 30 min in a refrigerated microcentrifuge. 
The supernatant was removed and the pellet was resuspended in 1 of 5 different detergents: 
RIPA buffer (1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS), 1% SDS (dissolved in 1x 
KHD buffer), 1.2% digitonin (dissolved in 1x KHD buffer), 8 mM CHAPS or 1% Triton X-100. 
The pellet was left to solubilize for 1 hour at 4
o
C and centrifuged at 21,000xg for 30 min in a 
refrigerated microcentrifuge. The supernatant was removed and placed into pre-chilled 1.5 ml 
Eppendorf tubes. Solubilization efficiency was checked by running both 7.5% SDS-PAGE gels 
or running 8 M Urea 7.5% SDS-PAGE gels. Solubilization of the CB receptors was also initially 
tested after extraction of the plasma membrane from HEK293 cells that were transfected with the 
receptors. The solubilization from the plasma membrane preparations proved to be inefficient. 
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2.4 Results and Discussion 
Cannabinoid receptor solubilization. Despite their critical importance, our current 
understanding of the structure and function of the cannabinoid receptors is limited because of 
their low natural abundance and the challenge of obtaining large quantities of purified protein. 
The same is true for other membrane proteins. Solubilization and stabilization of membrane 
proteins using detergents are the first critical steps in purifying membrane proteins, and 
constitute a bottleneck for the structural biology of membrane proteins (Hjelmeland and 
Chrambach, 1984; van Renswoude and Kempf, 1984). Membrane proteins require a membrane-
like environment to maintain their correctly folded structures and functions during and after 
purification. Detergent micelles provide such environments surrounding the hydrophobic 
domains of membrane proteins and keeping them soluble in an aqueous environment, and thus 
are widely used for their solubilization and purification (le Maire et al., 2000). Generally, the 
suitable detergent or detergent mixture should effectively solubilize the target protein, keep it 
stable, and prevent its self-aggregation. However, due to individual differences between 
membrane proteins, the choice of detergent or detergent mixture for a particular protein cannot 
be predicted. Therefore, a systematic approach is required to select the optimal detergents to 
achieve solubilization and stabilization of each target protein. It is also important to be able to 
isolate the target protein on a gel into a distinct band that is free of other contaminating proteins 
so that it can be excised in a semi-pure form from the gel for further analysis, namely mass 
spectrometry. 
For the cannabinoid receptors, five different detergents were tested based on their success in the 
solubilization of other GPCRs: CHAPS, 1.2% digitonin, 1% SDS, RIPA, and 1% Triton X-100. 
Figure 4.4a and 4.4b show four out of the five detergents used to solubilize the different tagged-
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CB1 receptors. These are 8 mM CHAPS and 1.2% digitonin in Figure 4.4a and RIPA and 1% 
SDS in Figure 4.4b. In these four cases the solubilization was unsuccessful for the CB receptors 
even after several conditions, such as temperature, incubation time, buffer sample preparation, 
membrane preparation extractions versus crude cell lysate, were changed. 
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Figure 4.4 Initial solubilization of the CB receptor with CHAPS, 1.2% digitonin, RIPA or 
1% SDS. Panels a and b show western blots of Flag- and c-myc CB tagged receptors under 
treatment with different detergents.  
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In Figure 4.5a, the use of Triton X-100 (plus 1% protease inhibitor cocktail) to solubilize and 
lyse HA tagged CB1 or CB2 receptors proved to be successful. Two bands corresponding to the 
molecular weights (MW) of HA-CB1 (53-60 kDa) and HA-CB2 (42-46 kDa) were visualized. 
However, the HA tagged CB2 receptor was chosen to be used in further experiments due in part 
to its higher level of expression in HEK293 cells, but mostly due to its slightly lower MW that 
produces a clear band that is not adjacent to any non-specific bands (see Figure 4.5a and 4.5b). 
 
Figure 4.5 Solubilization of the CB receptors using 1% Triton X-100. (a) two bands 
corresponding to the molecular weights (MW) of HA-CB1 (53-60 kDa) and HA-CB2 (42-46 
kDa). (b) The HA-CB2 band (42-46 kDa) is clear of any non-specific bands. 
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Amber codons and truncated CB2 receptors. As mentioned earlier, pBpaRS was engineered 
to only recognize pBpa and no other amino acids. It follows then, that if the cell growth medium 
is not supplemented with pBpa, that only the gene products truncated at the amber positions will 
be expressed. Figure 4.6 shows a shift in CB2 MW due to the successful incorporation of the 
stop codon and its truncation at positions Tyr137 in IC2 of CB2, positions Glu227 and Val231 in 
IC3 and positions Trp317, Val337 and Ile346 of the CB2 carboxyl terminus when no pBpa was 
added to the growth medium.  
 
Figure 4.6 Incorporation of the stop codon at different positions in HA-CB2 evident by a 
molecular weight shift. Western blots using anti-HA antibodies to detect the truncated HA-CB2 
receptors. 
 
Truncated to full length CB2 receptors. Upon the addition of 0.5 mM of pBpa (concentrations 
ranging from 0.5 mM to 2 mM were tested; 2mM was found to be slightly toxic to the cells) to 
the cell growth medium, pBpaRS could now recognize the pBpa and incorporate the unnatural 
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amino acid in place of the stop codon. We also varied the concentrations of the pcpBpaRS 
plasmid, which contained both the synthetase and the suppressor tRNA, and found that 2-3 µg of 
this plasmid produced the full-length CB2 receptor in the cell from its truncated Y137X receptor 
(Figure 4.7a) and its W317X receptor (Figure 4.7b). Increasing the concentration of the plasmid 
to 5 µg resulted in no bands on the blot (see Figure 4.8a lanes 6-8). In general, even after the 
addition of pBpa to the medium, the gene product truncated at the amber position is also 
expressed because the efficiency of amber suppression by the suppressor tRNA is not 100%. In 
the case that this truncated gene product is stable and exhibits some activity in the cell, future 
experimental results could be affected by the expression of this product and it may therefore 
need to be removed or taken into consideration. In Figure 4.7b, the amber suppression for the 
W317X receptor was not as efficient as the suppression for the Y137X receptor (Figure 4.7a). 
Because of this difference in amber suppression efficiency, the Y137X was used for future 
experiment optimization. 
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Figure 4.7 Truncated to full-length CB2 receptors. Concentrations of the pcpBpaRS plasmid, 
which contains both the synthetase and the suppressor tRNA, were varied. (a) The suppression of 
the amber codon in position Y137X was most effective when 2 or 3 µg of pcpBpaRS were used.  
This resulted in the formation of the full-length HA-CB2 receptor. (b) The suppression of the 
amber codon in position W317X was not as efficient as the suppression in a. This is evident by 
the faint band representing the full-length HA-CB2 receptor in b at approximately 45kDa. 
Control lanes 3 and 4 in both panels a and b show different concentrations of the plasmid alone 
and that the bands in other lanes are not due to the addition of the pcpBpaRS plasmid. 
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UV photo-cross-linking. Once the pBpa was successfully incorporated into the CB2 receptor, in 
order to see what the receptor could capture and what it interacts with, cross-linking requires 
exposure to 365 nm light. Most of the publications on the use of pBpa and the incorporation of 
unnatural amino acids have exposed their samples to UV light for 15 minutes while the sample 
was on ice (4
o
C) to avoid heating up of the cells and the drying up of the liquid medium. 
However, it has been shown that at 4
o
C, the internalization of the receptors does not occur 
(Burke et al., 2001). We also know that many of the critical cellular events within a cell occur 
within a short period of time after the receptors are activated by a ligand. For example, our lab 
has shown that at 5 minutes of treatment with the CB1 agonist CP55,940, the phosphorylation of 
ERK1/2 peaks (Ahn et al., 2012; Ahn et al., 2013). This means that some of the key cellular 
processes, such as G protein coupling or phosphorylation by kinases at the cell surface or the 
recruitment of signaling complexes such as β-arrestin may occur rapidly at the plasma membrane 
before endocytosis. Our purpose for studying the receptors using pBpa is to see some of these 
critical cellular processes and delineate the different proteins that are recruited at different 
receptor regions and at different time duration after treatment with different ligands. We 
therefore chose shorter UV exposure times and kept the cells at room temperature while being 
irradiated. 
To reduce the diversity in the activation states and localizations of the CB2 receptors, we pre-
treated the cells with 10 µM SR144528, a CB2 inverse agonist, for 8 h. This treatment is 
intended to bring the CB2 receptors to the cell surface and standardize their starting point so that 
they all begin at the same location. After 8 hours, (the minimum amount of time determined 
experimentally using confocal microscopy needed for more than 85% of the CB2 receptors to be 
expressed on the cell surface) the cells were washed to remove excess SR144528 and treated 
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with 10 µM CP55,940 for 1 min, 5 min or 20 min and then washed to remove excess CP55,940 
after each time point. The culture dishes containing these cells in PBS were then irradiated with 
365 nm light for 30sec, 1 min, 5 min and 15 min (Figure 4.8).  
Figure 4.8a (lanes 5 and 8) show that irradiation with 365 nm light for 15 min produced no bands 
on the blot. This may be due to several factors including the denaturation of the receptors. Lanes 
3 – 4 in Figure 4.8a, that were irradiated for a shorter time period, show the truncated CB2-
Y137X receptors and the successful amber suppression resulting in full length receptors. Lanes 
6-8 show that using more of the pcpBpaRS plasmid actually does not improve amber suppression 
efficiency but has the opposite effect. In addition, it is possible that some of the bands that are 
marked by a red asterisk are cross-linked CB2 complexes. Their apparent molecular weight is 
approximately 67kDa which very roughly estimates the molecular weight of a CB2-G protein 
complex (G protein kDa ~ 23kDa). 
Figure 4.8b shows irradiation with 365 nm light for 30sec, 1 min, and 5 min without CP55,940 
treatment (lanes 4 – 6) and with 10 µM of CP55,940 treatment for 5 minutes (lanes 7 – 9) of the 
truncated CB2-V231X receptor. With no CP55,940 treatment, a possible CB2-G protein complex 
band at ~67kDa is visible (lanes 4 – 5) when irradiated with 1 minute or less of UV, consistent 
with the results in Figure 4.7a using the truncated CB2-Y137X receptor. 5 minutes irradiation 
with no CP55,940 treatment showed no complex formation.  
After 5 minutes treatment with CP55,940 (lanes 7 – 9) and over 1 minute irradiation with UV 
(lanes 8 – 9), a new band appeared at approximately 130kDa, which roughly estimates the 
molecular weight of a CB2-kinase complex (kinase kDa ~ 80-85kDa). 
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Figure 4.8 Western blots showing the formation of possible CB2-binding partner complexes 
upon irradiation with UV and treatment with 10 µM of the inverse agonist SR144528. (a) 
Irradiating the Y137X HA-CB2 mutant receptor with UV for 15 minutes resulted in no bands. 
Using 5 µg of the pcpBpaRS plasmid resulted in no bands corresponding to the full-length HA-
CB2 receptor at 45kDa. (b) HA-CB2 V231X receptor using 3 µg of pcpBpaRS and treatment 
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with 10 µM of the agonist CP55,940 at the designated time points. Possible HA-CB2 complexes 
are shown using a red asterisk.  
4.5 Summary and Future Considerations 
The main focus of this chapter was to optimize the incorporation of the photo-crosslinkable 
amino acid pBpa into the intact receptor in live cells in order to identify and reveal the CB2 
binding partners in IC2, IC3 and the carboxyl-terminus regions of the receptor. Literature on the 
receptor strongly argues that G proteins, kinases and arrestins bind these regions. This chapter 
shows the successful application of this technique and may lead the way to the investigation of a 
plethora of other molecules believed to interact with the CB2 receptor and regulate its function. 
One of the major problems that I was faced with is the efficient suppression of the amber codon 
and the formation of a large enough amount of full-length CB2 receptor with incorporated pBpa. 
The literature discusses this low yield as being normal since the suppression of the amber codon 
will never truly be 100%. It is also mentioned that the amber suppression and formation of full-
length receptor in the presence of pBpa may entirely depend on the location in which the amber 
codon is incorporated. Some residues on the protein may be in locations that are sterically 
inaccessible to the suppressor tRNA or the synthetase compared to other residues and thus result 
in less efficient amber suppression. This is evident in my own results in Figure 4.7b where the 
suppression of the amber codon in position W317X on the CB2 receptor was not as efficient as 
the suppression in Figure 4.7a of the amber codon in position Y137X. The only solution 
suggested was to just keep trying other residues in different locations. 
One of the key tests that will need to be done on the HA-CB2 mutant receptors, is to ensure 
proper receptor folding and activity after the pBpa is incorporated into the amber positions. This 
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can be done using the ligand binding and G protein coupling activities of the receptor. Ligand 
binding assays are used to determine receptor affinities for ligands and can be indicative of 
proper receptor folding and activity compared to the wild-type receptor. The G protein coupling 
assay is an indicator of receptor activation and therefore, indirectly, the extent of desensitization.  
Once receptor activity is established, there are two possible ways by which the binding partners 
can be identified once they are cross-linked to the CB2 receptor. The first of these methods is to 
probe the same samples that resulted in possible complexes with antibodies specific to the 
receptor or to the putative cross-linked partner (e.g. kinase(s) or G protein(s)). Possible kinase 
candidates include G protein receptor kinases (GRKs), protein kinase A (PKA), and protein 
kinase C (PKC). This will serve to identify the locations that lead to successful crosslinking and 
under what in situ conditions.  
The second avenue for identifying receptor binding partners is by performing quantitative MS. 
Bands that are suspected to represent a CB2 complex will be isolated and proteolytically digested 
to generate a mixture of peptides that can be identified by MS. The proteins present in the sample 
can be deduced by recombining the sequences of the identified peptides using suitable 
informatics tools. Western blotting, as described above, with antibodies specific for the identified 
binding partners from MS can be used to confirm this interaction. A third confirmatory method 
can involve the co-localization of the CB2 receptor with its binding partners using confocal 
microscopy. This technique will also allow us to vary the amount of time the receptor is exposed 
to ligand and pinpoint the time when CB2 reacts with its partner. It will also enable us to observe 
the intracellular location and compartment at which this partnership takes place. 
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Another point of consideration is the differentiation between surface and internal CB2 receptors 
and the ability of the CB2 receptor to associate with specific signaling molecules after 
endocytosis. Initially, we treated the receptor with the inverse agonist SR144528 to bring all of 
the receptors to the cell surface and limit the variation in receptor location as well as activation 
state. However, the use of a reversibly biotinylated antibody against the CB2 receptor that would 
not interfere with ligand binding or receptor function can also be used to differentiate between 
surface and internal CB2 receptors to avoid any residual effects of inverse agonist treatment. The 
antibody would theoretically be biotinylated with sulfo-NHS-SS-biotin. The disulfide bond in 
sulfo-NHS-SS-biotin allows the release of the biotin without denaturing the antibody upon 
treatment with 50 mM of glutathione. Sulfo-NHS-SS-biotin has been used previously to 
nonspecifically label cell surface proteins and to follow their internalization (Le Bivic et al., 
1990; Schmidt et al., 1997). To isolate the CB2 receptor at different points in the endocytic 
pathway, the receptor can be treated with an agonist that will occupy the biotin-tagged CB2 
receptor and induce its endocytic trafficking as a synchronized pool. After glutathione treatment, 
only the surface CB2 receptor should be associated with nonbiotinylated antibody while the 
internalized receptors will be biotinylated. Streptavidin agarose followed by secondary 
antibodies coupled to protein A Sepharose can then be used to sequentially separate the two 
populations of receptors.  
This technique provides a lot of potential and a great avenue by which binding partners of the 
CB2 receptor can be captured. The idea of being able to engineer the unnatural amino acid, 
pBpa, into specific locations on the receptor and then being able to covalently bind any proteins 
that come within 3A opens up doors to engineering specific proteins that capture specific binding 
partners at specific locations on the protein. Taking that together with time points upon treatment 
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with different ligands would give us enormous insight into how the cell works and would help us 
understand the ligand-based modulation of receptor activity. We can ask: (1) which kinases are 
recruited upon treatment with a certain agonist? (2) which adapter proteins help receptor 
internalization upon this treatment? (3) what differentiates an inverse agonist signaling pathway 
from an agonist signaling pathway? (4) what are the time points at which these interactions 
occur? The kinetics as well as the identity of these binding partners is essential in being able to 
fine-tune receptor activity. With the increase in the development of new ligands and drugs for 
GPCRs in general, such as was the case for the research presented in Chapters 2 and 3, 
understanding their downstream effect on receptor activity is crucial to the design and 
optimization of drugs. These optimized drugs will ultimately be used for the therapeutic 
treatment of many diseases and will abolish severe side effects. Future studies of these 
mechanisms of GPCR modulation may also lead to important new insights relevant to 
neuropsychiatric disease and may identify exciting new targets for the development of novel 
therapeutic drugs.  
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